See the document
Transcription
See the document
The crucial link ANNUAL REPORT 2012 www.gustaveroussy.fr On the front page: KEVIN PULIDO, patient at Gustave Roussy’s Child and Adolescent Cancer Department. The crucial link Past, present and future; care-givers, patients and families; research, care and teaching; local, national and international partners… So many bonds forged each day by Gustave Roussy’s teams. So many relationships nurtured around the care provided by the teams of doctors and care-givers, the energy of researchers and the solidarity of families and volunteers. So many forces working together to beat cancer. SUMMARY Discover Gustave Roussy 02 Interlinked portraits 04 Our Key Missions 08 Key figures 10 Actors of the cancer network 11 Governance 12 Highlights 2012 14 Management board interview 16 See further 20 A global problem 22 A global mementum 24 The scientific project Cancer Campus 25 Therapeutic innovations 26 Precision medicine 28 Act on… Care Research Teaching Fundraising Financial Results 30 32 38 42 46 50 2012 activity 52 Auditor’s report 53 2012 balance sheet 54 2012 profit and loss account 56 Overall annual use of resources 58 Uses of donations and bequests 59 Gustave Roussy’s scientific publications Synthesis International comparisons International publications 60 60 62 63 Our 2012 annual report and its annexes can be found online • The activity of the departments and the tumor boards • Presentation of the research groups gustaveroussy.fr heading: annual reports ANNUAL REPORT 2012 / GUSTAVE ROUSSY 03 CATHERINE VERGELY, director of ISIS, an association of parents and friends of the children treated at Gustave Roussy. “There are dozens of volunteer associations helping out at the Gustave Roussy Institute. Our work has been recognised to be of public interest; we form an integral part of the hospital system by helping to improve the quality of life of cancer patients. We know that our role is important.” “I’ve had highs and lows, as the weeks go by. Sometimes, activities organised for the patients by volunteers have helped us escape. These moments are truly important.” KEVIN PULIDO, a patient at Gustave Roussy’s Department of Child and Adolescent Cancer Pr FABRICE ANDRÉ, oncologist and Head of The Unit for Translational Research at Gustave Roussy. “Generosity of the public and solidarity of our donors are essential for the success of cancer research programs currently being conducted at Gustave Roussy. I would sincerely like to thank all our donors; it is their generosity that allows us to exist.“ “Donating money to research is something very tangible. Every month, by donating a few dozen euros by automated bank transfer, I am actively helping to fund a team. My contribution allows a research program to exist. The more of us there are, the more we can do to advance research.” CHRISTELLE DUMONT, sponsor of Professor Fabrice André’s team for research against breast cancer. CAROLE MAZELIER, medical-technical manager in nuclear medicine. “Every day, thanks in particular to the training we are given, I can improve my skills for the benefit of the patients and thus serve them better. I share that with all my colleagues. We see what is at stake and it makes our work all the more meaningful.” “I am keen to pass on, through the training I provide to the medical teams at Gustave Roussy, the correct methodology for conducting clinical studies under optimal conditions for patients.” Dr ISABELLE BORGET, a university lecturer in health economics at Université Paris-Sud Gustave Roussy. “I am proud to follow a training program focused on innovation and to rub shoulders with the brilliant people at Gustave Roussy. I consider myself very lucky to have had this opportunity to spend 3 years studying in such a stimulating and scientific environment.” NILS TERNÈS, master’s student, part of the “Path to excellence in cancer studies group – Fondation Philanthropia”, and pursuing an education at the Cancer Sciences School – Université Paris-Sud and Gustave Roussy. Pr MARTIN SCHLUMBERGER, director of the Cancer Sciences School “Training young talent is fundamental to make sure there is a constant renewal of innovation in care and oncology research. These are the talents which, tomorrow, will beat cancer.” DISCOVER GUSTAVE ROUSSY OUR KEY MISSIONS THREE PILLARS: CARE, RESEARCH AND EDUCATION AT THE FOREFRONT OF CENTERS IN THE FIGHT AGAINST CANCER The Gustave Roussy cancer center, founded in 1926 by professor Gustave Roussy, distinguished itself from the very beginning by its wholly integrated approach to research, care and teaching; today, it is one of the ten world leaders in the fight against cancer. A key actor on the European and international oncology scene, Gustave Roussy applies a global approach to cancer, employing multidisciplinary teams to care for each patient and define by a multidisciplinary process the best treatments for them. Top level research, conducted at the very heart of the Institute, is aimed at the integration of basic, translational and clinical approaches, so that the results can be applied as quickly as possible for the benefit of the patient. The teaching provided to the students, researchers and practitioners, enables them to bring into practice new developments in cancer treatment, and introduce innovations. Its internationally renown professionals are specialists with regard to all different types of cancer, at all stages and at all ages. As an expert center in dealing with complex cancers, Gustave Roussy brings together cutting-edge medical care and human support. Gustave Roussy’s specificity is also based on its therapeutic innovation, which today puts it at the forefront in very promising areas such as personalised medicine – which takes into account the patient and their tumour’s genetic characteristics – and tomorrow’s therapies (immunotherapy, DNA repair inhibitors, epigenetic modulators). The Institute is a driving force in the dissemination of knowledge and training by exporting its working models, its experience and medical expertise abroad. Further, numerous academic partnerships are nurtured with the greatest cancer centers in the world for worldwide research projects. Gustave Roussy’s holds a central position in the project Cancer Campus – a campus of international scope which structures, around the Institute, university activities in research and health innovation – and Grand Paris, a future Greater Paris Area which links the major economical centers of mainland France. 08 ANNUAL REPORT 2012 / GUSTAVE ROUSSY A GLOBAL FRONT-RUNNER IN CANCER TREATMENT INNOVATIONS FOR OVER 90 YEARS • Our missions: care, research, train, and mobilise. • Our vision: set up the best group of researchers, doctors, care-givers, teachers and donors for the benefit of each patient. • Our commitment: create the medicine of tomorrow by speeding up the translation of scientific and medical discoveries to new treatments for cancer patients. • Our values caring creativity distribution energy A mission of public interest Gustave Roussy is a private health care establishment of public interest and a not-for-profit organisation. As a Cancer Center, its status has been established by decree (number 45-2221) of 1 October 1945, modified by decree (number 2005-406) of 2 May 2005 and by the “HPST” law of 21 July 2009 concerning hospital reforms and relative to patients, health and territories. There are 18 ex-officio members on the Board of Directors, chaired by the Prefect of the Paris region, the Prefect of Paris. He determines general policies, conducts evaluation processes and controls the execution of policies. At executive level, Gustave Roussy is led by a physician, appointed for 5 years by the Minister of Health, after consultation with the Board of Directors and the National Federation of Cancer Centers. The General Director, who manages the general conduct of the establishment, is aided by the Assistant General Director who is in charge of the operational management of the Institute, appointed by the Minister of Health, and the Research Director who is appointed for 5 years by a decree of the Ministers in charge of Health and Research. Gustave Roussy is a member of UNICANCER, which federates the Cancer Centers in France. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 09 KEY FIGURES ACTIVITIES AND TEAMS an overall budget of 2,600 290 M € employees A research budget of 60 M Of which 20% € €20 M 530 physicians 965 270 care-givers researchers raised from the public CARE 200,000 consultations 24% 47,000 356 hospital beds of the patients involved in a biomedical research program (compared with 11% nationwide) patients of which 11,400 first visits per year and 88 beds/chairs in day-care RESEARCH 29 research groups 300 clinical 1,300 studies in progress, international scientific publications divided into 13 units more than 50 sponsored by Gustave Roussy Almost 2,500 Over 130 patents filed patients treated by a personalised approach between 2009 and the end of 2012 TEACHING 2,800 medical students, nurse students, engineers and researchers trained every year 40,000 hours of initial and/or in-house training every year 17 University 26 degrees 10 ANNUAL REPORT 2012 / GUSTAVE ROUSSY university teachers 214 teaching practitioners 3,400 electronic or paper publications THE ACTORS OF THE CANCER NETWORK As a global public health issue, the fight against cancer requests, by its very nature, a global and combined approach between its many different actors: research centers, universities, hospitals, other centers involved in the fight against cancer both in France and on the international scene, pharmaceutical and biotechnological industries, supervisory authorities, patient associations, small and large donors, sponsoring firms… So many driving forces joined together to encourage innovation in care and research. Inca French National Cancer League Plan Cancer Departmental p Council for the Paris region ARC Unicancer Grand Paris AP-HP Departmental p Council for the “Val de Marne” region French Ministryy of Higher g Education and Research Federation of Cancer Centers of France Front-line health professionals French Ministryy of Social Affairs and Health Campus Grand Parc ONCO 94 Cancer Campus (Villejuif) Inserm Fondation Gustave Roussy Groupe p Dassault Natixis Printemps Cancer Sciences School Fondation Philanthropia Université Paris-Sud Universityy Department p of Medical Studies Universityy Department p of Pharmaceutical Studies MMO HAS MD Anderson Universityy Cancer Center Department p of Sciences SOCRATE PACRI PATIENTS Donors ARS CNRS UFR Law Economics Management nt MOSCATO ANSM Patient Associations EORTC Union for International Cancer Control Organisation g of European p Cancer Institutes Universityy Hospital Sharjah (UAE) Erasmus University MC DKFZ Karolinska Institute SAFIR NCI Donors “PA Attitude” Research sponsors Odysséa Gustave Roussyy Transfert “Route to excellence in cancer studies – ‘Fondation Philanthropia’” ENS Cachan — INSTITUTIONS — CARE ORGANISMS — RESEARCH ORGANISMS — TEACHING PARTNERS — FUNDRAISING AND PATRONAGE Génopôle p Évryy biocluster Institut Curie Institut Pasteur WIN Consortium ANNUAL REPORT 2012 / GUSTAVE ROUSSY 11 GOVERNANCE PROMOTING EFFICIENCY, INTEGRATION, FORWARD-THINKING AND TRANSPARENCY Gustave Roussy has implemented, at the general management level, a governance model to guide its activities in care, research and teaching. This model, which guarantees an overall perspective and responsiveness, allows the main strategic and operational guidelines to be defined, while assuring that long-term decisions are made and that sustainable growth is assured. Gustave Roussy is implementing a contractualizing model with its medical departments to define objectives and budgets. This principle of delegation and co-governance is a key element in developing common projects and the participatory principles in running the institution. THE COMPOSITION OF THE BOARD OF DIRECTORS OF GUSTAVE ROUSSY ON 31 JULY 2013 EX OFFICIO MEMBERS (18) Mr Jean Daubigny President, Prefect of the Paris region, Prefect of Paris Professor Fabien Calvo Representative of the National Cancer Institute Mr Thierry Damerval Representative of the Institute of National Scientific Studies and Medical Research Mr Laurent Garnier Member of Val-de-Marne’s General Council Mrs Mireille Faugère Managing Director of Welfare – Paris Hospitals Dr Jean-Marie Le Guen Member of the Council of Paris Professor Serge Bobin Dean of the Faculty of Medicine Mr André Rouquié Member of the Economic, Social and Environmental Council Mrs Véronique Paquis Representative of the Ministry of Research MEMBERS ACTING IN AN ADVISORY CAPACITY Mr Pierre Dartout Prefect of the Department of Val-de-Marne Represented by Mr Ivan Bouchier Assistant Prefect of L’Haÿ-les-Roses Professor Alexander M.M. Eggermont General Director of Gustave Roussy Mr Claude Évin General Director of the Paris regional Health Agency Professor Claude Huriet Mr Jean-Pierre Davant Mrs Annie Podeur Qualified Individuals Mrs Catherine Vergely Mr Jean-Pierre Escande Users’ Representatives Dr Dominique Valteau-Couanet Dr Sylvie Bonvalot Members of the medical personnel Mrs Christine Fontaine Dr Pierre Duvillard Members of the Works Council INVITED MEMBERS Mr Éric Vechard ARS Territorial Representative (Val-de-Marne) MANAGEMENT AND ADMINISTRATION OF GUSTAVE ROUSSY Mr Charles Guépratte Assistant General Director Professor Éric Solary Research Director Mrs Sophie Beaupère Director of Activities and Finances SECRETARIAT Mr Robert Servat Director of Financial Affairs, Treasurer Mrs Katia Laffargue Cabinet Chief Dr Ellen Benhamou Borowski President of the Medical Commission 12 ANNUAL REPORT 2012 / GUSTAVE ROUSSY Mr Stéphane Stépanian Director of Investments and of Logistics Mr Philippe Bourassin Director of Human Resources Mrs Christine Lascombe Communication Director Professor Michel Ducreux Medical Coordinator Mrs Anne Montaron Care Management Mrs Psylvia Dewas-Tasseau Project Manager Mr Jean Gatinaud Auditor (KPMG) GENERAL MANAGEMENT International Task Team General Director A. M.M. Eggermont Assistant General Director C. Guépratte Research director É. Solary Internal contractualisation assistance and performance support task team V. Brière ACTIVITY UNIT Medical Coordinator M. Ducreux RESEARCH AND TEACHING TUMOUR BOARDS DEPARTMENTS Research Management É. Solary Cervico-facial Pathology S. Temam Medical Oncology K. Fizazi Clinical Research Management G. Vassal Thoracic Pathology B. Besse Child and Adolescent cancer research department D. Valteau-Couanet Teaching Management M. Schlumberger HEAD OF STRATEGY Quality and Management of Risks Management E. Minvielle Gastro-digestive D. Malka Breast S. Delaloge Gynecology C. Lhommé Endocrine tumors E. Baudin Radioprotection N. Guilabert Urology B. Escudier Legal Affairs Department N. Verotte Dermatology C. Robert Communication Management C. Lascombe Soft Tissues - Bone A. Le Cesne HEAD OF PROJECTS Care Sectors M. Di Palma Project Cancer Campus G. Lenoir Neurology F. Dhermain Haematology V. Ribrag Paediatric Pathology J. Grill Early Trials J.-C. Soria Genetical oncologist O. Caron DEPARTMENT OF HUMAN RESOURCES AND FINANCE General surgery D. Elias Cervico-facial cancer research F. Janot DITEP* J.-C. Soria Acute care B. Gachot Medical imaging M. Schlumberger Medical Pathology and Biology J.-M. Bidart Pharmacy F. Lemare DISSPO** S. Dauchy Activity and finances management S. Beaupère Medical information service M. Mons Financial/treasury affairs R. Servat Human resources Ph. Bourassin Care management A. Montaron Information systems management N. Mezaour Investments and logistics management S. Stépanian Fundraising and Partnerships E. Le Roy “Fondation Gustave Roussy” Ambulatory care M. Di Palma Operating rooms J.-L. Bourgain Radiotherapy E. Deutsch Medical physics D. Lefkopoulos * DITEP: Department of therapeutic innovations and early trials (created in September 2013). ** DISSPO: Interdisciplinary Department of supportive care for onco-haematology patients. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 13 DISCOVER GUSTAVE ROUSSY HIGHLIGHTS 2012 JANUARY INAUGURATION OF THE NOVALIS TX Gustave Roussy installed a high-precision stereotactic radiotherapy system, financed partly by the Institute’s donors. LAUNCH OF THE PROGRAMME “LIVING WITH CANCER” unconventional care facilities are set up to improve the wellbeing of patients: art, culture, sport, physical well-being. To find out FEBRUARY page 34 MARCH ALLIANCE OF PARISIAN INSTITUTES FOR CANCER RESEARCH (APICR) Gustave Roussy brings together its teaching activities within the Cancer Sciences School, together with Université Paris-Sud, to offer training programs in new cancer-related jobs. in cancer research in the Paris region, in the context of APICR, a national project of “Future Investments in Health”. To find out APRIL To find out page 42 FIRST PUBLIC/PRIVATE PARTNERSHIP IN CLINICAL RESEARCH FOR GUSTAVE ROUSSY This partnership with Sanofi aims to facilitate the patients’ access to new drugs according to their tumour’s molecular profile. page 40 JUNE Launch of the international study WINTHER, the first of its kind in the world. This trial is conducted over a period of two years in Gustave Roussy (Fr), MDAnderson (USA), McGill University (Canada), Sheeba Medical Center (Israel) and Val d’Hebron (Spain). To find out 14 ANNUAL REPORT 2012 / GUSTAVE ROUSSY page 29 JULY ACCREDITATION OF “SIRIC STATUS” Roussy the label “Integrated cancer research site” for the SOCRATE project, which brings together three innovative programs (DNA repair, tumour immunology, molecular medicine). OCTOBER SEPTEMBER FOUNDING OF THE THORACIC ONCOLOGY INSTITUTE Gustave Roussy and the Marie Lannelongue surgical center have founded a joint institute to offer global and multidisciplinary care to patients with thoracic cancers. THE ODYSSÉA RACE IN PARIS 2012 The 2012 edition of the event: the Odysséa race raised €320,000 for the support breast cancer research which was donated to Gustave Roussy to finance its clinical research programs and the development p of p personalised treatments. NOVEMBER ARRIVAL OF A STATE OF THE ART MRI SCANNER Gustave Roussy strengthened its technical platform with a high resolution and highprecision MRI Scanner of 3 Tesla, which is capable of detecting very small tumors and a spectral scanner which allows the dose of X-rays in MRI-guided radiotherapy to be reduced by 30%. RECOGNITION OF THE SAFIR 01 TRIAL AT THE ESMO CONGRESS The first results of the SAFIR 01 study demonstrates the feasibility and value of analysing molecular portraits of breast cancers, in order to detect molecular changes that can be treated with targeted therapies. To find out page 29 DECEMBER PARTNERSHIP WITH NATIXIS TO SUPPORT RESEARCH Natixis has chosen to sponsor three new research groups at Gustave Roussy over a three year period to contribute to the development of personalised medicine, in the context of Gustave Roussy’s program “Révolution Cancer”. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 15 MANAGEMENT BOARD INTERVIEW INCREASE IN ACTIVITIES AND PROJECTS COHESION AND MOBILISATION OF TEAMS DEDICATED TO PATIENTS The increase of Gustave Roussy’s activity is accompanied by the launch of major projects and of structural research programs. Interview with Professor Alexander M.M. Eggermont (General Director), Charles Guépratte (Assistant General Director) and Professor Éric Solary (Research Director). What are the results of Gustave Roussy’s activity throughout 2012 ? ALEXANDER M.M. EGGERMONT : After many years of growth, number of interventions and overall productivity has risen again in 2012. This effort, in which all of the Institute’s teams have participated, demonstrates their strength and collaborative spirit. This year has also been marked by the launch of a number of major projects, in particular the construction of a building largely dedicated to personalised medicine – or precision medicine –, the founding of the Cancer Sciences School, and the development of major research programs. In summary, 2012 was a remarkable year in terms of the achievements of our missions and the implementation of our strategic vision. of care. This is evidenced by a 2% rise in overall activity concerning full hospitalisation, and 4% for ambulatory care. Our ability to implement new structures, such as the new “diagnosis in a day” which, like the model of the one set up 8 years ago for breast cancer, has now been expanded to other types of tumours too. The considerable number of long-term projects started in 2012 demonstrates the respo onsiveness of all the teams in the face e of practical developments. In 2012 we also finalised the internal contractualisation proce ess with the drafting of contracts settting out targets and means by th he medical and surgical departmen nts. Additional income came e from the treatment of foreign patients with CHARLES GUÉPRATTE : It is largely this growth in activity which has allowed us to balance our budget, despite the freeze in public financing caused by the challenging economic conditions and which made us initially fear a deficit. Thanks to the continued momentum, supported by everyone, we have been able to increase the number of patients treated while maintaining an excellent quality CHARLES GUÉPRATTE Assistant General Director 16 ANNUAL REPORT 2012 / GUSTAVE ROUSSY serious medical conditions. The value of our expertise is demonstrated by our first partnership with a foreign hospital; a Gustave Roussy unit was established in Sharjah (UAE). Lastly, we must acknowledge the support of private enterprise, in particular donors and sponsors (companies) and associations. >>> >>> In a difficult financial context, and despite their own challenges, they maintained their financial support and solidarity. A. E. : Indeed, that is an essential factor. To develop our projects, we must further increase our resources. This is why we are going to continue to enhance our expertise, both in France and on the international scene. After Sharjah, we are planning to sign new agreements with other hospitals or Cancer Institutes abroad. We also wish to position ourselves to win tenders, in the framework of the “Big Loan” (for France), and the “Horizon 2020” program at European level. What is the current state of cancer research and what are your plans in this field ? ÉRIC SOLARY : The progress in DNA sequencing has given us a more precise knowledge of tumour cells’ genetic anomalies. Moreover it has been demonstrated that novel agents for immunotherapy seem quite effective in treating cancer. Further, a considerable number of new drugs with various mechanisms of action have come onto the market. These advances signify a breakthrough in research and care. The priority areas of research at Gustave Roussy are: precision medicine which takes into account the patient and their tumour’s genetic specificity; immunotherapy; DNA repair; haematology and stem cells. Pr ALEXANDER M.M. EGGERMONT General Director A. E. : These four priorities are at the very heart of our research programs, launched in January 2013. Completed by a medical-economic analysis, they strengthen our project which was supported by the large fundraising campaign, “Révolution Cancer”, initiated in 2010. Each theme mobilises basic, translational and clinical research groups and integrates studies of different types of tumours, whether common or rare. New research teams have been established and others will be set up during the next five years. >>> Pr ÉRIC SOLARY Research Management ANNUAL REPORT 2012 / GUSTAVE ROUSSY 17 MANAGEMENT BOARD INTERVIEW Massive investments in the fight against cancer.” >>> The ICRS award (the integrated cancer research site) for our SOCRATE program strengthens our position: we employ an integrated approach to treating cancer which combines research, clinical trials and care. E. S. : Further efforts should enable us to better understand the wide variation of tumours and the mechanics of genetic mutations. Clinical trials are also necessary to validate the concept of precision medicine by achieving the right combinations of drugs, in particular, and eventually try to implement these advances in the early screening stage and personalised preventions. 18 ANNUAL REPORT 2012 / GUSTAVE ROUSSY Pr ÉRIC SOLARY Research Management Will Gustave Roussy continue to invest in equipment? C. G. : The research programs which Alexander M.M. Eggermont and Éric Solary have just spoken about are themselves accompanied by investments in cutting-edge equipment and the development of technological platforms. The Scientific Project Management (SPM) Unit has been created to bring together the Research Management, those in charge of large research programs, the Director of Human Resources and the Activity and Finances Management. This unit validates each research program’s financial commitments, with regard to equipment in particular. In a larger context, Gustave Roussy invests each year to renew its materials and d to ensure tha that it remains at the forefront of technologyy. So, in 2012 an MRI machine was replaced, a new scanner was installed and the Novalis TX, a new and high-precision radiation machine, went into service, thus enabling us to upgrade radiation therapy services. It is our 7th acceler erator, and we intend to purchasse yet another one in the years rs to come. E. S. : To conclude, I would like to highlight the major interest of another project, carried out in conjunction with the Curie Institute: the construction of a 5,000m² building at Villejuif, dedicated to preclinical research. This building will be part of the e large national research facilities ities in France. How would you summarise Gustave Roussy’s strategy in the coming years ? A. E. : In the Institute’s guiding principles, you find a major objective which is shared by all three of us, and by all employees: pursue a strategy centered completely on the patient. One of our priorities is to offer the patient the very best technological platforms in imaging, radiotherapy and in sequencing and other cutting edge diagnostic procedures, with as much comfort as possible. We are going to continue to invest in Pr ALEXANDER M.M.EGGERMONT General Director these fields, hoping that we can quickly transform the most advanced technologies into new standards. Of course we will continue further integration of our significant commitments to basic, translational and clinical research with treatment programs, both in the domain of common and rare cancers. We are planning to further increase clinical trial activity, especially in the field of early drug development. On the international scene, as Charles Guépratte mentioned, our objective is to valorise our expertise and expand our partnership strategy. Gustave Roussy is an Institute that benefits from its territorial development as well as its international scope. These two dimensions are combined in a project which is ongoing at an urban campus – the Cancer Campus – which federates, inside a bio park, activities in research and in health innovation, with numerous partners like the AH-HP and both public and private research institutions. Gustave Roussy and the Cancer Sciences School, which is linked to the Medical Faculty of the Université Paris-Sud, is at the heart of a network which has both a local and a global dimension, bringing together cutting-edge expertise, a wide range of skills, modern tools and committed teams: it is an excellent combination to improve patient care. CHARLES GUÉPRATTE Assistant General Director ANNUAL REPORT 2012 / GUSTAVE ROUSSY 19 See further A GLOBAL PROBLEM_22 A GLOBAL MEMENTUM_24 THE SCIENTIFIC PROJECT CANCER CAMPUS_25 THERAPEUTIC INNOVATIONS _26 PRECISION MEDICINE_28 SEE FURTHER THE FIGHT AGAINST CANCER, A GLOBAL PROBLEM According to the latest WHO report, approximately 13 million new cases of cancer are recorded each year throughout the world. Thanks to the research conducted, increasingly innovative therapies are proven to be effective. A BETTER UNDERSTANDING OF THE DISEASE The considerable achievements of the research projects conducted over the past few decades have given us a better understanding of the causes and development stages of different types of cancer and how best to treat them. The transformation of a healthy cell into a tumour cell is a process involving several stages. The shift from a precancerous lesion to a malignant tumour is the result of interactions between genetic factors, which are specific to the patient, and external elements. The latter are divided into three categories: physical carcinogens (e.g: ultraviolet radiation, ionising radiation…), chemical (e.g.: asbestos, elements resulting from tobacco smoke, aflatoxin, arsenic…) and biological (e.g.: infections caused by certain viruses, bacteria or parasites…). Another crucial parameter is ageing. Cancer incidence increases with age, no doubt due to the accumulation of specific risks throughout a lifetime, in combination with a loss of effective repair mechanisms. AN INCREASINGLY PRECISE CHARACTERISATION The fight against cancer involves prevention, early detection, disease management and research. With early detection and adequate treatment, the chance for cure is high for many types of cancer, in particular some of those which are the most widespread (breast cancer, cervical cancer, oral cavity cancers and colorectal cancer). Cancer treatment involves commonly a combination of one or more types of treatment – surgery, radiotherapy or chemotherapy. The aim is to cure the disease or to considerably prolong the patient’s life while also improving his quality of life during the treatment period and the “post-cancer” stage. Another component currently is the in-depth study of molecular characteristics of both the patient’s genetic constitution and the abnormalities of his tumour. Cancer research, in developed countries, has changed in dimension. Technological advances allow an increasingly precise characterisation of tumours. In clinical research, new drugs and new therapeutic approaches are shown to be effective each year. Molecular medicine, also known as personalised medicine or precision medicine, has opened up significant new possibilities. Finally, immunotherapy has recently become a very promising field to be explored in depth. For Gustave Roussy, pain management, psychological support, accompanying activities and palliative care are now crucial elements of treatment planning. The basic research conducted at the Institute has, in particular, enabled new mechanisms to be discovered which allow the cell to repair its DNA. In translational research new genetic, hereditary or acquired, mutations which are predisposed to the development of cancer have been discovered these past years. 22 ANNUAL REPORT 2012 / GUSTAVE ROUSSY CANCER WORLDWIDE 5 RISK FACTORS CAUSE ALMOST 1/3 OF THE DEATHS 13% global mortality rate 13 million 50% new cases per year of patients diagnosed with cancer will be alive in 5 years Smoking 22% of the mortality by cancer 38% will be cured MAIN TYPES OF CANCER IN THE WORLD High body mass index 6% —Breast 458,000 deaths 9.1% — Liver 695,000 deaths 8% — Colorectal 608,000 deaths 9.7% — Stomach 736,000 deaths Low fruit and vegetable consumption 18% — Lung 1,370,000 deaths 7.6 6million 49.2% — Other types of cancer 3,733,000 deaths deaths per year Lack of physical exercise 27% Only of low-income countries have plans to combat cancer that have been allocated a budget 2/3 More than of the deaths occur in developing countries Alcohol consumption Source: WHO – Last report GLOBOCAN. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 23 SEE FURTHER A GLOBAL MEMENTUM BUILD A LEADING GLOBAL CANCER RESEARCH CENTER Gustave Roussy’s dynamism on the international scene is illustrated by the influx of international patients, the export of medical and medico-technical expertise and know-how as a high value French product, as well as by the commitment to its prestigious academic partnerships. A GUSTAVE ROUSSY UNIT IN THE UNITED ARAB EMIRATES The Institute is deploying a unique global strategy which has already borne fruit by the signature of a cooperation agreement for the founding of a breast cancer unit in Sharjah (United Arab Emirates). Jointly piloted by the Sharjah University Hospital and Gustave Roussy, this multidisciplinary unit, designed on the basis of the model as used at Gustave Roussy, aims to propose at all stages a coordinated model treatment plan to patients. It covers the quick diagnosis of breast lesions, the elaboration of treatment plan, breast cancer surgery – including oncoplastic surgery – and chemotherapy or other systemic therapy, in particular outpatient treatment. Intended to last 5 years, the unit will receive regular visits from one of Gustave Roussy’s medical teams specialising in mammary pathology. Other cooperation projects are ongoing, in particular in Kuwait and Kazakhstan. Depending upon the geographical location, they are concentrated on the creation of specific specialized structures (for palliative care, skin cancer, sarcoma…), operational planning, treatment planning, and also on teaching programs in various oncologic disciplines and clinical research. * Signature in effect from the 31st March 2013. 24 ANNUAL REPORT 2012 / GUSTAVE ROUSSY ACCESS TO TREATMENT… BEYOND BORDERS Gustave Roussy has always embraced a tradition of welcoming foreign patients who have serious medical problems. In order to facilitate their treatment and take cultural differences into account, an international unit was created in 2011. A total of 900 patients from abroad came to the Institute in 2012 (5% of its global activity). For Gustave Roussy, this activity provides additional revenues, which have allowed it to invest in the acquisition of new cutting edge equipments. EXCELLENCE IN ACADEMIC PARTNERSHIPS Gustave Roussy has a strong tradition of sharing its knowledge and practices with the international medical and scientific community. The third priority of international development, the partnerships with foreign centers, allow for the process to be accelerated, for the benefit of patients. One such example is an agreement signed with DKFZ, the largest cancer research center in Europe (Heidelberg, Germany). With Gustave Roussy, complementarity is built around 4 programs: paediatric oncology, molecular epidemiology, immunology/ immunotherapy and personalised medicine. Seen in the light of “Horizon 2020”, the future European research programs (and its financing), setting up this French/German partnership takes on a true significance. Other recent partnerships include: those nurtured with the Erasmus University Medical Center (Rotterdam) concerning RAMAN spectroscopy – an innovative method to the invasive border of tumors and to diagnose pigmented lesions and melanoma, also with the Karolinska Institute, the NKI (Amsterdam), the MD Anderson Cancer Institute (Houston), and cofounder with Gustave Roussy of the WIN Consortium. CANCER CAMPUS: A RESPONSE TO ACCELERATE INNOVATION IN CANCER RESEARCH GUSTAVE ROUSSY AT THE CENTER OF A TERRITORIAL, MEDICAL AND SCIENTIFIC PROJECT Launched in 2006, Cancer Campus aims to develop a center for research and innovation at Villejuif. Its objective will be to create a biocluster, dedicated to the fight against cancer, of international stature. T back to 2006 when Cancer Campus was founded with the idea of creating, around Gustave Roussy, a scientific campus open to companies specialising in life sciences and health innovations, around a common basic infrastructure for research and training: laboratories, biotech companies, imaging, medical engineering and systems, cutting-edge IT and telemedicine. In November 2011, the Bio Park was inaugurated at Villejuif, the first step in the creation of the Cancer Campus project. The metro station Gustave Roussy on line 15 will become operational in 2020 and will intersect with line 14 (Orly Airport – Gare de Lyon) in 2027, which will place the Institute at the very center of Grand Paris. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 25 SEE FURTHER THERAPEUTIC INNOVATIONS, A CLINICAL RESEARCH STUDY OF GLOBAL SCOPE As the leading center for clinical research in oncology with 24% of its patients included in biomedical studies, Gustave Roussy is amongst the top 10 worldwide leaders in the field of conducting early therapeutic trials, a feat well recognised by the ASCO (American Society of Clinical Oncology) congress program committee in 2012. T plemented at Gustave Roussyy are mainly conducted in the field of drug development, imaging guided. AUGMENT NEW DRUG DEVELOPMENT PROGRAM The research done with regard to drugs can be divided into two areas: early testing (phases I and II) and advanced trials (phases II randomised and III). “Worldwide, the Institute is one of a handful of establishments which are capable off implementing useful precision medicine, that is, integrating not only molecularr analysis of the tumour, but also recommending, accordingly, a drug which is adapted to its particular characteristics”, emphasizes Professor 26 ANNUAL REPORT 2012 / GUSTAVE ROUSSY Jean-Charles So Soria,, h head ad o of the De Department o of therapeutic innovations novati and d early clinical trials. tria INTENSIFYING RESEARCH In 2012, the phase I & II clinical trial activity confirmed that Gustave Roussy is the leading center in France for early therapeutic innovation. With 57 phase I-II trials involving 524 patients, Gustave Roussy carried out more than half of all such activities in the 16 approved units for such studies in France. These trials are either trials conducted on all types of tumour, tumour-specific trials, haemato-oncology trials, or trials with new drugs associated with radiotherapy. The clinical drug development unit was extended 3 PHASES FOR THE CLINICAL TRIALS OVER 5 YEARS In a randomised trial, the participants are divided randomly between two treatment arms. PHASE I - II RANDOMISED PHASE II 100 to 300 patients 200 to 400 patients with additional beds in 2012 and will become a separate medical department in 2013. “Setting up a department dedicated to therapeutic testing not only reflects the importance of early testing in clinical research at Gustave Roussy, it also bears witness to a strong desire to strengthen bonds with trial implementers, ‘organ’ committees as well as the research teams and platforms”. Professor Jean-Charles Soria continues: “in particular, we are participating very actively in the development of a new class of inhibiting agents, called FGFR, and Gustave Roussy is the only center in the world to have at its disposal their entire spectrum.” PHASE III 500 to 2,000 patients EVIDENCE OF PROGRESS BY RANDOMISED TRIALS (phases II randomised, and III) A hallmark of 2012 was the reporting by Gustave Roussy Investigators on a number of major advances in the development of new immunotherapies for melanoma, therapeutic strategies for testicular cancer, personalised treatments for thyroid cancer and post-operative lung cancer at the ASCO annual meeting in Chicago in 2013. Innovations ON DIFFERENT FRONTS The therapeutic innovations developed by Gustave Roussy touch on numerous fields including: microwave technology which destroys tumours (alternative to surgery); the development of new and high-precision radiotherapy technologies reducing secondary effects, and so-called “all-in” surgery (complex surgical interventions that can take up to 16 hours and involve a large medical team with several surgeons). ANNUAL REPORT 2012 / GUSTAVE ROUSSY 27 SEE FURTHER PRECISION MEDICINE, A PERSONALISED APPROACH TO CLINICAL REALITY Personalised medicine, a major aspect of the Institute’s strategic project, made significant progress in 2012. Studies conducted by Gustave Roussy demonstrate that highthroughput analysis technologies which identify molecular anomalies particular to a tumour, are now no longer reserved for basic research and can be transferred to clinical practice. Making tomorrow’s treatments available to a growing number of patients is becoming a reality. study of personalised medicine used against breast cancer, promoted by UNICANCER. These studies confirm that precision medicine may well play an important role in the future, and affirm that Gustave Roussy is at the forefront in this field, internationally. S tandard therapeutic approaches have resulted in todays situation where one out of every two cancer patients still dies as a result of his cancer. The aim of personalised medicine is to identify the anomalies proper to each tumour and then to develop tests for detecting them; patients identified as carrying the anomaly can then be prescribed specific and targeted treatment. Recently, important technological advances have allowed the implementation of this innovative approach in clinical practice. Gustave Roussy has created all necessary infrastructure and developed a number of clinical trials in this domaine: promising results across two major studies, in particular: MOSCATO, promoted by Gustave Roussy, and SAFIR 01, a prospective SOCRATE THREE RESEARCH PROGRAMMES FOR FUTURE CANCER STUDIES Gustave Roussy was awarded the accolade “IRSC” (Integrated Research Site for Cancer) by the National Cancer Institute, in reference to its SOCRATE* project. One of the SOCRATE programs concerns primarily personalised medicine. * Stratified Oncology Cell DNA Repair And Tumor immune Elimination. To find out page 40 28 ANNUAL REPORT 2012 / GUSTAVE ROUSSY MOSCATO: ENCOURAGING RESULTS The MOSCATO trial covers a large variety of tumours, including: lung, head and neck, urogenital, cervical and gastro-intestinal cancers. Presented at ASCO’s 49 th annual meeting, MOSCATO uses high-throughput genomics as a decision-making tool for targeted molecular treatments. Specifically, this trial accrued 129 patients in nine months: in 112 a biopsy of their tumour was obtained.To analyse the tumour DNA and to spot the point mutations and chromosome aberrations, two technologies were used: sequencing, using a new-generation high-throughput sequencer and comparative genomic hybridization. A therapeutic target could be identified for 53 of the patients (47%), of which 33 received a treatment adapted to their molecular anomaly. Seven partial responses to the treatment were observed, corresponding to a response rate of 21% which is higher than the classical response rate for phase I trials (5 to 10%). More and more patients are being SAFIR 01 Targeted therapies for breast cancer thanks to molecular diagnosis brought in to MOSCATO, in order to confirm initial results: the goal is to enlarge the trial to cover 900 patients. ALGORITHMS AND NEW GENERATION TRIALS Work is currently ongoing concerning decision-making algorithms. The goal is to create an intelligent database, populated by billions of patients, in order to be able to form the best treatment plans for each of them. With this in mind, the bio-computing center has been bolstered by recruiting international-level researchers and purchasing some new equipment; these have all been brought together in the brand new molecular medicine building (building works started in 2012 and were completed in June 2013). WINTHER AN INNOVATIVE CLINICAL TRIAL Launched in 2012, Winther is a clinical, academic and international trial coordinated by Gustave Roussy. It is the first clinical trial to propose, to all patients in the study, a choice of therapies, guided by personalised biological analysis. Each of them is offered a personalised treatment which has been based on a complete biological analysis. A double biopsy of the tumour and of healthy tissue of the organ of origin is taken from each patient, while the complete genomic characteristics of the tumour, modulated by those of the healthy tissue, guide the choice of therapy which is discussed with the aid of a bio-computing decision-making tool. The main objective is to compare the progression-free survival when a treatment suggested by biology is used, to the progression-free survival when the last standard treatment is prescribed. The European Community has provided a subsidy to support this trial. This acknowledgment by Europe is a measure of the Winther trial’s scientific value – in particular, its concept and methodology. SAFIR 01 is a large prospective study in metastatic breast cancer patients where the choice of therapy is determined by a genomic profile of a biopsy of a metastasis. The objective is to identify a gene anomaly for which there is a “targeted” drug available, or being developed, which will act specifically on the cells which contain this anomaly. The study, conducted by the institute, reveals that genomic profiles can be prepared daily and on a large scale in clinical practice, and demonstrates the importance of molecular diagnosis for directing patients to targeted treatment. It is an important step in the implementation of personalised medicine. In addition, gene sequencing allows for a better understanding of the metastatic process. The researchers are pursuing their work with the launch, in 2013, of SAFIR 02, which aims to prove the effectiveness of personalised medicine in cancer treatment for patients affected by lung or breast cancer. The preliminary results of SAFIR 01 in 2012 were promising and considered to be a major achievement at the ESMO (European Society for Medical Oncology) congress. Following their updated presentation at the 49th ASCO congress, SAFIR 01 was chosen for the “Best of ASCO, ground-breaking studies” award. 25% of the patients present signs of effectiveness ANNUAL REPORT 2012 / GUSTAVE ROUSSY 29 Act on... CARE_32 RESEARCH_38 TEACHING_42 FUNDRAISING_46 ACT ON CARE GIVING PATIENTS THE BEST CHANCE Providing quality patient care is Gustave Roussy’s primary mission, and this consumes much of resources. Each day, teams of doctors and care-givers devote their energy to consultation, diagnosis and treatment of adults and children. T welve clinical and medical-technological departments and fourteen multidisciplinary committees comprised of surgeons, medical oncologists, radiotherapists, radiologists and pathologists specialising in organ pathology, work together every day to provide optimal care. Cutting-edge technology, laboratories and integrated research teams allow new therapies to be proposed, and adapted, thereby offering patients realistic chances of recovery. Special remedies are employed in complex cases and for rare tumours – pathologies which make up 20% of its activity – and the Institute welcomes all types of patients and treats all types of cancer. CARE ACTIVITIES IN 2012 For the third consecutive year, Gustave Roussy saw an increase in activity, as a result of a concerted effort from all of the Institute’s teams. The number of patient consultations increased by 1.3% (on 2011) with an increase of 4% in hospitalised patients (an increase of 5,688 patients). With regard to hospitalisation services, the overall occupancy rate – another key indicator for care activities – went up to 90% in 2012 (88% in 2011). Some departments saw a significant increase in activity, the fruit of new approaches employed with regard to patient care. For example, the ambulatory care activity exceeded the yearly targets and has increased by 6% with 2,238 additional hospital visits; this increase is slightly greater for some of the other departments including: the medical oncology department (+5%), outpatient surgery (+6%) and outpatient imaging (+29%). Full hospitalisation activity is in line with objectives, with a growth of 2%, reaching 11% in cervical-facial oncology, 3% in medical oncology and 9% in radiotherapy hospitalisation. PATIENTS ADMITTED TO HOSPITAL BY MALIGNANT TUMOUR SITES DISCUSSED BY EACH TUMOUR BOARD Breast 23.7% Head&Neck 11.9% Digestive 10.8% Gynaecology 8% Skin 7% Haematology 6.7% Paediatric 6.6% Lung 6.6% Urology 6.3% Thyroid and neuroendrocrine 4.7% Sarcoma and mesenchymal 4.2% Neurology 1.8% Early clinical trials across tumor types 1.2% Others 0.6% 32 ANNUAL REPORT 2012 / GUSTAVE ROUSSY The activity of interventional radiology (medical imaging) increased by 7.4%, while the number of patients and conventional radiology interventions increased slightly. The total number of procedures completed increased by 4%. >>> 90% (88% in 2011) A positive development in the hospitalisation services occupancy rate. >>> increase of 16.7% in procedures completed, due to an increase in the number of psychologist consultations (+23.1%) and follow-ups with a care provider (+45.8%). Medical nutrition consultations rose by 24.8% and dietician consultations by 37.5%. AN INNOVATIVE TECHNOLOGICAL PLATFORM FOR CARE SERVICES 2012 saw a number of major investments to keep up to date with the developments in technical equipment. The diagnostic imaging platform received new, sophisticated equipment beginning with the acquisition of a second scanner, a best-of-class model featuring dose-reduction algorithms and a module for spectral and monochromatic analysis, to obtain perfect organ contrast. In September 2012, a new MRI scanner was also put in operation, replacing the MRI 1.5T installed in 1998 and revamped in 2005. The new MRI has a magnetic field of 3 Tesla and a 70cm opening tunnel. A second examining table has also been purchased, so that children can be sedated and heavy patients resuscitated. Other investments have also been made throughout 2012 – in particular, thanks to gifts and bequests: 1 Gamma Camera Discovery NM 630 and 1 Solution Rapid-Arc for the Novalis radiotherapy machine. INNOVATIVE TECHNICAL PLATFORMS • 14 operating theatres • The largest interventional radiology suites for oncology in Europe • 1 MRI • 2 scanners • 10 ultrasound scanners • 2 gamma-cameras • 6 external beam accelerators • 1 Novalis TX radiotherapy accelerator 2012 ACTIVITY • Number of patient consultations: +1.3% • Number of hospitalised patients: +4% • Ambulatory activity: +6% • Overall hospital activity: +2% • Interventional radiology activity: +7.4% • Supportive care: +16.7% To find out gustaveroussy.fr heading : annual reports AN ORGANISATION TO HEIGHTEN PERFORMANCE: OBJECTIVES AND MEANS CONTRACTS (O.M.C) Following a trial period in two departments – Medical oncology and Radiotherapy – that is currently being implemented, internal contractualisation reached an important milestone in 2012 with a number of departments drafting their own multi-year Contracts defining objectives and means. By these contracts, each party – clinical and medico-technological departments on the one hand and general management on the other – undertakes to implement a three year departmental project, setting out the establishment’s strategy. This method of contractualisation entails setting up a special body to manage means and take related decisions. This method results in better management of the actual situation on the hospital floor, since the necessary applications are implemented with the contractualisation support service. In 2012, there were six professionals appointed to delegated management positions for the twelve departments. One of the benefits of these contracts is that they improve patient service. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 33 ACT ON CARE RECONCILING CUTTING-EDGE MEDICINE AND CARE: “CARING DIFFERENTLY” Gustave’s Roussy’s teams of doctors and care-givers ensure that patient care always integrates the treatment of the cancer, the particular characteristics of each pathology and of each patient as a person. This way of thinking is reflected in the considerable progress that has been made in the very nature of the care – programs for teenagers and young adults, same-day diagnosis – as well as in the patient’s physical, psychological and social quality of life. SUPPORTIVE CARE, ANOTHER PILLAR OF THE CARE PROVIDED AT GUSTAVE ROUSSY The Department of Supportive Care coordinates all the care intended to improve the patients’ quality of life during the treatment and “post-cancer” phases: pain management, psychological consultations and palliative care. Adopted in 2012, the “Living with Cancer” program completes the Supportive Care program and offers less conventional therapies based around four aspects of care: well-being and self-perception (relaxation, aesthetic care), artistic and cultural aspects (music, poetry), adapted sports activities. The activities implemented in the context of the “Living with Cancer” program contribute to improving 34 ANNUAL REPORT 2012 / GUSTAVE ROUSSY one’s bodily image, damaged by illness and treatments, and can restore the patient’s self-confidence. These aspects form part of the overall personalised care provided by the teams at Gustave Roussy. They illustrate the “tailor-made” nature of patient care which is considered to be so fundamental at the Institute. A PROGRAMME FOR ADOLESCENT PATIENTS AND YOUNG ADULTS In 2012, Gustave Roussy celebrated the 10th anniversary of the “Teenagers and Young Adults” program, which is dedicated to the specialised care provided for teenager and young adults with cancer. At the pivotal age of 13-25 years old, these patients don’t always have the same likelihood of post-cancer recovery or life quality, depending on whether they are treated in the adult oncology or the paediatrics departments. This program provided by Gustave Roussy relies on a mobile transversal team placed under the medical responsibility of a paediatrician and an adults’ doctor. It aims to provide equal access to care, a good quality of life during and after the disease and access to research protocols in order to improve the chances of recovery. Adolescents are hospitalised in a dedicated unit within the Adolescent and Child Cancer Department. The young adults are cared for within the Medical Oncology Department, with a relaxation area reserved for them. >>> >>> This is completed by a job-search program for 15 to 25 year olds, an important step in helping them overcome the physical and psychological effects of cancer. This initiative is innovative: no other center provides such care in France. Around 245 young cancer patients are monitored each year by Gustave Roussy; 80 of these are new patients. SAME-DAY DIAGNOSIS AND FAST-TRACK PATIENT CONSULTATIONS In 2004, Gustave Roussy was the first center in France to introduce patient consultations which diagnosed breast cancer in a day. Since then, the Institute has extended this Anglo-Saxon model to other types of cancer: cancers with a long latency period between first diagnosis and treatment. Time is of the essence in such cases and a delay between the diagnosis and the start of treatment can be crucial. These same-day consultations are currently offered for breast cancer and three other types of cancer: thyroid tumours, ovarian tumours and sarcomas. The Institute has introduced thyroid cancer diagnosis morning sessions for patients with nodules, during which all the tests necessary for the diagnosis are carried out (neck ultrasound, biopsy, blood test and, if necessary, thyroid scan). If necessary, this is followed by a meeting with a surgeon and a date may be set for the operation. In 2012, there were 8 to 10 such consultations each week. A consultation with a gynaecological surgeon is also available for suspicious ovarian tumours: blood test, meeting with a surgeon and then with an anaesthetist, meeting with a dietician and a nutritionist, pelvic or colposcopy MRI scans. >>> ANNUAL REPORT 2012 / GUSTAVE ROUSSY 35 ACT ON CARE >>> There are many steps that can lengthen the diagnostic pathway and delay diagnosis and, ultimately, have an impact on prognosis. Gustave Roussy, one of three national reference centers for sarcoma care, has eventually introduced an initial one-day consultation for suspicious tumours. This allows patients to be diagnosed and receive tailored care: liver biopsy using ultrasound or scanner and assessment. As a result, the risk of relapse for abdominal sarcomas can be halved, and reduced to less than 10% for limb sarcomas, with only a 1% risk of amputation in the reference centers. In 2012, more than 500 new patients underwent these multidisciplinary sarcoma consultations, putting the Institute amongst the five most active centers worldwide in this area. FOREIGN PATIENTS: A TRADITION OF WELCOME AND ACCESS TO CARE Patients coming from abroad have been welcomed at the Institute since the international unit was founded in 2011; in 2012 almost 900 foreign patients were treated, representing approximately 5% of the Institute’s activity. These foreign patients, attracted by the high quality care, have serious medical conditions requiring most often complex cancer treatments. They come to the Institute for medical care far superior to that which they are offered in their country of origin. KEY CARE UNIT FIGURES • 47,000 patients of which 11,400 first visits • 200,000 consultations • 356 hospital beds • 88 outpatient places • 42,000 ambulatory visits • 12,700 surgical procedures • 7,200 radiotherapy sessions per year • 75,000 chemotherapy preparation sessions 36 ANNUAL REPORT 2012 / GUSTAVE ROUSSY CARE HIGHLIGHTS 2012 THE FRENCH NATIONAL AUTHORITY FOR HEALTH Gustave Roussy received the V2010 certificate, in recognition of the quality and security of health care provided. This award caps a long process that commenced in 2010. FOUNDING OF THE THORACIC ONCOLOGY INSTITUTE GUSTAVE ROUSSY QUALIFIED for the “Culture Culture and Health” He label, launched by the French Regional al Health Agenc Agency and the General Management of Cultural ral Affairs, to en encourage the use of art in hospitals. GUSTAVE ROUSSY’S HEALTH PROFESSIONALS are trained in therapeutic education, defined as all the advisory and learning activities which engage patients and help them live better with cancer. Therapeutic education is a national priority which has been integrated into the Hospital, Patient, Health and Territory Law 2 and is also included in the Institute’s mission statement. at the initiative of Gustave Roussy and the Marie Lannelongue Surgical Center. It will be a first in France, and the objective is to offer a comprehensive care service to patients with thoracic cancers. THE CHILD AND TEENAGER CANCER DEPARTMENT restructured its department, one aspect of which involves outreach procedures aimed at getting parents and volunteers involved. The goal is to create a structure tailored to young patients with long-term monitoring. In order to finance the works, a fundraising campaign (Poussons les murs) was launched. The project starts in 2013. ELECTRONIC MEDICAL TREATMENT RECORD, the treattment part of the Electronic Medical Record, entered the param meterisation phase. Shared tools which will improve data safety, y, coordination and the traceability. This major revamp of th he Institute’s computer systems is expected to be deployed ed in 2013. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 37 ACT ON RESEARCH PROMOTE RESEARCH AS A DRIVER OF INNOVATION Within Gustave Roussy, all the types of expertise necessary for developing cutting-edge cancer research are brought into play. They are based on the principle of integrated research which encompasses basic research, clinical research and, between the two, translational research. I t is the guarantee of continuity between research and care which favours diagnostic and therapeutic progress, as well as the efficient transfer of the fruits of progress to patients. Gustave Roussy’s research is organised around three elements: clinical research, accredited research (INSERM and CNRS units) carried out by IICRV (the Institute of Integrated Cancer Research at Villejuif), and the shared technological platforms. Researchers and clinicians work together to deepen their knowledge and implement therapeutic innovations which will be useful to patients. The research at Gustave Roussy is based around a number of strategic priorities. Included amongst these are: • personalised medicine (or molecular medicine), which aims to prove the effectiveness of the concept of biology and image-guided treatment; • early testing, to develop new anticancerous agents and their biomarkers; • tumour immunology and immunotherapy; • DNA repair; • haematology/stem cells; • health technology assessment (HTIA): with the goal of evaluating the psycho-social and mediccal-economical impact of innovations in cancer trea eatment. CLINICAL RESEARCH: PROMISING RESULTS With one in four patients included in a biomedical study in 2012, Gustave Roussy has become a national and international reference with regard to clinical trials. At the national level, only 11% of cancer patients are included in clinical trials and in many countries this percentage is only around 5%, Gustave Roussy registered a 25% inclusion rate in 2012, which was 10% more than in 2011. Thus 2,813 people treated for a malignant tumour at the Institute benefited last year from the most innovative diagnostic and therapeutic measures, and contributed to 322 biomedical research projects. This is a very significant figure, and it represents the willingness of the entire Institution to enable patients to benefit from the most promising strategies available. Gustave Roussy has boosted its ability to run its own trials (20% of studies) and attract industrial partners (accounting for 50% of studies). As regards organizing and running trials, the Institute demonstrated its abilities in 2012 by a number of striking results/achievements: • the ESTIMABLE trial led to improved care for thyroid cancer patients; • COU-AA-302, a large, multicentric international phase III trial (involving 151 centers in 12 countries) established the potential interest of a new drug associated with the common treatment of metastatic hormone refractory prostate cancer; • the MOSCATO trial, uses high-throughput genomics as a decision-making tool for targeted molecular treatment, has encouraging preliminary results, suggesting that high-throughput molecular analysis of tumour DNA can enable therapeutic targets to be repaired in almost 50% of patients. IMPROVE ACCESS TO INNOVATIVE MOLECULES Thanks to SITEP – renamed the Department of Therapeutic Innovations and Early Clinical Trials – the number of patients included in phase I trials has considerably increased (22% of trials) >>> 38 ANNUAL REPORT 2012 / GUSTAVE ROUSSY PLATFORMS >>> and Gustave Roussy has become a preferred partner for phase I trials involving both adults and children. In 2012, a total of 524 patients were included in the phases I and II trials, a welcome increase on 2010 and 2011, with just 216 and 316 respectively. One of Gustave Roussy’s missions is to offer patients, whose treatment has failed, fast access to promising drugs that have not yet received Marketing Authorization. Early testing is becoming an indispensable pillar for the implementation of personalised medicine. COMMITTING TO RESEARCH FOR PERSONALISED CANCER TREATMENTS The personalised medicine program – or molecular medicine – was launched to steer the use of innovative therapies by the analysis of biomarkers and images of the patient’s tumour. The Institute has made significant investments in this area in recent years, such as the construction of a new research building dedicated to molecular medicine, at a cost of €13.5 M, for current and future research teams. The construction of this building was launched in 2012. RESOURCES AVAILABLE FOR RESEARCH The development of platforms reflects Gustave Roussy’s desire to propose services shared by accredited research and clinical research, for medical-researchers inside and outside the Institute. The creation in 2012 of the Biocomputing platform and the developments to the imaging and cytometrics platform reflect this general movement. Biocomputing platform In 2012, the reorganisation of the bio-computing services made it possible to introduce new services such as analysing large volumes of data coming from next generation sequencing (NGS), which requires a major calculating infrastructure. Basic research groups, as well all the clinical trial investigators can use it, since the sequencing is carried out by the laboratory for translational research. Cellular imaging The imaging and cytometrics platform (ICP) at Gustave Roussy ensures that there is a link between basic research done on imaging and clinical application of this research: this is a rare asset. Equipped with more than fifteen latest-generation machines, this technological platform provides services in three main areas: cytometry (analysis and sorting of cells), cellular imaging (microscopy) and small animal imaging. In 2012, the platform participated in research projects aiming to provide a better understanding in real time of the mechanisms governing the development of tumours. In a larger sense, the platform is increasingly requested for basic, translational and clinical research program interface >>> developments. • 29 research groups across 13 units • 270 researchers: researchers, clinicians and post-docs • 300 ongoing clinical studies, of which more than 50 are supported by Gustave Roussy • More than 1,300 international scientific publications (125 IF>10) • €60 M funding from the Institute’s overall budget • More than €53 M funding from external resources • €50 M in research contracts ANNUAL REPORT 2012 / GUSTAVE ROUSSY 39 ACT ON RESEARCH >>> MAJOR RESEARCH PROGRAMS Three years of work were required to structure the main research programs which will, in part, shape the research plan at Gustave Roussy for the next five years. As with the “Révolution Cancer*” program, which has already raised almost €10 M through donations, these new programs finance the Institute’s main research priorities in a number of ways, and impact our momentum greatly. MMO The research topics of the program Molecular Medecine in Oncology cover personalised medicine, immunotherapy, Induced Pluripotent Stem Cells (IPS) – an alternative to embryonic stem cells – as well as the medico-economic study of personalised medicine. Costing €11.8 M, this project is piloted by Professor Éric Solary. Five new research groups and two extra technological platforms have been brought on board for this purpose. This program will improve the Biocomputing and genomics infrastructures. SOCRATE The NCI (National Cancer Institute: INCa) has awarded Gustave Roussy the title “ICRS” (Integrated Cancer Research Site “SIRIC”), for the SOCRATE project, and has allocated €3.35 M to it. This project aims to facilitate the transformation from empirical cohort medicine to biology-guided medicine. The first part, dedicated to DNA repair and to radiobiology, should enhance our understanding of the molecular medicine involved in maintaining genetic stability and allow the development of new diagnostic, prognosis and therapeutic tools. NEW BASIC RESEARCH GROUPS Starting in 2012, Natixis has committed, alongside Gustave Roussy, to support the creation and installation of three new basic research groups over three years. Thus in December 2012, the first team, headed by Dr Jean-Luc Perfettini, was established to research “Cell death and Senescence” linked to radiotherapy treatment. Two other groups were formed soon thereafter, headed up by Dr Fanny Jaulin, researching the causes of formation and dissemination of colon cancer metastases, and Dr Mehdi Khaled, specialised in melanoma research. 40 ANNUAL REPORT 2012 / GUSTAVE ROUSSY The second part concerns anti-tumour immunologyy and is expected to facility the development of therapeutic vaccinations, in particular. The final part is entirely dedicated to personalised medicine and individual treatments, according to the tumour’s molecular anomalies. “Fondation Philanthropia” Created by the Lombard Odier & Cie bank to facilitate private donations, the “Fondation Philanthropia” has decided to support innovative approaches in the fight against cancer by donating to 3 main programs run by Gustave Roussy: • €2.42 M over four years dedicated to the development of a biocomputing algorithm to help therapeutic decision-making in personalised medicine; • €1 M over four years for health technology assessments (HTA) regarding socio-economic aspects of cancer and the modelling of a new patient treatment plans adapted for more chronic cancer cases and adapted for the increase in personalised treatments; • €2 M allocated to the “excellent cancer path ‘Fondation Philanthropia’” implemented within the Cancer Sciences School, aiming to train ten young doctors or pharmacists in new clinical cancer jobs and cancer research. PACRI – Paris Alliance of Cancer Research Institute PACRI is one of two projects selected to as part of an investment in “University Hospitals for Cancer Centers” which aims to spawn international centers of excellence. PACRI favours new synergies between the actors of basic, translational and clinical oncology in the Paris region. By allowing the mutualisation of technologies and research platforms and encouraging an improved integration of genomics, epi-genomics and cellular biology data, this program will contribute to the assessment of new therapeutic plans to improve the patients’ quality of life throughout the treatment period. Gustave Roussy has contributed €2.5 M – out of a total of €10 M – to PACRI’s funding. >>> fundraising campaign “Révolution Cancer” which began in 2010 and will be completed in 2013. €5.4 M donated by the “Fondation Philanthropia” PATENTS Gustave Roussy’s patents: tomorrow’s care B >>> PARTNERSHIPS The fight against cancer involves a multidisciplinary and collaborative approach. Researchers, practitioners and industry have all partnered up with the Institute to develop new therapeutic strategies, focused on the patient. On the academic front, close links have been established in France with the Université Paris-Sud, and in particular with its Faculty of Medicine, the ENS Cachan, Génopôle d’Évry and the CEA (Atomic Energy Commissioner). In the context of Cancéropole Île-de-France – of which Gustave Roussy is a founding member –, healthy partnerships exist with AP-HP, the Curie Institute, IUH Saint-Louis and the Pasteur Institute. The same network dynamic exists on an international level, based around specific research programs: • The DKFZ (Heidelberg): for paediatrics/cerebral tumours, immunology, molecular epidemiology and functional imaging. • Erasmus University (Rotterdam): for the RAMAN spectroscopy program. • The MD Anderson Center (Houston): for the WINTHER trial in personalised medicine. y regularly registering new patents through its subsidiary company “Gustave Roussy Transfert”, the Institute transforms its research into breakthroughs benefiting its patients. In 13 years, Gustave Roussy Transfert (which used to be “IGR&D”) has registered more than 130 patent families worldwide: biomarkers, molecules, medical apparatus, therapy procedures, software… The 2012 “vintage” has turned out to be very rich, especially in three thematic areas: immunogenic cell death (stimulation of the immune system to help destroy tumours), circulating tumour cells (cells detached from primary tumours, which are then tracked, allowing the cancer to be characterised and the treatment validated) and cellular cannibalism (an elimination mechanism which could be used to neutralise tumours using healthy cells). Gustave Roussy Transfert is also involved in the industrial implementation of these findings. For that, the entity explores and communicates these patents (through publications, conferences, direct contact…) in order to encourage industrial partners to develop and commercialise the technologies which will be used in tomorrow’s cancer studies. The royalties from these patents are then returned to the inventors and to the research labs. The fight against cancer requires a considerable amount of scientific research, which itself implies partnerships with pharmaceutical companies or other private businesses. Based on the translational research concept, public-private partnerships guarantee the continuity between research and care, so that therapeutic innovations can be of direct benefit to cancer patients as quickly as possible. In April 2012, Gustave Roussy and Sanofi announced a partnership for clinical research, destined to facilitate access to new drugs inspired by the “molecular portrait” of the patients’ tumours. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 41 ACT ON TEACHING THE CANCER SCIENCES SCHOOL ANTICIPATES THE REVOLUTIONS IN CANCER STUDIES Along with Treatment and Research, Teaching is one of Gustave Roussy’s three core missions. Sharing knowledge and training in cancer professions is deeply anchored in the Institute’s culture; this takes place at the Bicêtre Faculty of Medicine at the Université Paris-Sud. C reated in 2012, the Cancer Sciences School brings together Gustave Roussy’s teaching activities and the Université Paris-Sud. An essential actor in cancer training at the university, 90% of the teaching is provided by highly-qualified teaching staff who carry out their clinical activities and research at Gustave Roussy, as well as numerous other teachers from the Faculties of Medicine, Pharmacy, Sciences and Law-Economics-Management at Paris-Sud, the top-ranking university in France. 42 ANNUAL REPORT 2012 / GUSTAVE ROUSSY The objective is to train 500 new professionals per year (doctors, pharmacists, nurses, researchers, scientists, engineers, care givers), in degree programs or training which leads to a qualification but not a degree. Equally, creating new professions in various areas, from basic and clinical research to care and the accompaniment of ill people, is considered important and is in line with the Cancer Plan. Faced with unprecedented therapeutic innovations, the Cancer Sciences School is developing a new teaching model based on the principles of cancer care: global, transversal and multidisciplinary. The teaching courses comprise several components: • theoretical: physical or virtual classes; • practical: immersion in the clinical departments or laboratories, online seminars; • contributive: sharing experiences, contributory online sessions, constructive. >>> “FONDATION PHILANTHROPIA” “Path to excellence in cancer studies” >>> The Cancer Sciences School complements the Faculty of Medicine and Gustave Roussy’s system of training, by bringing together the majority of academic and clinical research conducted at the Université Paris-Sud, in collaboration with the regional, national and international networks already in place. EDUCATION The school for learning The acquisition of oncology expertise is the result of an education mixing theoretical knowledge with clinical practice or research. The lectures and accompanying tutorials form the foundations of the Cancer Sciences School. The e-school for sharing Digital technology has provided opportunities for enriching learning tools and consolidating knowledge acquired through e-learning, social network skills and the exceptional Images Center which includes rooms equipped with networks, medical imaging networks, databases of molecular, tissue and dermatological pictures, and video, computer graphics and illustration databases. The d-school for innovating Oncology is a science marked by recent breakthroughs and huge possibilities. The Cancer Sciences School contributes by organising the conditions of co-creation which allow students, teachers and patients to collectively imagine new solutions for training and teaching. >>> A t the end of 2012, the program “Path to excellence in cancer studies – ‘Fondation Philanthropia’” was founded, with the intention of training ten future talents in worldwide cancer studies. The project, to which the “Fondation Philanthropia” has contributed €2 M, aims to trains ten young doctors or pharmacists possessing considerable potential, in the innovations and new professions of clinical cancer studies and research. More specifically, a dual degree will be created at the Cancer Sciences School -Université Paris-Sud and Gustave Roussy, offering ten student interns tailored training as part of a science thesis aimed at scientific innovation and research in cancer studies. The training, which will be both theoretical and practical, will take place at Gustave Roussy, with individual coaching by a senior doctor or researcher at the Institute. During their thesis, the interns will familiarise themselves with personalised medicine. From October 2013, these new PhD students will attend the Doctorate School of cancer studies, which is part of the Cancer Sciences School, and which welcomes more than 200 PhD students in a three-year cycle. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 43 ACT ON TEACHING TRAINING HIGHLIGHTS 2012 CREATION OF A DOZEN MASTER’S CLASSES for industrial health managers. CREATION OF TWO UNIVERSITY DEGREES “Coordination in establishments and networks in cancer studies” and “economic assessment of health products”. DEVELOPMENT OF E-LEARNING MODULES • in interventional radiology, • in intensive and acute care, • in oncology/haematology. DEVELOPMENT OF MASTER’S • in Clinical Sciences, • in Cancer Care. DOCUMENTARY RESOURCES ↗ Access to more than 4,800 medicine, science and technology publications online ↗ More than 400 e-books ↗ Bibliographic databases: PubMed, Medline, Scopus, ISI Web Of Knowledge, Faculty of 1000, Cochrane Library ↗ Collection of video documents for surgery, radiotherapy and cancer which can be watched onsite 44 ANNUAL REPORT 2012 / GUSTAVE ROUSSY ACCESSIBILITY BY EXTRANET at the medical and scientific library. IMMEDIATELY OPERATIONAL FOR STUDENTS: A REGULAR ASSESSMENT OF THE RESOURCES SYSTEM FOR TEACHING RESPONSIVE TO NEEDS IN NEW CANCER PROFESSIONS DISSEMINATE NEW KNOWLEDGE AND PRACTICES Personalised medicine Center of knowledge in cancer sciences Home support for patients Modelling new professions Pharmaceutical industry First-aid training specific to cancer TEACHING RESOURCES 40 2,800 and Master’s classes (nurses, engineers, researchers and doctors) seminars students trained per year 214 40,000 - 14 practitioners/doctors in pharmacy, - 115 non-university practitioners/doctors in medicine, - 85 non-practitioners per year (initial and/or in-house training) employees hours of training 17 university degrees 26 university teachers: - 14 “PUPH(1)”, 1 “PU(2)” and 2 “MCU(3)” at the Faculty of Medicine, - 1 “PUPH” and 1 “MCU” at the Faculty of Pharmacy, - 3 “PU” and 1 “MCU” at the Faculty of Science, - 1 “PU” at ENS Cachan (1) PUPH: University Professor and Hospital Doctor. (2) PU: University Professor. (3) MCU: University Lecturer. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 45 ACT ON FUNDRAISING GENEROSITY IN ACTION TO SUPPORT INNOVATION IN TREATMENT AND RESEARCH Gustave Roussy, a collective-interest health establishment, is authorised to receive donations and bequests, as is its research foundation (the “Fondation Gustave Roussy”). Public generosity, year after year, has become essential for financing the innovations developed at Gustave Roussy, for supporting excellence in research and for ceaselessly improving the quality of care provided. T hanks to the ever reliable support of donators and sponsors, Gustave Roussy was able to commence, in 2012, construction of a new research building dedicated to molecular medicine, to completely renovate the paediatric department and to acquire cutting-edge imaging equipment. The confidence of donators and sponsors allows the Institute to keep funding innovation and create the cancer care of tomorrow, all in name of the fight against cancer. INCREASED RESOURCES RAISED FROM THE PUBLIC Donations More than 20,000 new donators gave money to Gustave Roussy in 2012 for the first time. A total of €7,059,916 was raised in 2012, which represents a 6% increase on 2011. Although the number of donations decreased slightly in 2012, this has been compensated by an increase in the average amount donated. €16,152,793 in funds raised from the public 46 ANNUAL REPORT 2012 / GUSTAVE ROUSSY €17,911,717 cash outflows financed by the funds raised from the public Bequests The value of the bequests received is determined by the total amounts collected throughout 2012 and by the annual variation of bequest stocks on 31 December 2012. In 2012, bequests received rose to €9,002,574, an increase of 31.8% in comparison to 2011. This high increase is essentially due to the higher number received, twice the number received in 2011 (more than €5 M extra receipts than in 2011). Other revenues linked to public generosity These financial revenues have been realised thanks to the investment of donations and bequests in ad hoc bank accounts (investment in the context of management mandates in monetary instruments). Since 1 January 1998, financial revenue has been incorporated with bequeathed funds. In 2012, financial revenues stood at €90,000, a decrease of €45,000 in view of the low yield on money markets during the year. >>> >>> USE OF RESOURCES The total amount of cash outflows financed by resources raised from the public in 2012 was €17,911,717. Total cash outflows for 2012 increased to €7,409,551, a 2.1% increase on 2011. Social missions Social missions comprise actions realised directly by Gustave Roussy in France, the payment made by the Institute to the “Fondation Gustave Roussy” and the international mission of the Franco-African Paediatric Oncology Group. Social missions implemented in 2012 stood at €4,152,267 (a decrease of 0.5% in comparison to 2011). • Actions realised directly by Gustave Roussy in France concern financing basic research activities conducted by the Institute (€1,000,000), direct support to medical teams through targeted donations (€1,085,799), improvement of the patient reception and quality-of-life through dedicated accounts destined to finance innovative projects to receive patients and fund social service activities (€48,174). • The yearly payment to the “Fondation Gustave Roussy” stood at €2 M in 2012. Since 2005, following a decision of Gustave Roussy’s Board of Directors, an annual donation originating from donations and bequests is transferred to the Foundation to help finance research. These donations are then assigned to research projects by multiannual agreement. Six multiannual agreements were signed in 2012. THANKS TO DONATIONS AND BEQUESTS Many actions have been accomplished in 2012 S election of investments realised thanks to donations and bequests in 2012: • Construction of a modular building dedicated to molecular medicine: €13.5 M over two years (2012 and 2013). It is dedicated to research and teaching. This was partly funded (€3.5 M) by donations and bequests in 2012. • Financing research: €1 M was assigned to basic research teams and €2 M was paid to the “Fondation Gustave Roussy”, for developments and human resources in the communal technological platforms, for development, strategic and administrative support for research and for international collaboration programs. In total, more than €3 M of donations and bequests were ploughed back into research. • Acquisition of an MRI machine: €1.8 M. • Acquisition of a Discovery 750 HD SCANNER: €1.03 M. • 1 Gamma Camera Discovery NM 630: €406,000. • 1 Solution Rapid-Arc for the Novalis radiotherapy machine: €417,000. • The international mission realised by the Franco-African Paediatric Oncology Group is destined to train doctors in French-speaking African countries to treat cancer and to facilitate their access to drugs. The payment to this international mission accounted for a bit more than €18,000 in 2012. >>> €2,133,973 actions realised directly by Gustave Roussy in France in 2012 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 47 ACT ON FUNDRAISING IT HAPPENED IN 2012! FUNDRAISING EVENTS ODYSSÉA In October 2012, 26,000 people participated in the Odysséa walk/run in Paris to support the fight against breast cancer. Gustave Roussy will use the money they raised for research into personalised treatments for breast cancer – €320,000. “SHOPPING SOLIDAIRE” The 4th version of “Shopping solidaire”, organised by Spring Nation (selling branded products at a discount), allowed funds to be collected for research into personalised treatments for breast cancer – €65,000. “L’ÉTOILE DE MARTIN” The association, set up to support paediatric cancer research and to contribute to the well-being of ill children, conducted numerous fundraising events in 2012 and sent Gustave Roussy’s paediatric department a cheque for €270,000. THE ASSOCIATION “IMAGINE FOR MARGO” Rallying against child cancer, the association organised the first version of the run “Children without cancer” in September 2012; the funds raised were donated to the ITCC consortium (Innovative Therapies for Children with Cancer), which is chaired by Gustave Roussy – €200,000. “LES AMIS DE MIKHY” The association donated money to Gustave Roussy to support projects aiming to counter the pain experienced by hospitalised children and those accompanying them – €40,000. PATRONAGE LE CRÉDIT MUTUEL “TOGETHER AGAINST MELANOMA” MEETING OF SPONSORS AND RESEARCHERS THE LION’S CLUBS In 2012 the bank committed to supporting the head of the dermatology department, Dr Caroline Robert, team’s projects in the fight against melanoma. The bank will enlist the help of its network for five yyears through g the generous g project p “Together against melanoma”. At the end of February 2012, a hundred sponsors helped with the presentation of objectives and results for the research teams that they support and visited their laboratories. Mobilised around their association “Tulips against cancer”, the Lion’s Clubs actively support numerous projects of the paediatrics department, as well as an immunotherapy research program directed by Professor Laurence Zitvogel. 48 ANNUAL REPORT 2012 / GUSTAVE ROUSSY Created in 2005, the purpose of this research foundation, recognised to be of public utility, is to source additional financial support to quicken the pace of the research conducted at Gustave Roussy. “RÉVOLUTION CANCER” 2010-2013 In 2010, the “Fondation Gustave Roussy” considerably reinforced its fundraising initiative by targeting sponsoring businesses and large donators. To this end, it launched the campaign “Révolution Cancer 2010-2013”, an ambitious fundraising program which aims to raise €10 M over three years to finance research into personalised medicine. As of the end of 2012, €1 M remained to be collected. €2,8 M Donations collected by the Foundation in 2012. HIGHLIGHTS OF THE FOUNDATION IN 2012 Natixis supported the program The Charter Committee renewed its “TRUSTED DONATION” accreditation with the “Fondation Gustave Roussy” for another three years, following a favourable report given by the certification body in 2012. “RÉVOLUTION CANCER” under a sponsorship agreement, by directly helping three young research teams – directed by Dr Perfettini, Dr Jaulin and Dr Khaled. To find out page 40 The Swiss foundation, “FONDATION PHILANTHROPIA” GAVE A VERY LARGE SPONSORSHIP AMOUNTING TO €5.4 M TO THE “FONDATION GUSTAVE ROUSSY”, for the years to come. This will be used to finance three projects favouring the development of personalised medicine in the areas of research, treatment and training. To find out VÉRONIQUE WEILL, Director of AXA Group operations, JOINED THE FOUNDATION’S SUPERVISORY BOARD AS A QUALIFIED PERSON. Véronique Weill is a member of AXA’s Executive Committee and also sits on the Scientific Board of the AXA Research Fund. page 43 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 49 Financial results 2012 ACTIVITY_52 AUDITORS REPORT ON THE ANNUAL ACCOUNTS_53 2012 BALANCE SHEET_54 2012 PROFIT AND LOSS ACCOUNT_56 OVERALL ANNUAL USE OF RESOURCES_58 USES OF DONATIONS AND BEQUESTS_59 FINANCIAL RESULTS 2012 ACTIVITY AND RESULTS In terms of hospital activity, 2012 marks a significant change to Gustave Roussy’s development model: after three years of focusing on further developing the range of treatments, the current emphasis is on maintaining the level of success achieved whilst keeping overall spending under control. A lthough an active recruitment policy has been pursued over the past three years, resulting in a labour force increase of 6.4% and 245 new hires under permanent contracts, corresponding largely to the recruitment procedure designed by the employment arbitration committee, Gustave Roussy nevertheless almost broke even in 2012, with a deficit of just €547,201 for a overall budget of €290 M (0.19% of revenue). This result compares reassuringly favourably with the deficit of almost €2.5 M in the 2012 budget. This €1.9 M improvement came from increased revenue from all sources (Health Insurance activity: +€3 M; Paying and foreign patients: +€2.6 M; Other income: +€2.1 M). Expenses have risen at a lower rate (€5.8 M), with €3.5 M allocated to provisions for risks and extraordinary items which were not budgeted. In view of this result, the capacity for self-financing rose to €13.9 M. Annual resources rose to €29.9 M, thus overtaking the total annual outflows (€29.4 M) due to major investments (€21.5 M) and other spending (€7.9 M, of which €5.9 M was used in the repayment of loans). The contribution to working capital thus rose to €493,646. At the same time, the negative working capital requirements improved by more than €14 M (a sharp increase in research credits). Consequently, ready cash flow grew by €14.5 M. As in previous years, the financial balance ratios have improved; this improvement concerns both the financial independence ratio (56.7%) and the debt to revenue ratio (31.6%), which are moving gradually towards the criteria established by decree. While there have been few changes to hospitalisation circumstances, the development of the technological platform continued, with an increase in outpatient surgery and an update to the imaging platform (acquisition of a new scanner and a latest-generation MRI) in particular. The number of patients hospitalised increased by 4% with 5,688 extra patients treated. The number of hospitalisations is thus in line with objectives; an increase of 2% has been registered in comparison to 2011, amounting to 323 extra hospitalisations. More specifically: outpatient procedures performed exceeded the target by 4%, increasing by 6% (+2,238 stays); there was a decrease of 2% in radiotherapy activity (1,734 sessions less), as a result of the partial functioning of the Varian, following a breakdown, and the use of the Novalis. Thus, PMSI(1) activity exceeded targets by 2%, and the 2011 result by 7%, thanks to a number of walk-ins in line with what was anticipated for full and outpatient hospitalisations, and a PMCT(2) close to the forecast. All the research components have considerably developed. Gustave Roussy won tenders for structured projects including the Site of Integrated Cancer Research (SICR-SOCRATE) with an €8 M budget over 5 years, and a grant of €5.4 M accorded by the “Fondation Philanthropia” at the end of the year. This success motivated the Institute to propose that a new infrastructure, dedicated to research, be built. Consequently, it was decided that a 6,000m² building, dedicated to personalised medicine, will be built at a cost of merely €13.5 M. (1) PMSI: Program for the Medicalisation of Informations Systems. (2) PMCT: Average Burden of Cases Treated. +4% Increase in the number of patients hospitalised 52 ANNUAL REPORT 2012 / GUSTAVE ROUSSY AUDITOR’S REPORT ON THE ANNUAL ACCOUNTS Financial year ending 31 December 2012 To whom it may concern, In accordance with our appointment by your Board of Directors, we hereby report to you for the year ending 31 December 2012 on: - the audit of Gustave Roussy’s annual accounts, as attached to this report; - the justification of our assessments; - the specific verifications and information required by law. The annual accounts have been drawn up by the Board of Directors. Our role is to express an opinion on these accounts, based on our audit. 1- Opinion based on the annual accounts We have conducted our audit in accordance with the professional standards applicable in France; these standards require that due diligence be practiced in order to obtain a reasonable assurance that these annual accounts contain no significant anomalies. An audit includes examining, on a test basis or through other selection methods, evidence supporting the amounts and disclosures in the annual accounts. It also involves assessing the accounting principles used, any significant estimates made and the overall presentation of the financial statements. We believe that our audit has provided us with sufficient relevant information on which to base our opinion. We certify that the annual accounts are, in accordance with accounting rules and principles, regular and sincere and give a faithful idea of the result of the past fiscal year and of the financial situation and assets of the Institute at the end of this fiscal year. 2- Justification of our assessments Pursuant to the provisions of article L. 829-9 of the Commercial Code, relating to the grounds for our assessment, we hereby inform you that our assessments focused on the appropriateness of the accounting principles applied and on the reasonableness of the significant estimates chosen, in particular regarding the fixed assets, the receivables and the provisions for liabilities and charges. 3- Specific verifications and information We have also conducted, in accordance with the professional standards applicable in France, specific verifications required by the law. We have no comments or reservations about the fair presentation and consistency of the annual accounts with the information given in the “Balance Sheet and the 2012 Financial Account” and in the documents addressed to the members of the Board of Directors on the financial situation and annual accounts. Paris La Défense, 30 April 2013 KPMG Audit KPMG S.A. Jean Gatinaud Associate ANNUAL REPORT 2012 / GUSTAVE ROUSSY 53 FINANCIAL RESULTS 2012 BALANCE SHEET Fiscal year ending 31 December 2012 Assets 2012 (in euros) 2011 Depreciations and write-offs Gross Net Net FIXED ASSETS Intangible fixed assets - start-up costs - costs of studies and research and development - concessions and similar rights, patents, licences, trademarks & processes, similar rights and assets 0.00 0.00 0.00 0.00 6,954,047.43 3,640,689.82 3,313,357.61 3,099,196.04 11,383,921.14 8,248,105.27 3,135,815.87 2,763,114.80 Tangible fixed assets - land 6,387,508.90 2,986,570.10 3,400,938.80 3,407,236.69 259,376,871.11 115,705,956.30 143,670,914.81 148,110,638.90 - technical installations, plant and equipment 95,381,271.68 66,899,205.04 28,482,066.64 27,736,402.94 - other tangible fixed assets 28,152,688.09 21,837,544.35 6,315,143.74 6,574,933.44 9,522,574.14 0.00 9,522,574.14 1,750,144.75 212,722.45 0.00 212,722.45 212,722.45 15,344.90 0.00 15,344.90 15,344.90 2,000,000.00 0.00 2,000,000.00 0.00 21,807.15 0.00 21,807.15 17,307.15 419,408,756.99 219,318,070.88 200,090,686.11 193,687,042.06 - raw materials 2,212,555.25 0.00 2,212,555.25 2,276,32 327.60 - other supplies 424,421.46 0.00 424,421.46 446,6 ,638.65 - products 104,811.71 0.00 104,811.71 104 04,993.71 7,126,443.88 0.00 7,126,443.88 8,167,671.24 167 671 24 - buildings - tangible fixed assets in progress Financial fixed assets - investments and receivables related to investments - other fixed securities - loans - others TOTAL I CURRENT ASSETS Inventories and works in progress - other inventories Operating receivables - patients and consultants - pivot fund - other third-party payers 9,792,177.28 506,589.92 9,285,587.36 6,145,727.05 27,960,352.77 0.00 27,960,352.77 31,469,214.30 1,178,603.67 0.00 1,178,603.67 967,832.20 Miscellaneous receivables 13,121,723.07 0.00 13,121,723.07 13,440,903.78 Investment securities 26,195,349.02 0.00 26,195,349.02 17,063,684.26 2,907,977.01 0.00 2,907,977.01 639,792.51 410,695.09 0.00 410,695.09 508,256.87 91,435,110.21 506,589.92 90,928,520.29 81,231,042.17 510,843,867.20 219,824,660.80 291,019,206.40 274,918,084.23 Liquid assets Prepaid expenses TOTAL II OVERALL TOTAL 54 ANNUAL REPORT 2012 / GUSTAVE ROUSSY Liabilities (in euros) 2012 2011 EQUITY Contributions and association funds Reserves 40,532,124.47 40,532,124.47 2,586,409.90 2,586,409.90 -29,289,509.46 -30,647,531.80 Retained earnings Accumulated deficit Fiscal year result (surplus or deficit) -547,200.94 1,358,022.34 Investment grants 46,124,222.15 38,391,927.73 TOTAL I 59,406,046.12 52,220,952.64 10,648,486.45 10,334,085.21 PROVISIONS FOR LIABILITIES AND CHARGES Provisions for liabilities Provisions for charges TOTAL II 0.00 200,000.00 10,648,486.45 10,534,085.21 93,564,839.31 94,081,339.26 LIABILITIES Financial debts - loans from credit institutions - loans and miscellaneous financials debts - credit lines 5,635.00 6,900.00 0.00 3,055,813.62 Accounts payable - advances received - supplier payables and nd related accounts - patient advances an nd down-payments 0.00 0.00 25,146,229.46 23,414,276.12 4,148,255.80 4,902,425.64 - pivot fund/health iinsurance advance 11,984,656.46 14,727,062.46 - tax and social de ebts 12,642,576.47 12,319,250.84 Miscellaneous liabilities - liabilities in respect of fixed assets and related accounts - other miscellaneous liabilities (pending donations and legacies, accounts payable for research and teaching) - deferred income 9,255,724.90 5,126,744.24 62,813,912.53 53,718,726.27 1,402,843.90 810,507.93 TOTAL III 220,964,673.83 212,163,046.38 OVERALL TOTAL 291,019,206.40 274,918,084.23 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 55 FINANCIAL RESULTS 2012 PROFIT AND LOSS ACCOUNT BY NATURE (in euros) 2012 2011 OPERATING REVENUE Sales of medicines Revenue from auxiliary activities Revenue from hospital activity Operating grants and investments Reversals of write-offs, depreciations and provisions Transfers of operating costs Other everyday management revenue TOTAL I 7,434,856.82 4,691,962.90 12,768,101.77 10,523,554.40 233,108,854.04 226,986,311.29 15,104,533.46 13,764,920.40 2,541,553.71 4,036,173.89 0.00 60,085.60 7,923,298.67 6,723,881.34 278,881,198.47 266,786,889.82 50,808,866.50 47,130,859.57 OPERATING COSTS Purchases held in inventory; other supplies Inventory changes 86,171.54 303,247.69 Cost of materials and supplies not held in inventory 18,674,013.32 16,920,296.80 External services and other external services 41,303,948.67 37,861,682.26 10,848,290.38 10,311,164.24 17,981.00 13,651.00 Remunerations and other personnel-related costs 94,270,942.16 88,923,218.94 Social security costs 42,431,548.58 39,978,330.98 18,915,307.28 18,125,340.08 TAXES, DUTIES AND ASSIMILATED PAYMENTS On remunerations Others PERSONNEL COSTS DEPRECIATION CHARGES AND PROVISIONS On fixed assets: depreciation charges and amortisation On current assets: provision for impairment For liabilities and charges: depreciation charges and provisions OTHER CHARGES OF EVERYDAY MANAGEMENT TOTAL II 1 – OPERATING INCOME (I-II) 56 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 38,380.47 105,280.59 2,655,954.95 5,935,410.14 827,958.05 158,723.75 280,879,362.90 265,767,206.04 -1,998,164.43 1,019,683.78 (in euros) 2012 2011 FINANCIAL REVENUE Investments and other financial fixed assets and other receivables 83,967.79 48,938.63 1,590.33 1,442.47 Reversals of provisions 0.00 0.00 Transfers of financial charges 0.00 0.00 Exchange gains 0.00 0.00 Net income from sales of marketable securities 0.00 0.00 85,558.12 50,381.10 Financial income from investments, discounts obtained and other financial revenue TOTAL III FINANCIAL CHARGES Depreciation, impairment and provisions 0.00 0.00 3,661,694.30 3,915,120.31 Exchange losses 0.00 35.16 Net losses from disposals of marketable securities 0.00 0.00 3,661,694.30 3,915,155.47 2 – FINANCIAL INCOME (III-IV) -3,576,136.18 -3,864,774.37 3 – OPERATING INCOME BEFORE TAX AND EXCEPTIONAL ITEMS (I-II+III-IV) -5,574,300.61 -2,845,090.59 Interests and assimilated charges TOTAL IV EXTRAORDINARY INCOME On management operations - current financial year - previous financial years On capital operations Reversals on provisions and depreciations TOTAL V 168,535.40 75,911.76 2,067,856.77 3,733,376.26 4,627,144.73 3,363,153.62 0.00 0.00 6,863,536.90 7,172,441.64 EXTRAORDINARY CHARGES On management operations - current financial year - previous financial years On capital operations 51,556.75 4,016.22 1,782,398.58 2,919,494.34 0.00 39,969.84 Depreciation, impairment and provisions - regulated provisions 0.00 0.00 2,481.90 5,848.31 TOTAL VI 1,836,437.23 2,969,328.71 4 – EXTRAORDINARY INCOME (V-VI) 5,027,099.67 4,203,112.93 - depreciation charges and extraordinary write-offs Company Tax 0.00 0.00 5 – TOTAL REVENUE (I+III+V) 285,830,293.49 274,009,712.56 6 – TOTAL CHARGES (II+IV+VI) 286,377,494.43 272,651,690.22 -547,200.94 1,358,022.34 SURPLUS OR DEFICIT (5 – 6) ANNUAL REPORT 2012 / GUSTAVE ROUSSY 57 FINANCIAL RESULTS OVERALL ANNUAL USE OF RESOURCES (on 31 December 2012) (in euros) USES Uses of N = income statement Allocation by use of resources raised by the public on N RESOURCES Report on the resources raised from the public which have not been allocated or used at the start of the fiscal year 1 – Resources raised by the public 1.1. Donations and bequests received - Individual donations which have not been allocated - Individual donations which have been allocated - Bequests and other gifts which have not been allocated - Bequests and other gifts which have been allocated 1.2. Other income linked to public generosity 1 – Social missions 1.1. In France - Activities carried out directly 240,496,042.40 240,477,748.52 237,978,133.86 4,152,267.52 4,133,973.64 2,133,973.64 - Basic and clinical research 46,882,365.76 2,085,799.51 186,460,183.22 48,174.13 4,635,584.88 0.00 2,499,614.66 2,000,000.00 2,000,000.00 499,614.66 0.00 18,293.88 0.00 18,293.88 2,000,000.00 0.00 0.00 18,293.88 0.00 18,293.88 2,675,356.19 2,675,356.19 2,675,356.19 2 – Other private funds 2,675,356.19 Gustave Roussy Foundation - Patient care and quality of life - Teaching - Payments to other organisms operating in France - Gustave Roussy Foundation - Gustave Roussy Transfer (IGR&D) - Other organisms 1.2. Abroad - Activities carried out directly - Payments to a central organ or other organisms 2 – Cost of fundraising 2.1. Costs of fundraising from calls to general public generosity 2.2. Costs of fundraising from private funds 2.3. Charges due to researching grants and public tenders publics 3 – Operating costs I. Total use of resources for the financial year recorded on the profit and loss account II. Provisions expenses III. Projected uses of allocated funds IV. Surplus in the financial year’s resources V. TOTAL VI. Share of the gross fixed asset acquisitions for the financial year financed by resources raised from the public VII. Neutralisation of depreciation charges of fixed assets financed from the date of the first application of the Regulation by resources raised from the public VIII. Total cash outflows financed by the resources raised form the public 0.00 0.00 Gustave Roussy Transfer (IGR&D) 0.00 0.00 Other bodies 50,972,627.56 294,144,026.15 2,694,335.42 8,196,040.97 305,034,402.54 58 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 581,927.56 3 – Grants and public tenders 4 – Other Income 7,409,551.27 I. Total resources for the financial year recorded on the profit and loss account II Reversals of provisions III. Report on the resources allocated but not used from previous financial years IV. Change in funds dedicated which have been raised by the public (cf. see table of dedicated funds) V. Shortfall in the financial year’s resources VI. TOTAL 10,502,166.57 VI. Total cash outflows financed by the resources raised from the public Remaining resources raised from the public which were not allocated or used by the end of the fiscal year 17,911,717.84 Resources collected on N = income statement Monitoring of resources raised by the public and used on N 11,646,943.45 16,152,793.18 16,062,491.20 4,882,745.72 16,152,793.18 16,062,491.20 4,882,745.72 2,177,170.98 2,177,170.98 9,002,574.50 9,002,574.50 0.00 0.00 90,301.98 90,301.98 28,462,802.43 2,946,179.29 321,963.63 25,194,659.51 210,346,490.87 47,530,762.35 302,492,848.83 2,541,553.71 305,034,402.54 16,152,793.18 17,911,717.84 9,888,018.79 USES OF DONATIONS AND BEQUESTS Justification of uses in 2012 and report in 2013 (in euros) Biomedical equipment Seed projects IT & Subtotal furnishings Investments Research Foundation Basic research Others (GFAOP) Total WITHDRAWALS Previous amounts earmarked but not spent (balance on 31/12/2011) 2,606,995.44 0.00 0.00 2,606,995.44 0.00 0.00 0.00 2,606,995.44 Amounts used in 2012 4,717,951.18 5,232,277.45 31,477.49 9,981,706.12 2,000,000.00 1,000,000.00 18,293.88 13,000,000.00 TOTAL AMOUNTS AVAILABLE FOR USE 7,324,946.62 5,232,277.45 31,477.49 12,588,701.56 2,000,000.00 1,000,000.00 18,293.88 15,606,995.44 SPENDING BREAKDOWN OF DONATIONS AND BEQUESTS FOR 2012 Gamma camera 406,180.40 406,180.40 406,180.40 Scanner 1,030,060.46 1,030,060.46 1,030,060.46 MRI 3T 1,826,306.21 1,826,306.21 1,826,306.21 416,635.48 416,635.48 416,635.48 1,559,229.08 1,559,229.08 1,559,229.08 Solution Rapidarc / Novalis Other Biomedical uses Building for molecular medicine 3,500,000.00 3,500,000.00 3,500,000.00 Works for the extension of the MRI and scanner 1,050,561.67 1,050,561.67 1,050,561.67 Other works 681,715.78 Other fixed assets TOTAL SPENDING 681,715.78 31,477.49 5,238,411.63 681,715.78 31,477.49 2,000,000.00 1,000,000.00 18,293.88 3,049,771.37 5,232,277.45 31,477.49 10,502,166.57 2,000,000.00 1,000,000.00 18,293.88 13,520,460.45 BALANCE TO BE CARRIED OVER IN N+1 Earmarked but not spent as of 31/12/2012 2,086,534.99 0.00 0.00 2,086,534.99 0.00 0.00 0.00 2,086,534.99 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 59 GUSTAVE ROUSSY’S PUBLICATIONS SYNTHESIS OF GUSTAVE ROUSSY’S INTERNATIONAL PUBLICATIONS In 2012, Gustave Roussy’s teams were behind 124 international publications which had an impact factor of greater than 10, and 45 of which were higher than 20. Publications with an impact factor higher than 20 in 2012 IF>20 (2012) Cell 1 Lancet 9 Lancet Oncology 15 Nature Genetics 4 Nature Immunology 2 Nature Medicine 1 Nature Reviews Drug Discovery 1 Nature Reviews Molecular Cell Biology 1 New England Journal of Medicine 10 Science 1 TOTAL 60 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 45 Publications with an impact factor included between 10 and 20 in 2012 2012 Ar c hives of I nter na l Medic ine 1 Blood 16 C a ncer & Meta s ta s is r eviews 1 C ir c ul a tion R es ea r c h 2 C ur r r ent Opinion in I m m unol ogy 1 EMBO Journal 2 E MB O Mol ec ul a r Medic ine 2 E ur opea n H ea r t J our na l 1 Gut 3 J our na l of Al l er gy a nd C l inica l I m m unol ogy 1 J our na l of C l inica l I nves tiga tion 2 J our na l of C l inica l Oncol ogy 27 J our na l of E xper im enta l Medic ine 2 J our na l of the N a tiona l C a ncer I ns titute 2 Molecular Cell 4 Nano Letters 1 N a tur e R eviews C l inica l Oncol ogy 6 N a tur e S tr uc tur a l a nd Mol ec ul a r B iol ogy 1 Plos Medicine 2 P r oceedings of the N a tiona l Aca dem y of S c iences U S A 1 Tr ends in I m m unol ogy 1 T OTAL 79 International publications with an impact factor between 5 and 10 in 2012 In 2012, Gustave Roussy's teams have published 415 international publications with an impact factor between 5 and 10. To find out See the full list of these publications page 72. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 61 GUSTAVE ROUSSY’S PUBLICATIONS INTERNATIONAL COMPARISON Over the past 10 years, Gustave Roussy has produced 7,060 publications. There were 21.38 citations per article (Web of Knowledge database). France Publications Dates H-index Gustave Roussy 7,060 2003-2012 150 Institut Curie 4,896 2003-2012 118 Institut J Paoli-Calmettes 1,820 2003-2012 69 Centre Léon Bérard 2,034 2003-2012 77 Publications Dates H-index Dana-Farber Cancer Institute 17,892 2003-2012 273 Memorial Sloan-Kettering Cancer Center 20,433 2003-2012 222 M. D. Anderson Cancer Center 38,552 2003-2012 198 Publications Dates H-index Gustave Roussy 7,060 2003-2012 150 Institut Curie 4,896 2003-2012 118 Netherlands Cancer Institute, Amsterdam 4,148 2003-2012 144 Royal Marsden Hospital, London 2,375 2003-2012 89 Istituto Nazionale Tumori, Milan 2,602 2003-2012 58 Christie Hosp & Holt Radium Inst, Manchester 2,767 2003-2012 65 Hospital Vall d’Hebron, Barcelona 6,383 2003-2012 116 753 2003-2012 56 United States Europe Daniel Den Hoed Cancer Center, Rotterdam 62 ANNUAL REPORT 2012 / GUSTAVE ROUSSY INTERNATIONAL PUBLICATIONS BY GUSTAVE ROUSSY With an impact factor higher than 20 (45 publications in 2012) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] K. T. Flaherty, C. Robert, and D. Schadendorf, “The authors reply : MEK Inhibition in BRAF-Mutated Melanoma,” New England Journal of Medicine, vol. 367, no. 14, p. 1365, [2012]. J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. De Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T.-W. Chang, Z. Horváth, M. Coccia-Portugal, J. Domont, L.-M. Tseng, G. Kunz, J. H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R. D. Gelber, and M. PiccartGebhart, “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial,” in Lancet, [2012], vol. 379, no. 9816, pp. 633–640. F. Boissier, A. Khalil, L. Chalumeau-Lemoine, F.-X. Lescure, and A. Parrot, “Rash diagnosis of blood expectoration.,” Lancet, vol. 379, no. 9821, p. 1170, [Mar. 2012]. J. Bourhis, C. Sire, P. Graff, V. Grégoire, P. Maingon, G. Calais, B. Gery, L. Martin, M. Alfonsi, P. Desprez, T. Pignon, E. Bardet, M. Rives, L. Geoffrois, N. Daly-Schveitzer, S. Sen, C. Tuchais, O. Dupuis, S. Guerif, M. Lapeyre, V. Favrel, M. Hamoir, A. Lusinchi, S. Temam, A. Pinna, Y. G. Tao, P. Blanchard, and A. Aupérin, “Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial,” The Lancet Oncology, vol. 13, no. 2, pp. 145–153, [2012]. J. Bourhis, Y. G. Tao, P. Blanchard, C. Sire, and A. Aupérin, “Absent benefit of accelerated concomitant chemoradiotherapy - Authors’ reply,” The Lancet Oncology, vol. 13, no. 4, pp. e136–e137, [2012]. J.-F. Brasme, M. Morfouace, J. Grill, A. Martinot, R. Amalberti, C. Bons-Letouzey, and M. Chalumeau, “Delays in diagnosis of paediatric cancers: A systematic review and comparison with expert testimony in lawsuits,” The Lancet Oncology, vol. 13, no. 10, pp. e445–e459, [2012]. S. Corbacioglu, S. Cesaro, M. Faraci, D. Valteau-Couanet, B. Gruhn, A. Rovelli, J. J. Boelens, A. Hewitt, J. Schrum, A. S. Schulz, I. Müller, J. Stein, R. Wynn, J. Greil, K.-W. Sykora, S. Matthes-Martin, M. Führer, A. O’Meara, J. Toporski, P. Sedlacek, P. G. Schlegel, K. Ehlert, A. Fasth, J. Winiarski, J. Arvidson, C. Mauz-Körholz, H. Ozsahin, A. Schrauder, P. Bader, J. Massaro, R. D’Agostino, M. Hoyle, M. Iacobelli, K.-M. Debatin, C. Peters, and G. Dini, “Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial,” Lancet, vol. 379, no. 9823, pp. 1301–1309, [2012]. L. Couronné, C. Bastard, and O. A. Bernard, “TET2 and DNMT3A mutations in human T-Cell lymphoma,” New England Journal of Medicine, vol. 366, no. 1, pp. 95–96, [2012]. F. de Vathaire, C. El-Fayech, F. F. Ben Ayed, N. Haddy, C. Guibout, D. Winter, C. Thomas-Teinturier, C. Veres, A. Jackson, H. Pacquement, M. Schlumberger, M. Hawkins, I. Diallo, and O. Oberlin, “Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study.,” The Lancet Oncology, vol. 13, no. 10, pp. 1002–10, [Oct. 2012]. J. Delyon, C. Mateus, and T. Lambert, “The authors reply : More on Hemophilia A Induced by Ipilimumab,” New England Journal of Medicine, vol. 366, no. 3, p. 281, [Jan. 2012.] M. Ducreux, D. Malka, and J.-P. Pignon, “Chemotherapy for colorectal cancer - Authors’ reply,” The Lancet Oncology, vol. 13, no. 1, [2012]. M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D. J. Torpy, V. Stepan, D. E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone, A. Sundin, I. Hermsen, S. Hahner, H. S. Willenberg, A. Tabarin, M. Quinkler, C. De La Fouchardière, M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly, W. Kenn, T. Fojo, H.-H. Müller, and B. Skogseid, “Combination chemotherapy in advanced adrenocortical carcinoma,” New England Journal of Medicine, vol. 366, no. 23, pp. 2189–2197, [2012]. K. T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L. V Demidov, J. C. Hassel, P. Rutkowski, P. Mohr, R. Dummer, U. Trefzer, J. M. G. Larkin, J. Utikal, B. Dreno, M. Nyakas, M. R. Middleton, J. C. Becker, M. Casey, L. J. Sherman, F. S. Wu, D. Ouellet, A.-M. Martin, K. Patel, and D. Schadendorf, “Improved survival with MEK inhibition in BRAF-mutated melanoma,” New England Journal of Medicine, vol. 367, no. 2, pp. 107–114, [2012]. K. T. Flaherty, C. Robert, D. Schadendorf, and M. S. Grp, “The autors reply : Early Surgery for Infective Endocarditis,” New England Journal of Medicine, vol. 367, no. 14, p. 1365, Oct. [2012]. L. Galluzzi, O. Kepp, and G. Kroemer, “Mitochondria: Master regulators of danger signalling,” Nature Reviews Molecular Cell Biology, vol. 13, no. 12, pp. 780–788, [2012.] L. Galluzzi, L. Senovilla, L. Zitvogel, and G. Kroemer, “The secret ally: Immunostimulation by anticancer drugs,” Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 215–233, [2012]. S. Gouy, P. Morice, F. Narducci, C. Uzan, J. Gilmore, H. Kolesnikov-Gauthier, D. Querleu, C. Haie-Meder, and E. Leblanc, “Nodal-staging surgery for locally advanced cervical cancer in the era of PET,” The Lancet Oncology, vol. 13, no. 5, pp. e212–e220, [2012]. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 63 GUSTAVE ROUSSY’S PUBLICATIONS [18] [19] N. Hamajima, K. Hirose, K. Tajima, T. Rohan, C. M. Friedenreich, E. E. Calle, S. M. Gapstur, A. V Patel, R. J. Coates, J. M. Liff, R. Talamini, N. Chantarakul, S. Koetsawang, D. Rachawat, Y. Marcou, E. Kakouri, S. W. Duffy, A. Morabia, L. Schuman, W. Stewart, M. Szklo, P. F. Coogan, J. R. Palmer, L. Rosenberg, P. Band, A. J. Coldman, R. P. Gallagher, T. G. Hislop, P. Yang, S. R. Cummings, K. Canfell, F. Sitas, P. Chao, J. Lissowska, P. L. Horn-Ross, E. M. John, L. M. Kolonel, A. M. Y. Nomura, R. Ghiasvand, J. Hu, K. C. Johnson, Y. Mao, V. Beral, D. Bull, K. Callaghan, B. Crossley, A. Goodill, J. Green, C. Hermon, T. Key, I. Lindgard, B. Liu, K. Pirie, G. Reeves, R. Collins, R. Doll, R. Peto, T. Bishop, I. S. Fentiman, S. De Sanjose, C. A. Gonzalez, N. Lee, P. Marchbanks, H. W. Ory, H. B. Peterson, P. Wingo, K. Ebeling, D. Kunde, P. Nishan, J. L. Hopper, H. Eliassen, S. Hankinson, V. Gajalakshmi, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Neugut, R. Santella, C. J. Baines, N. Kreiger, A. B. Miller, C. Wall, A. Tjonneland, T. Jorgensen, C. Stahlberg, A. T. Pedersen, D. Flesch-Janys, N. Hakansson, J. Cauley, I. Heuch, H. O. Adami, I. Persson, E. Weiderpass, C. Magnusson, J. Chang-Claude, R. Kaaks, M. McCredie, C. Paul, D. C. G. Skegg, G. F. S. Spears, M. Iwasaki, S. Tsugane, G. Anderson, J. R. Daling, J. Hampton, W. B. Hutchinson, C. I. Li, K. Malone, M. Mandelson, P. Newcomb, E. A. Noonan, R. M. Ray, J. L. Stanford, M. T. C. Tang, D. B. Thomas, N. S. Weiss, E. White, A. Izquierdo, P. Viladiu, E. O. Fourkala, I. Jacobs, U. Menon, A. Ryan, H. R. Cuevas, P. Ontiveros, A. Palet, S. B. Salazar, N. Aristizabal, A. Cuadros, L. Tryggvadottir, H. Tulinius, E. Riboli, N. Andrieu, A. Bachelot, M. G. Le, A. Bremond, B. Gairard, J. Lansac, L. Piana, R. Renaud, F. Clavel-Chapelon, A. Fournier, M. Touillaud, S. Mesrine, N. Chabbert-Buffet, M. C. Boutron-Ruault, A. Wolk, G. Torres-Mejia, S. Franceschi, I. Romieu, P. Boyle, F. Lubin, B. Modan, E. Ron, Y. Wax, G. D. Friedman, R. A. Hiatt, F. Levi, K. Kosmelj, M. Primic-Zakelj, B. Ravnihar, J. Stare, A. Ekbom, G. Erlandsson, W. L. Beeson, G. Fraser, J. Peto, R. L. Hanson, M. C. Leske, M. C. Mahoney, P. C. Nasca, A. O. Varma, A. L. Weinstein, M. L. Hartman, H. Olsson, R. A. Goldbohm, P. A. van den Brandt, D. Palli, S. Teitelbaum, R. A. Apelo, J. Baens, J. R. de la Cruz, B. Javier, L. B. Lacaya, C. A. Ngelangel, C. La Vecchia, E. Negri, E. Marubini, M. Ferraroni, M. C. Pike, M. Gerber, S. Richardson, C. Segala, D. Gatei, P. Kenya, A. Kungu, J. G. Mati, L. A. Brinton, M. Freedman, R. Hoover, C. Schairer, R. Ziegler, E. Banks, R. Spirtas, H. P. Lee, M. A. Rookus, F. E. van Leeuwen, J. A. Schoenberg, G.-I. S., R. Selmer, L. Jones, K. McPherson, A. Neil, M. Vessey, D. Yeates, K. Mabuchi, D. Preston, P. Hannaford, C. Kay, S. E. McCann, L. Rosero-Bixby, Y. T. Gao, F. Jin, J.-M. Yuan, H. Y. Wei, T. Yun, C. Zhiheng, G. Berry, J. Cooper Booth, T. Jelihovsky, R. MacLennan, R. Shearman, A. Hadjisavvas, K. Kyriacou, M. Loisidou, X. Zhou, Q.-S. Wang, M. Kawai, Y. Minami, I. Tsuji, E. Lund, M. Kumle, H. Stalsberg, X. O. Shu, W. Zheng, E. M. Monninkhof, N. C. Onland-Moret, P. H. M. Peeters, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou, K. A. Baltzell, A. Dabancens, L. Martinez, R. Molina, O. Salas, F. E. Alexander, K. Anderson, A. R. Folsom, M. D. Gammon, B. S. Hulka, R. Millikan, C. E. D. Chilvers, F. Lumachi, C. Bain, F. Schofield, V. Siskind, T. R. Rebbeck, L. R. Bernstein, S. Enger, R. W. Haile, A. Paganini-Hill, R. K. Ross, G. Ursin, A. H. Wu, M. C. Yu, M. Ewertz, E. A. Clarke, L. Bergkvist, G. L. Anderson, M. Gass, M. J. O’Sullivan, A. Kalache, T. M. M. Farley, S. Holck, O. Meirik, and A. Fukao, “Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies,” The Lancet Oncology, vol. 13, no. 11, pp. 1141–1151, [2012]. K. B. Jacobs, M. Yeager, W. Zhou, S. Wacholder, Z. Wang, B. Rodriguez-Santiago, A. Hutchinson, X. Deng, C. Liu, M.-J. Horner, M. Cullen, C. G. Epstein, L. Burdett, M. C. Dean, N. Chatterjee, J. Sampson, C. C. Chung, J. Kovaks, S. M. Gapstur, V. L. Stevens, L. T. Teras, M. M. Gaudet, D. Albanes, S. J. Weinstein, J. Virtamo, P. R. Taylor, N. D. Freedman, C. C. Abnet, A. M. Goldstein, N. Hu, K. Yu, J.-M. Yuan, L. Liao, T. Ding, Y.-L. Qiao, Y.-T. Gao, W.P. Koh, Y.-B. Xiang, Z.-Z. Tang, J.-H. Fan, M. C. Aldrich, C. Amos, W. J. Blot, C. H. Bock, E. M. Gillanders, C. C. Harris, C. A. Haiman, B. E. Henderson, L. N. Kolonel, L. Le Marchand, L. H. McNeill, B. A. Rybicki, A. G. Schwartz, L. B. Signorello, M. R. Spitz, J. K. Wiencke, M. Wrensch, X. Wu, K. A. Zanetti, R. G. Ziegler, J. D. Figueroa, M. GarciaClosas, N. Malats, G. Marenne, L. Prokunina-Olsson, D. Baris, M. Schwenn, A. Johnson, M. T. Landi, L. Goldin, D. Consonni, P. A. Bertazzi, M. Rotunno, P. Rajaraman, U. Andersson, L. E. B. Freeman, C. D. Berg, J. E. Buring, M. A. Butler, T. Carreon, M. Feychting, A. Ahlbom, J. M. Gaziano, G. G. Giles, G. Hallmans, S. E. Hankinson, P. Hartge, R. Henriksson, P. D. Inskip, C. Johansen, A. Landgren, R. McKean-Cowdin, D. S. Michaud, B. S. Melin, U. Peters, A. M. Ruder, H. D. Sesso, G. Severi, X.-O. Shu, K. Visvanathan, E. White, A. Wolk, A. Zeleniuch-Jacquotte, W. Zheng, D. T. Silverman, M. Kogevinas, J. R. Gonzalez, O. Villa, D. Li, E. J. Duell, H. A. Risch, S. H. Olson, C. Kooperberg, B. M. Wolpin, L. Jiao, M. Hassan, W. Wheeler, A. A. Arslan, H. B. Bueno-De-Mesquita, C. S. Fuchs, S. Gallinger, M. D. Gross, E. A. Holly, A. P. Klein, A. Lacroix, M. T. Mandelson, G. Petersen, M.-C. Boutron-Ruault, P. M. Bracci, F. Canzian, K. Chang, M. Cotterchio, E. L. Giovannucci, M. Goggins, J. A. H. Bolton, M. Jenab, K.T. Khaw, V. Krogh, R. C. Kurtz, R. R. McWilliams, J. B. Mendelsohn, K. G. Rabe, E. Riboli, A. Tjønneland, G. S. Tobias, D. Trichopoulos, J. W. Elena, H. Yu, L. Amundadottir, R. Z. Stolzenberg-Solomon, P. Kraft, F. Schumacher, D. Stram, S. A. Savage, L. Mirabello, I. L. Andrulis, J. S. Wunder, A. P. García, L. Sierrasesà maga, D. A. Barkauskas, R. G. Gorlick, M. Purdue, W.-H. Chow, L. E. Moore, K. L. Schwartz, F. G. Davis, A. W. Hsing, S. I. Berndt, A. Black, N. Wentzensen, L. A. Brinton, J. Lissowska, B. Peplonska, K. A. McGlynn, M. B. Cook, B. I. Graubard, C. P. Kratz, M. H. Greene, R. L. Erickson, D. J. Hunter, G. Thomas, R. N. Hoover, F. X. Real, J. F. Fraumeni Jr., N. E. Caporaso, M. Tucker, N. Rothman, L. A. Pérez-Jurado, and S. J. Chanock, “Detectable clonal mosaicism and its relationship to aging and cancer,” Nature Genetics, vol. 44, no. 6, pp. 651–658, [2012]. 64 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] H. C. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, and M. H. Dreyling, “Treatment of older patients with mantle-cell lymphoma,” New England Journal of Medicine, vol. 367, no. 6, pp. 520–531, [2012]. S. Leboulleux, L. Bastholt, T. Krause, C. de la Fouchardiere, J. Tennvall, A. Awada, J. M. Gómez, F. Bonichon, L. Leenhardt, C. Soufflet, M. Licour, and M. J. Schlumberger, “Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial,” The Lancet Oncology, vol. 13, no. 9, pp. 897–905, [2012]. C. J. Logothetis, E. Basch, A. Molina, K. Fizazi, S. A. North, K. N. Chi, R. J. Jones, O. B. Goodman, P. N. Mainwaring, C. N. Sternberg, E. Efstathiou, D. D. Gagnon, M. Rothman, Y. Hao, C. S. Liu, T. S. Kheoh, C. M. Haqq, H. I. Scher, and J. S. de Bono, “Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised tri,” The Lancet Oncology, vol. 13, no. 12, pp. 1210–1217, [2012]. G. V Long, U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto, P. B. Chapman, I. Puzanov, A. Hauschild, C. Robert, A. Algazi, L. Mortier, H. Tawbi, T. Wilhelm, L. Zimmer, J. Switzky, S. Swann, A.-M. Martin, M. Guckert, V. Goodman, M. Streit, J. M. Kirkwood, and D. Schadendorf, “Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 11, pp. 1087–1095, [2012]. S. Luc, T. C. Luis, H. Boukarabila, I. C. Macaulay, N. Buza-Vidas, T. Bouriez-Jones, M. Lutteropp, P. S. Woll, S. J. Loughran, A. J. Mead, A. Hultquist, J. Brown, T. Mizukami, S. Matsuoka, H. Ferry, K. Anderson, S. Duarte, D. Atkinson, S. Soneji, A. Domanski, A. Farley, A. Sanjuan-Pla, C. Carella, R. Patient, M. De Bruijn, T. Enver, C. Nerlov, C. Blackburn, I. Godin, and S. E. W. Jacobsen, “The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential,” Nature Immunology, vol. 13, no. 4, pp. 412–419, [2012]. O. Mir and P. Berveiller, “Increased evidence for use of chemotherapy in pregnancy.,” The Lancet Oncology, vol. 13, no. 9, pp. 852–4, [Sep. 2012]. O. Mir and R. Coriat, “Aprepitant for pruritus: drug-drug interactions matter.,” The Lancet Oncology, vol. 13, no. 10, pp. 964–5, [Oct. 2012]. P. Morice, C. Uzan, R. Fauvet, S. Gouy, P. Duvillard, and E. Darai, “Borderline ovarian tumour: Pathological diagnostic dilemma and risk factors for invasive or lethal recurrence,” The Lancet Oncology, vol. 13, no. 3, pp. e103–e115, [2012]. P. Morice, C. Uzan, S. Gouy, C. Verschraegen, and C. Haie-Meder, “Gynaecological cancers in pregnancy,” Lancet, vol. 379, no. 9815, pp. 558–569, [2012]. P. Morice, C. Uzan, and S. Uzan, “Cancer in pregnancy: A challenging conflict of interest,” Lancet, vol. 379, no. 9815, pp. 495–496, [2012.] M. Peifer, L. Fernández-Cuesta, M. L. Sos, J. George, D. Seidel, L. H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen, C. Müller, V. Di Cerbo, H.-U. Schildhaus, J. Altmüller, I. Baessmann, C. Becker, B. De Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J. M. Heuckmann, X. Lu, S. L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.-S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M. Brockmann, W. Engel-Riedel, L. A. Muscarella, V. M. Fazio, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. A. M. Heideman, P. J. F. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O. T. Brustugun, M. Lund-Iversen, J. Sänger, J. H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J.-C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P. M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Büttner, J. Wolf, P. Nürnberg, S. Perner, L. C. Heukamp, P. K. Brindle, S. Haas, and R. K. Thomas, “Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer,” Nature Genetics, vol. 44, no. 10, pp. 1104–1110, [2012]. S. Postel-Vinay and A. Ashworth, “AXL and acquired resistance to EGFR inhibitors,” Nature Genetics, vol. 44, no. 8, pp. 835–836, [2012]. S. Postel-Vinay, A. S. Véron, F. Tirode, G. Pierron, S. Reynaud, H. Kovar, O. Oberlin, E. Lapouble, S. Ballet, C. Lucchesi, U. Kontny, A. González-Neira, P. Picci, J. Alonso, A. Patino-Garcia, B. B. De Paillerets, K. Laud, C. Dina, P. Froguel, F. Clavel-Chapelon, F. Doz, J. Michon, S. J. Chanock, G. Thomas, D. G. Cox, and O. Delattre, “Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma,” Nature Genetics, vol. 44, no. 3, pp. 323–327, [2012]. I. Ray-Coquard, J.-Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, F. Heil, R. Rueger, B. Graves, M. Ding, D. Geho, S. A. Middleton, L. T. Vassilev, G. L. Nichols, and B. N. Bui, “Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proofof-mechanism study,” The Lancet Oncology, vol. 13, no. 11, pp. 1133–1140, [2012]. H. I. Scher, K. Fizazi, F. Saad, M.-E. Taplin, C. N. Sternberg, K. Miller, R. De Wit, P. Mulders, K. N. Chi, N. D. Shore, A. J. Armstrong, T. W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J. S. De Bono, “Increased survival with enzalutamide in prostate cancer after chemotherapy,” New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, [2012]. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 65 GUSTAVE ROUSSY’S PUBLICATIONS [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie, C. Schvartz, P. Vera, O. Morel, D. Benisvy, C. Bournaud, F. Bonichon, C. Dejax, M.-E. Toubert, S. Leboulleux, M. Ricard, and E. Benhamou, “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” New England Journal of Medicine, vol. 366, no. 18, pp. 1663–1673, [2012]. M. Schlumberger, S. Leboulleux, and I. Borget, “Dr. Schlumberger and colleagues reply : Radioiodine Ablation in Low-Risk Thyroid Cancer,” New England Journal of Medicine, vol. 367, no. 7, pp. 673–674, [2012]. L. Senovilla, I. Vitale, I. Martins, M. Tailler, C. Pailleret, M. Michaud, L. Galluzzi, S. Adjemian, O. Kepp, M. NisoSantano, S. Shen, G. Mariño, A. Criollo, A. Boilève, B. Job, S. Ladoire, F. Ghiringhelli, A. Sistigu, T. Yamazaki, S. Rello-Varona, C. Locher, V. Poirier-Colame, M. Talbot, A. Valent, F. Berardinelli, A. Antoccia, F. Ciccosanti, G. M. Fimia, M. Piacentini, A. Fueyo, N. L. Messina, M. Li, C. J. Chan, V. Sigl, G. Pourcher, C. Ruckenstuhl, D. Carmona-Gutierrez, V. Lazar, J. M. Penninger, F. Madeo, C. López-Otín, M. J. Smyth, L. Zitvogel, M. Castedo, and G. Kroemer, “An immunosurveillance mechanism controls cancer cell ploidy,” Science, vol. 337, no. 6102, pp. 1678–1684, [2012]. M. R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damião, T. L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gómez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, and C. Goessl, “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial,” Lancet, vol. 379, no. 9810, pp. 39–46, [2012]. C. Uzan, S. Gouy, C. Haie Meder, and P. Morice, “Authors’ reply : Lymphadenectomy for pregnant women with stage I cervical cancer,” Lancet, vol. 379, no. 9830, pp. 1949–1950, [2012]. C. Uzan, S. Gouy, C. H. Meder, and P. Morice, “Lymphadenectomy for pregnant women with stage I cervical cancer reply,” Lancet, vol. 379, no. 9830, pp. 1949–1950, [2012.] W. T. A. Van Der Graaf, J.-Y. Blay, S. P. Chawla, D.-W. Kim, B. Bui-Nguyen, P. G. Casali, P. Schöffski, M. Aglietta, A. P. Staddon, Y. Beppu, A. Le Cesne, H. Gelderblom, I. R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge, M. R. Dewji, C. Coens, G. D. Demetri, C. D. Fletcher, A. P. Dei Tos, and P. Hohenberger, “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial,” Lancet, vol. 379, no. 9829, pp. 1879–1886, [2012]. Q. Wen, B. Goldenson, S. J. Silver, M. Schenone, V. Dancik, Z. Huang, L.-Z. Wang, T. A. Lewis, W. F. An, X. Li, M.A. Bray, C. Thiollier, L. Diebold, L. Gilles, M. S. Vokes, C. B. Moore, M. Bliss-Moreau, L. Verplank, N. J. Tolliday, R. Mishra, S. Vemula, J. Shi, L. Wei, R. Kapur, C. K. Lopez, B. Gerby, P. Ballerini, F. Pflumio, D. G. Gilliland, L. Goldberg, Y. Birger, S. Izraeli, A. S. Gamis, F. O. Smith, W. G. Woods, J. Taub, C. A. Scherer, J. E. Bradner, B.C. Goh, T. Mercher, A. E. Carpenter, R. J. Gould, P. A. Clemons, S. A. Carr, D. E. Root, S. L. Schreiber, A. M. Stern, and J. D. Crispino, “Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL,” Cell, vol. 150, no. 3, pp. 575–589, [2012]. P. J. Woll, P. Reichardt, A. Le Cesne, S. Bonvalot, A. Azzarelli, H. J. Hoekstra, M. Leahy, F. Van Coevorden, J. Verweij, P. C. W. Hogendoorn, M. Ouali, S. Marreaud, V. H. C. Bramwell, and P. Hohenberger, “Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial,” The Lancet Oncology, vol. 13, no. 10, pp. 1045–1054, [2012]. L. Zitvogel, O. Kepp, L. Galluzzi, and G. Kroemer, “Inflammasomes in carcinogenesis and anticancer immune responses,” Nature Immunology, vol. 13, no. 4, pp. 343–351, [2012]. L. Zitvogel and G. Kroemer, “Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system,” Nature Medicine, vol. 18, no. 3, p. 346, [2012.] 66 ANNUAL REPORT 2012 / GUSTAVE ROUSSY INTERNATIONAL PUBLICATIONS BY GUSTAVE ROUSSY With an impact factor between 10 and 20 (79 publications in 2012) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] L. Albiges, S. Oudard, S. Negrier, A. Caty, G. Gravis, F. Joly, B. Duclos, L. Geoffrois, F. Rolland, A. Guillot, B. Laguerre, E. Legouffe, F. Kohser, P.-Y. Dietrich, C. A. Theodore, and B. Escudier, “Complete remission with tyrosine kinase inhibitors in renal cell carcinoma,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 482–487, [2012.] I. Antony-Debré, D. Bluteau, R. Itzykson, V. Baccini, A. Renneville, F. Boehlen, M. Morabito, N. Droin, C. Deswarte, Y. Chang, G. Leverger, E. Solary, W. Vainchenker, R. Favier, and H. Raslova, “MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations,” Blood, vol. 120, no. 13, pp. 2719–2722, [2012]. T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J.-M. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J.-C. Eymard, M. Debled, D. Spaëth, E. Legouffe, D. Allouache, C. El Kouri, and E. Pujade-Lauraine, “Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2718–2724, [2012]. V. Beral, C. Hermon, R. Peto, G. Reeves, L. Brinton, P. Marchbanks, E. Negri, R. Ness, P. H. M. Peeters, M. Vessey, E. E. Calle, S. M. Gapstur, A. V Patel, L. D. Maso, R. Talamini, A. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki, N. Allen, D. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, T. Key, K. Moser, R. Collins, R. Doll, C. A. Gonzalez, N. Lee, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Tjonneland, L. Titus-Ernstoff, T. Byers, T. Rohan, B. J. Mosgaard, D. Yeates, J. L. Freudenheim, J. Chang-Claude, R. Kaaks, K. E. Anderson, A. Folsom, K. Robien, M. A. Rossing, D. B. Thomas, N. S. Weiss, E. Riboli, F. Clavel-Chapelon, D. Cramer, S. E. Hankinson, S. S. Tworoger, S. Franceschi, C. La Vecchia, C. Magnusson, T. Riman, E. Weiderpass, A. Wolk, L. J. Schouten, P. A. Van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black, A. Berrington de Gonzalez, L. A. Brinton, D. M. Freedman, P. Hartge, A. W. Hsing, J. V Lacey Jr., R. N. Hoover, C. Schairer, S. Graff-Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, S. E. Mccann, P. Hannaford, C. Kay, C. W. Binns, A. H. Lee, M. Zhang, R. B. Ness, P. Nasca, P. F. Coogan, J. R. Palmer, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou, A. Dabancens, L. Martinez, R. Molina, O. Salas, M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilkens, L. Hartman, J. Manjer, H. Olsson, J. A. Grisso, M. Morgan, J. E. Wheeler, J. Casagrande, M. C. Pike, R. K. Ross, A. H. Wu, A. B. Miller, M. Kumle, E. Lund, L. Mcgowan, X. O. Shu, W. Zheng, T. M. M. Farley, S. Holck, O. Meirik, and H. A. Risch, “Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies,” PLoS Medicine, vol. 9, no. 4, [2012.] J. Bergh, I. M. Bondarenko, M. R. Lichinitser, A. Liljegren, R. Greil, N. L. Voytko, A. N. Makhson, J. Cortes, A. Lortholary, J. Bischoff, A. Chan, S. Delaloge, X. Huang, K. A. Kern, and C. Giorgetti, “First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study,” Journal of Clinical Oncology, vol. 30, no. 9, pp. 921–929, [2012]. P. Blanchard, M. Rodrigues, and P. Colombat, “On the prevalence and causes of oncologist burnout,” Journal of Clinical Oncology, vol. 30, no. 24, pp. 3029–3030, [2012]. D. Bluteau, A. C. Glembotsky, A. Raimbault, N. Balayn, L. Gilles, P. Rameau, P. Nurden, M. C. Alessi, N. Debili, W. Vainchenker, P. G. Heller, R. Favier, and H. Raslova, “Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression,” Blood, vol. 120, no. 13, pp. 2708–2718, [2012]. C. Bourgier, A. Levy, M.-C. Vozenin, and E. Deutsch, “Pharmacological strategies to spare normal tissues from radiation damage: Useless or overlooked therapeutics?,” Cancer and Metastasis Reviews, vol. 31, no. 3–4, pp. 699–712, [2012]. L. Brugieres, A. Remenieras, G. Pierron, P. Varlet, S. Forget, V. Byrde, J. Bombled, S. Puget, O. Caron, C. Dufour, O. Delattre, B. Bressac-de Paillerets, and J. Grill, “High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2087–2093, [2012]. M. S. Cairo, R. Sposto, M. Gerrard, A. Auperin, S. C. Goldman, L. Harrison, R. Pinkerton, M. Raphael, K. McCarthy, S. L. Perkins, and C. Patte, “Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age ( ≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: Results of the FAB LM,” Journal of Clinical Oncology, vol. 30, no. 4, pp. 387–393, [2012]. C. Callens, F. Baleydier, E. Lengline, R. Ben Abdelali, A. Petit, P. Villarese, A. Cieslak, V. Minard-Colin, A. Rullier, A. Moreau, A. Baruchel, C. Schmitt, V. Asnafi, Y. Bertrand, and E. Macintyre, “Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1966–1973, [2012.] ANNUAL REPORT 2012 / GUSTAVE ROUSSY 67 GUSTAVE ROUSSY’S PUBLICATIONS [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] C. E. Cano, M. J. Sandí, T. Hamidi, E. L. Calvo, O. Turrini, L. Bartholin, C. Loncle, V. Secq, S. Garcia, G. Lomberk, G. Kroemer, R. Urrutia, and J. L. Iovanna, “Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer,” EMBO Molecular Medicine, vol. 4, no. 9, pp. 964–979, [2012]. D. Carmona-Gutierrez, G. Kroemer, and F. Madeo, “When Death Was Young: An Ancestral Apoptotic Network in Bacteria,” Molecular Cell, vol. 46, no. 5, pp. 552–554, [2012]. C. Chargari and E. Deutsch, “MET targeting: Perspectives for the radiation oncologist,” Nature Reviews Clinical Oncology, vol. 9, no. 9, [2012]. T. C. Chua, B. J. Moran, P. H. Sugarbaker, E. A. Levine, O. Glehen, F. N. Gilly, D. Baratti, M. Deraco, D. Elias, A. Sardi, W. Liauw, T. D. Yan, P. Barrios, A. G. Portilla, I. H. J. T. De Hingh, W. P. Ceelen, J. O. Pelz, P. Piso, S. GonzaĎezMoreno, K. Van Der Speeten, and D. L. Morris, “Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2449–2456, [2012]. G. Cornelis, O. Heidmann, S. Bernard-Stoecklin, K. Reynaud, G. Véron, B. Mulot, A. Dupressoir, and T. Heidmann, “Ancestral capture of syncytin-Car1, a fusogenic endogenous retroviral envelope gene involved in placentation and conserved in Carnivora,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. E432–E441, [2012]. F. Damm, O. Kosmider, V. Gelsi-Boyer, A. Renneville, N. Carbuccia, C. Hidalgo-Curtis, V. Della Valle, L. Couronné, L. Scourzic, V. Chesnais, A. Guerci-Bresler, B. Slama, O. Beyne-Rauzy, A. Schmidt-Tanguy, A. StamatoullasBastard, F. Dreyfus, T. Prébet, S. De Botton, N. Vey, M. A. Morgan, N. C. P. Cross, C. Preudhomme, D. Birnbaum, O. A. Bernard, and M. Fontenay, “Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes,” Blood, vol. 119, no. 14, pp. 3211–3218, [2012]. E. Dardenne, S. Pierredon, K. Driouch, L. Gratadou, M. Lacroix-Triki, M. P. Espinoza, E. Zonta, S. Germann, H. Mortada, J.-P. Villemin, M. Dutertre, R. Lidereau, S. Vagner, and D. Auboeuf, “Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness,” Nature Structural and Molecular Biology, vol. 19, no. 11, pp. 1139–1146, [2012]. A. De Masson, J.-D. Bouaziz, R. P. De Latour, S. Wittnebel, P. Ribaud, M.-T. Rubio, J.-B. Micol, F. Suarez, S. Nguyen, J.-H. Dalle, K. Yakouben, M. Robin, A. Xhaard, L. Adès, J.-H. Bourhis, M. Rybojad, M. Bagot, and G. Socié, “Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD,” Blood, vol. 120, no. 25, pp. 5089–5090, [2012]. C.-A. Dutertre, S. Amraoui, A. DeRosa, J.-P. Jourdain, L. Vimeux, M. Goguet, S. Degrelle, V. Feuillet, A.-S. Liovat, M. Mueller-Trutwin, N. Decroix, C. Deveau, L. Meyer, C. Goujard, P. Loulergue, O. Launay, Y. Richard, and A. Hosmalin, “Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNF alpha overproduction in response to microbial products,” Blood, vol. 120, no. 11, pp. 2259–2268, [Sep. 2012]. A. M. M. Eggermont and C. Robert, “Melanoma in 2011: A new paradigm tumor for drug development,” Nature Reviews Clinical Oncology, vol. 9, no. 2, pp. 74–76, [2012.] A. M. M. Eggermont, S. Suciu, A. Testori, M. Santinami, W. H. J. Kruit, J. Marsden, C. J. A. Punt, F. Salès, R. Dummer, C. Robert, D. Schadendorf, P. M. Patel, G. De Schaetzen, A. Spatz, and U. Keilholz, “Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma,” Journal of Clinical Oncology, vol. 30, no. 31, pp. 3810–3818, [2012.] A. M. M. Eggermont and C. Robert, “A new paradigm tumor for drug development,” Nature Reviews Clinical Oncology, vol. 9, no. 2, pp. 74–76, [2012.] T. Eisen, C. N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, and B. Escudier, “Targeted therapies for renal cell carcinoma: Review of adverse event management strategies,” Journal of the National Cancer Institute, vol. 104, no. 2, pp. 93–113, [2012]. B. Escudier, C. Szczylik, C. Porta, and M. Gore, “Treatment selection in metastatic renal cell carcinoma: Expert consensus,” Nature Reviews Clinical Oncology, vol. 9, no. 6, pp. 327–337, [2012]. E. Frisan, J. Vandekerckhove, A. De Thonel, C. Pierre-Eugène, A. Sternberg, J.-B. Arlet, C. Floquet, E. Gyan, O. Kosmider, F. Dreyfus, A.-S. Gabet, G. Courtois, P. Vyas, J.-A. Ribeil, Y. Zermati, C. Lacombe, P. Mayeux, E. Solary, C. Garrido, O. Hermine, and M. Fontenay, “Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes,” Blood, vol. 119, no. 6, pp. 1532–1542, [2012]. L. Galluzzi, O. Kepp, and G. Kroemer, “Enlightening the impact of immunogenic cell death in photodynamic cancer therapy,” EMBO Journal, vol. 31, no. 5, pp. 1055–1057, [2012]. L. Galluzzi, O. Kepp, C. Trojel-Hansen, and G. Kroemer, “Mitochondrial control of cellular life, stress, and death,” Circulation Research, vol. 111, no. 9, pp. 1198–1207, [2012]. L. Galluzzi and G. Kroemer, “Autophagy mediates the metabolic benefits of endurance training,” Circulation Research, vol. 110, no. 10, pp. 1276–1278, [2012]. E.-F. Gautier, M. Picard, C. Laurent, C. Marty, J.-L. Villeval, C. Demur, F. Delhommeau, E. Hexner, S. Giraudier, N. Bonnevialle, B. Ducommun, C. Récher, G. Laurent, S. Manenti, and V. Mansat-De Mas, “The cell cycle regulator CDC25A is a target for JAK2 V617F oncogene,” Blood, vol. 119, no. 5, pp. 1190–1199, [2012]. 68 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] H. Ghesquières, G. Cartron, J. F. Seymour, M.-H. Delfau-Larue, F. Offner, P. Soubeyran, A. Perrot, P. Brice, R. Bouabdallah, A. Sonet, J. Dupuis, O. Casasnovas, J. V Catalano, A. Delmer, F. Jardin, A. Verney, P. Dartigues, and G. Salles, “Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms,” Blood, vol. 120, no. 13, pp. 2650–2657, [2012]. L. Gineau, C. Cognet, N. Kara, F. P. Lach, J. Dunne, U. Veturi, C. Picard, C. Trouillet, C. Eidenschenk, S. Aoufouchi, A. Alcaïs, O. Smith, F. Geissmann, C. Feighery, L. Abel, A. Smogorzewska, B. Stillman, E. Vivier, J.-L. Casanova, and E. Jouanguy, “Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency,” Journal of Clinical Investigation, vol. 122, no. 3, pp. 821–832, [2012]. S. Gourgou-Bourgade, C. Bascoul-Mollevi, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J.-L. Raoul, V. Boige, J. Bérille, and T. Conroy, “Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial.,” Journal of Clinical Oncology, vol. 31, no. 1, pp. 23–9, [Dec. 2013]. D. Hannani, Y. Ma, T. Yamazaki, J. Déchanet-Merville, G. Kroemer, and L. Zitvogel, “Harnessing Ȗį T cells in anticancer immunotherapy,” Trends in Immunology, vol. 33, no. 5, pp. 199–206, [2012]. S. D. Haveli, P. Walter, G. Patriarche, J. Ayache, J. Castaing, E. Van Elslande, G. Tsoucaris, P.-A. Wang, and H. B. Kagan, “Hair fiber as a nanoreactor in controlled synthesis of fluorescent gold nanoparticles,” Nano Letters, vol. 12, no. 12, pp. 6212–6217, [2012]. M. Ignatiadis, S. K. Singhal, C. Desmedt, B. Haibe-Kains, C. Criscitiello, F. Andre, S. Loi, M. Piccart, S. Michiels, and C. Sotiriou, “Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1996–2004, [2012]. A. Jacquel, S. Obba, L. Boyer, M. Dufies, G. Robert, P. Gounon, E. Lemichez, F. Luciano, E. Solary, and P. Auberger, “Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions,” Blood, vol. 119, no. 19, pp. 4527–4531, [2012.] M. Jemaà, I. Vitale, O. Kepp, F. Berardinelli, L. Galluzzi, L. Senovilla, G. Mariño, S. A. Malik, S. Rello-Varona, D. Lissa, A. Antoccia, M. Tailler, F. Schlemmer, F. Harper, G. Pierron, M. Castedo, and G. Kroemer, “Selective killing of p53-deficient cancer cells by SP600125,” EMBO Molecular Medicine, vol. 4, no. 6, pp. 500–514, [2012]. A. Joosse, S. Collette, S. Suciu, T. Nijsten, F. Lejeune, U. R. Kleeberg, J. W. W. Coebergh, A. M. M. Eggermont, and E. De Vries, “Superior outcome of women with stage I/II cutaneous melanoma: Pooled analysis of four European organisation for research and treatment of cancer phase III trials,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2240–2247, [2012]. C. Langenberg, S. J. Sharp, M. B. Schulze, O. Rolandsson, K. Overvad, N. G. Forouhi, J. Spranger, D. Drogan, J. M. Huerta, L. Arriola, B. de Lauzon-Guillan, M.-J. Tormo, E. Ardanaz, B. Balkau, J. W. J. Beulens, H. Boeing, H. B. Bueno-de-Mesquita, F. Clavel-Chapelon, F. L. Crowe, P. W. Franks, C. A. Gonzalez, S. Grioni, J. Halkjaer, G. Hallmans, R. Kaaks, N. D. Kerrison, T. J. Key, K. T. Khaw, A. Mattiello, P. Nilsson, T. Norat, L. Palla, D. Palli, S. Panico, J. R. Quirós, D. Romaguera, I. Romieu, C. Sacerdote, M.-J. Sánchez, N. Slimani, I. Sluijs, A. M. W. Spijkerman, B. Teucher, A. Tjonneland, R. Tumino, D. L. van der A, Y. T. van der Schouw, E. J. M. Feskens, E. Riboli, and N. J. Wareham, “Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study.,” PLoS medicine, vol. 9, no. 6, p. e1001230, [Jan. 2012]. P. Laurent-Puig, G. Manceau, V. Boige, and H. Blons, “Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations?,” Gut, vol. 61, no. 5, pp. 637–638, [2012]. H. Leleu, F. Capuano, M. Ferrua, G. Nitenberg, E. Minvielle, and F. Schiele, “Onset-to-needle times in patients with ST-segment elevation myocardial infarction: shortest referral route to a primary coronary intervention facility,” European Heart Journal, vol. 33, no. 1, p. 843, [2012]. F. Lemonnier, L. Couronné, M. Parrens, J.-P. Jaïs, M. Travert, L. Lamant, O. Tournillac, T. Rousset, B. Fabiani, R.A. Cairns, T. Mak, C. Bastard, O. A. Bernard, L. De Leval, and P. Gaulard, “Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with T FH-like features and adverse clinical parameters,” Blood, vol. 120, no. 7, pp. 1466–1469, [2012]. C. Massard, S. Sandhu, M. Blanco, D. Papadatos-Pastos, C. Carden, J. De Bono, F. Saran, L. R. Molife, S. B. Kaye, J.-C. Soria, and U. Banerji, “Author reply : Toward a better dialogue between neuro-oncologists and phase I investigators,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 562–563, [2012]. A. Mauguen, C. Le Péchoux, M. I. Saunders, S. E. Schild, A. T. Turrisi, M. Baumann, W. T. Sause, D. Ball, C. P. Belani, J. A. Bonner, A. Zajusz, S. E. Dahlberg, M. Nankivell, S. J. Mandrekar, R. Paulus, K. Behrendt, R. Koch, J. F. Bishop, S. Dische, R. Arriagada, D. De Ruysscher, and J.-P. Pignon, “Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2788–2797, [2012]. E. Missiaglia, D. Williamson, J. Chisholm, P. Wirapati, G. Pierron, F. Petel, J.-P. Concordet, K. Thway, O. Oberlin, K. Pritchard-Jones, O. Delattre, M. Delorenzi, and J. Shipley, “PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification,” Journal of Clinical Oncology, vol. 30, no. 14, pp. 1670–1677, [2012]. E. Missiaglia, D. Williamson, J. Chisholm, P. Wirapati, G. Pierron, F. Petel, J.-P. Concordet, K. Thway, O. Oberlin, K. Pritchard-Jones, O. Delattre, M. Delorenzi, and J. Shipley, “Reply to S. Stegmaier et al : Questionable Universal Validity of PAX3/FOXO1 Fusion Gene Status As Molecular Marker for Improvement of Risk Stratification in Rhabdomyosarcoma Therapy,” Journal of Clinical Oncology, vol. 30, no. 32, pp. 4040–4041, [Nov. 2012]. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 69 GUSTAVE ROUSSY’S PUBLICATIONS [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] F. Nowak, J.-C. Soria, and F. Calvo, “Tumour molecular profiling for deciding therapy-the French initiative,” Nature Reviews Clinical Oncology, vol. 9, no. 8, pp. 479–486, [2012.] P. A. Oberholzer, D. Kee, P. Dziunycz, A. Sucker, N. Kamsukom, R. Jones, C. Roden, C. J. Chalk, K. Ardlie, E. Palescandolo, A. Piris, L. E. MacConaill, C. Robert, G. F. L. Hofbauer, G. A. McArthur, D. Schadendorf, and L. A. Garraway, “RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 316–321, [2012]. O. Oberlin, A. Rey, J. Sanchez De Toledo, H. Martelli, M. E. M. Jenney, M. Scopinaro, C. Bergeron, J. H. M. Merks, N. Bouvet, C. Ellershaw, A. Kelsey, D. Spooner, and M. C. G. Stevens, “Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of Pediatr,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2457–2465, [2012]. K. A. Olaussen, F. André, and J.-C. Soria, “Auhor reply : DNA repair capacity in circulating lymphocytes and influence on platinum effect in tumor cells,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1567–1568, [2012]. D. Olmos, R. P. A’Hern, S. Marsoni, R. Morales, C. Gomez-Roca, J. Verweij, E. E. Voest, P. Schöffski, J. E. Ang, N. Penel, J. H. Schellens, G. Del Conte, A. T. Brunetto, T. R. J. Evans, R. Wilson, E. Gallerani, R. Plummer, J. Tabernero, J.-C. Soria, and S. B. Kaye, “Patient selection for oncology phase I trials: A multi-institutional study of prognostic factors,” Journal of Clinical Oncology, vol. 30, no. 9, pp. 996–1004, [2012]. C. Pecquet, C. C. Diaconu, J. Staerk, M. Girardot, C. Marty, Y. Royer, J.-P. Defour, A. Dusa, R. Besancenot, S. Giraudier, J.-L. Villeval, L. Knoops, P. J. Courtoy, W. Vainchenker, and S. N. Constantinescu, “Thrombopoietin receptor down-modulation by JAK2 V617F: Restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes,” Blood, vol. 119, no. 20, pp. 4625–4635, [2012.] D. Peiffert, L. Tournier-Rangeard, J.-P. Gérard, C. Lemanski, E. François, M. Giovannini, F. Cvitkovic, X. Mirabel, O. Bouché, E. Luporsi, T. Conroy, C. Montoto-Grillot, F. Mornex, A. Lusinchi, J.-M. Hannoun-Lévi, J.-F. Seitz, A. Adenis, C. Hennequin, B. Denis, and M. Ducreux, “Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1941–1948, [2012]. G. Piessen, W. B. Robb, M. Messager, J. H. Lefevre, V. Pichot-Delhaye, A. Souadka, and C. Mariette, “Palliative resection for Advanced Gastric and Junctional Adenocarcinoma (AGJA): which patients will benefit from surgery?,” Gut, vol. 61, no. 2, p. A364, [2012]. S. Postel-Vinay, E. Vanhecke, K. A. Olaussen, C. J. Lord, A. Ashworth, and J.-C. Soria, “The potential of exploiting DNA-repair defects for optimizing lung cancer treatment,” Nature Reviews Clinical Oncology, vol. 9, no. 3, pp. 144–155, [2012]. I. Ray-Coquard, J.-Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, F. Heil, R. Rueger, B. Graves, M. Ding, D. Geho, S. A. Middleton, L. T. Vassilev, G. L. Nichols, and B. N. Bui, “Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proofof-mechanism study,” The Lancet Oncology, vol. 13, no. 11, pp. 1133–1140, [2012]. W. B. Robb, C. Mariette, L. Dahan, E. Maillard, F. Mornex, B. Meunier, V. Boige, C. Genet, D. Pezet, P. A. Thomas, and J. P. Triboulet, “Surgery alone vs chemoradiotherapy followed by surgery for stage I and II oesophageal cancer: final analysis of a randomised controlled phase III trial-FFCD 9901,” Gut, vol. 61, no. 2, pp. A37–A38, [2012]. D. A. Rodriguez, S. Zamorano, F. Lisbona, D. Rojas-Rivera, H. Urra, J. R. Cubillos-Ruiz, R. Armisen, D. R. Henriquez, E. H Cheng, M. Letek, T. Vaisar, T. Irrazabal, C. Gonzalez-Billault, A. Letai, F. X. Pimentel-Muiéos, G. Kroemer, and C. Hetz, “BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1_,” EMBO Journal, vol. 31, no. 10, pp. 2322–2335, [2012]. S. Salas, A. Dufresne, B. Bui, J.-Y. Blay, P. Terrier, D. Ranchere-Vince, S. Bonvalot, E. Stoeckle, L. Guillou, A. Le Cesne, O. Oberlin, V. Brouste, and J.-M. Coindre, “Reply to Y. Nishida et al,” Journal of Clinical Oncology, vol. 30, no. 12, p. 1391, [2012]. S. Salas, A. Dufresne, B. Bui, J.-Y. Blay, P. Terrier, D. Ranchere-Vince, S. Bonvalot, E. Stoeckle, L. Guillou, A. Le Cesne, O. Oberlin, V. Brouste, and J.-M. Coindre, “Is It Possible to Identify Clinically Useful Prognostic Groups for Patients With Desmoid Tumors? Reply,” Journal of Clinical Oncology, vol. 30, no. 12, p. 1391, [2012]. H. Salmon, K. Franciszkiewicz, D. Damotte, M.-C. Dieu-Nosjean, P. Validire, A. Trautmann, F. Mami-Chouaib, and E. Donnadieu, “Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors,” Journal of Clinical Investigation, vol. 122, no. 3, pp. 899–910, [2012]. E. Segura, J. Valladeau-Guilemond, M.-H. Donnadieu, X. Sastre-Garau, V. Soumelis, and S. Amigorena, “Characterization of resident and migratory dendritic cells in human lymph nodes,” Journal of Experimental Medicine, vol. 209, no. 4, pp. 653–660, [2012]. S. Shen, M. Niso-Santano, S. Adjemian, T. Takehara, S. A. Malik, H. Minoux, S. Souquere, G. Mariño, S. Lachkar, L. Senovilla, L. Galluzzi, O. Kepp, G. Pierron, M. C. Maiuri, H. Hikita, R. Kroemer, and G. Kroemer, “Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity,” Molecular Cell, vol. 48, no. 5, pp. 667–680, [2012]. 70 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] D. Sluik, B. Buijsse, R. Muckelbauer, R. Kaaks, B. Teucher, N. F. Johnsen, A. Tjønneland, K. Overvad, J. N. Ostergaard, P. Amiano, E. Ardanaz, B. Bendinelli, V. Pala, R. Tumino, F. Ricceri, A. Mattiello, A. M. W. Spijkerman, E. M. Monninkhof, A. M. May, P. W. Franks, P. M. Nilsson, P. Wennberg, O. Rolandsson, G. Fagherazzi, M. C. Boutron-Ruault, F. Clavel-Chapelon, J. M. H. Castaño, V. Gallo, H. Boeing, and U. Nöthlings, “Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis.,” Archives of internal medicine, vol. 172, no. 17, pp. 1285–1295, [Aug. 2012]. E. Solary, “PHAGOCYTES & GRANULOCYTES When monocyte life hangs by a thread,” Blood, vol. 119, no. 12, pp. 2699–2700, [Mar. 2012]. E. Soucie, K. Hanssens, T. Mercher, S. Georgin-Lavialle, G. Damaj, C. Livideanu, M. O. Chandesris, Y. Acin, S. Létard, P. De Sepulveda, O. Hermine, O. A. Bernard, and P. Dubreuil, “In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells,” Blood, vol. 120, no. 24, pp. 4846–4849, [2012]. A. S. Tarakhovsky and G. Kroemer, “Innate immunity,” Current Opinion in Immunology, vol. 24, no. 1, pp. 1–2, [2012]. C. Thiollier, C. K. Lopez, B. Gerby, C. Ignacimouttou, S. Poglio, Y. Duffourd, J. Guégan, P. Rivera-Munoz, O. Bluteau, V. Mabialah, M. Diop, Q. Wen, A. Petit, A.-L. Bauchet, D. Reinhardt, B. Bornhauser, D. Gautheret, Y. Lecluse, J. Landman-Parker, I. Radford, W. Vainchenker, N. Dastugue, S. de Botton, P. Dessen, J.-P. Bourquin, J. D. Crispino, P. Ballerini, O. A. Bernard, F. Pflumio, and T. Mercher, “Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models,” Journal of Experimental Medicine, vol. 209, no. 11, pp. 2017–2031, [2012]. M. Y. Tolstorukov, J. A. Goldman, C. Gilbert, V. Ogryzko, R. E. Kingston, and P. J. Park, “Histone Variant H2A.Bbd Is Associated with Active Transcription and mRNA Processing in Human Cells,” Molecular Cell, vol. 47, no. 4, pp. 596–607, [2012]. F. Touzot, L. Gaillard, N. Vasquez, T. Le Guen, Y. Bertrand, J. Bourhis, T. Leblanc, A. Fischer, J. Soulier, J.-P. De Villartay, and P. Revy, “Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita,” Journal of Allergy and Clinical Immunology, vol. 129, no. 2, pp. 473–482.e3, [2012]. K. Y. Urayama, R. F. Jarrett, H. Hjalgrim, A. Diepstra, Y. Kamatani, A. Chabrier, V. Gaborieau, A. Boland, A. Nieters, N. Becker, L. Foretova, Y. Benavente, M. Maynadié, A. Staines, L. Shield, A. Lake, D. Montgomery, M. Taylor, K. E. Smedby, R.-M. Amini, H.-O. Adami, B. Glimelius, B. Feenstra, I. M. Nolte, L. Visser, G. W. Van Imhoff, T. Lightfoot, P. Cocco, L. Kiemeney, S. H. Vermeulen, I. Holcatova, L. Vatten, G. J. MacFarlane, P. Thomson, D. I. Conway, S. Benhamou, A. Agudo, C. M. Healy, K. Overvad, A. Tjønneland, B. Melin, F. Canzian, K.-T. Khaw, R. C. Travis, P. H. M. Peeters, C. A. González, J. R. Quirós, M.-J. Sánchez, J. M. Huerta, E. Ardanaz, M. Dorronsoro, F. Clavel-Chapelon, H. B. Bueno-De-Mesquita, E. Riboli, E. Roman, P. Boffetta, S. De Sanjosé, D. Zelenika, M. Melbye, A. Van Den Berg, M. Lathrop, P. Brennan, and J. D. McKay, “Genome-wide association study of classical hodgkin lymphoma and epstein-barr virus status-defined subgroups,” Journal of the National Cancer Institute, vol. 104, no. 3, pp. 240–253, [2012]. M. A. E. Van Der Kaaij, N. Heutte, P. Meijnders, E. Abeilard-Lemoisson, M. Spina, E. C. Moser, A. Allgeier, B. Meulemans, A. H. M. Simons, P. J. Lugtenburg, B. M. P. Aleman, E. M. Noordijk, C. Fermé, J. Thomas, A. Stamatoullas, C. Fruchart, P. Brice, I. Gaillard, S. Bologna, F. Ong, H. Eghbali, J. K. Doorduijn, F. Morschhauser, C. Sebban, J. M. Roesink, M. Bouteloup, A. Van Hoof, J. M. M. Raemaekers, M. Henry-Amar, and H. C. KluinNelemans, “Premature ovarian failure and fertility in long-term survivors of Hodgkin’s lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’ÉTude des Lymphomes de l’Adulte Cohort Study,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 291–299, [2012]. M. A. E. Van Der Kaaij, N. Heutte, P. Meijnders, E. Abeilard-Lemoisson, M. Spina, L. C. Moser, A. Allgeier, B. Meulemans, B. Dubois, A. H. M. Simons, P. J. Lugtenburg, B. M. P. Aleman, E. M. Noordijk, C. Fermé, J. Thomas, A. Stamatoullas, C. Fruchart, P. Brice, I. Gaillard, J. K. Doorduijn, C. Sebban, W. G. J. M. Smit, S. Bologna, J. M. Roesink, F. Ong, M. P. E. André, J. M. M. Raemaekers, M. Henry-Amar, and H. C. Kluin-Nelemans, “Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study,” Journal of Clinical Oncology, vol. 30, no. 31, pp. 3854–3863, [2012]. N. Vey, J.-H. Bourhis, N. Boissel, D. Bordessoule, T. Prebet, A. Charbonnier, A. Etienne, P. Andre, F. Romagne, D. Benson, H. Dombret, and D. Olive, “A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission,” Blood, vol. 120, no. 22, pp. 4317–4323, [2012]. S. A. Wells Jr., B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J. R. Vasselli, J. Read, P. Langmuir, A. J. Ryan, and M. J. Schlumberger, “Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial,” Journal of Clinical Oncology, vol. 30, no. 2, pp. 134–141, [2012]. S. A. Wells Jr., B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J. R. Vasselli, J. S. Read, P. Langmuir, A. J. Ryan, and M. J. Schlumberger, “Reply to J.-F. Chatal et al. : Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2166–2167, [2012]. Y. Zermati, S. Mouhamad, L. Stergiou, B. Besse, L. Galluzzi, S. Boehrer, A.-L. Pauleau, F. Rosselli, M. D’Amelio, R. Amendola, M. Castedo, M. Hengartner, J.-C. Soria, F. Cecconi, and G. Kroemer, “Nonapoptotic role for apaf-1 in the DNA damage checkpoint,” Molecular Cell, vol. 48, no. 2, pp. 322–324, [2012]. L. Zitvogel and F. Housseau, “IKDCs or B220+ NK cells are pre-mNK cells,” Blood, vol. 119, no. 19, pp. 4345–4346, [2012]. ANNUAL REPORT 2012 / GUSTAVE ROUSSY 71 GUSTAVE ROUSSY’S PUBLICATIONS INTERNATIONAL PUBLICATIONS BY GUSTAVE ROUSSY With an impact factor between 5 and 10 (415 publications in 2012) [1] Abanesi, Marcello, Mancardi, David A., Macdonald, Lynn E., Iannascoli, Bruno, Zitvogel, Laurence, Murphy, Andrew J., Leusen, Jeanette H., and Bruhns, Pierre Cutting Edge : Fc gamma RIII (CD16) and Fc gamma R1 (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. [2012] Journal of Immunology (189) 12 : 5513-5517. Impact factor : 5.520 [2] Adam, Julien, Bollée, Guillaume, Fougeray, Sophie, Noël, Laure Hélène, Antignac, Corinne, Knebelman, Bertrand, and Pallet, Nicolas Endoplasmic reticulum stress in UMOD-related kidney disease: a human pathologic study. [2012] American journal of kidney diseases : the official journal of the National Kidney Foundation (59) 1 : 117-121. Impact factor : 5.294 [3] Adinolfi, E., Raffaghello, L., Giuliani, A. L., Cavazzini, L., Capece, M., Chiozzi, P., Bianchi, G., Kroemer, G., Pistoia, V., and Di Virgilio, F. Expression of P2X7 receptor increases in vivo tumor growth. [2012] Cancer Research (72) 12 : 2957-2969. Impact factor : 8.650 [4] Ahluwalia, Namanjeet, Tondeur, Laura, Boutron, Marie Christine, and Clavel-Chaperon, Francoise Healthy Mediterranean-like dietary pattern predicts reduced risk of acute myocardial infarction (MI) in women: The EpicFrance (E3N) prospective cohort study. [2012] FASEB Journal (26). Impact factor : 5.704 [5] Al Batran, S. E., Ducreux, M., and Ohtsu, A. MTOR as a therapeutic target in patients with gastric cancer. [2012] International Journal of Cancer (130) 3 : 491-496. Impact factor : 6.198 [6] Al Nakouzi, N., Bawa, O., le Pape, A., Lerondel, S., Gaudin, C., Opolon, P., Gonin, P., Fizazi, K., and Chauchereau, A. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/ blastic bone lesions observed in metastatic prostate cancer. [2012] Neoplasia (14) 5 : 376-387. Impact factor : 5.470 [7] Alapetite, Claire, Puget, Stephanie, Ruffier, Amandine, Habrand, Jean Louis, Bolle, Stephanie, Noel, Georges, Nauraye, Catherine, De Marzy, Ludovic, Boddaert, Nathalie, Brisse, Herve, Sainte-Rose, Christian, Zerah, Michel, Boetto, Sergio, Laffond, Christelle, Chevignard, Mathilde, Grill, Jacques, and Doz, Francois Protontherapy for craniopharyngioma in children: update of the Orsay proton center experience. [2012] Neuro-Oncology (14) supplt 1 : 24-24. Impact factor : 6.180 [8] Albanesi, M., Mancardi, D. A., Macdonald, L. E., Iannascoli, B., Zitvogel, L., Murphy, A. J., Leusen, J. H., and Bruhns, P. Cutting edge: FcyRIII (CD16) and FcyRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. [2012] Journal of Immunology (189) 12 : 55135517. Impact factor : 5.520 [9] Albiges, L., Chamming’s, F., Duclos, B., Stern, M., Motzer, R. J., Ravaud, A., and Camus, P. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. [2012] Annals of Oncology (23) 8 : 1943-1953. Impact factor : 7.384 [10] Albiges, L., Le Moulec, S., Loriot, Y., Goupil, M. Gross, Rouge, T. De La Motte, Guillot, A., Fizazi, K., and Massard, C. Reponse to Cabazitaxel in the Postchemotherapy Setting in CRPC Patients Previously Treated with Docetaxel and Abiraterone Acetate. [2012] Annals of Oncology (23) 9 : 313-313. Impact factor : 7.384 [11] Albiges, L., Riet, F., Massard, C., Le Moulec, S., Loriot, Y., Levy, A., Fizazi, K., and Escudier, B. Second line treatment in metastatic papillary renal cell carcinoma: retrospective analysis of a 48 patients cohort. [2012] Annals of Oncology (23) 9 : 277-277. Impact factor : 7.384 [12] Aleksandrova, K., Boeing, H., Jenab, M., Bueno-de-Mesquita, H. B., Jansen, E., Van duijnhoven, F. J., Fedirko, V., Rinaldi, S., Romieu, I., Riboli, E., Romaguera, D., Westphal, S., Overvad, K., Tjonneland, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., Kaaks, R., Lukanova, A., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Agnoli, C., Mattiello, A., Saieva, C., Vineis, P., Tumino, R., Peeters, P. H., Argüelles, M., Bonet, C., Sanchez, M., Dorronsoro, M., Huerta, J., Barricarte, A., Palmqvist, R., Hallmans, G., Khaw, K., Wareham, N., Allen, N. E., Crowe, F. L., and Pischon, T. Total and high-molecular weight adiponectin and risk of colorectal cancer: The European prospective investigation into cancer and nutrition study. [2012] Carcinogenesis (33) 6 : 1211-1218. Impact factor : 5.635 72 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [13] Aleksandrova, K., Boeing, H., Jenab, M., Bueno-de-Mesquita, H. B., Jansen, E., Van Duijnhoven, F. J. B., Rinaldi, S., Fedirko, V., Romieu, I., Riboli, E., Gunter, M. J., Westphal, S., Overvad, K., Tjonneland, A., Halkjaer, J., Racine, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., Kaaks, R., Lukanova, A., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Mattiello, A., Pala, V., Palli, D., Tumino, R., Vineis, P., Buckland, G., Sanchez, M. J., Amiano, P., Huerta, J. M., Barricarte, A., Menendez, V., Peeters, P. H., Soderberg, S., Palmqvist, R., Allen, N. E., Crowe, F. L., Khaw, K. T., Wareham, N., and Pischon, T. Leptin and soluble leptin receptor in risk of colorectal cancer in the European prospective investigation into cancer and nutrition cohort. [2012] Cancer Research (72) 20 : 5328-5337. Impact factor : 8.650 [14] Allard, D., Lacroix-Triki, M., Maillot, G., Mhamdi, L., Pierredon, S., Obrist, F., Goubar, A., Roche, H., Andre, F., and Vagner, S. A FEEDBACK REGULATORY LOOP BETWEEN MIR-125B AND BRMS1 LINKED TO BREAST TUMOR PROGRESSION. [2012] Annals of Oncology (23) 2. Impact factor : 7.384 [15] Andre, F., Conforti, R., Moeder, C. B., Mauguen, A., Arnedos, M., Berrada, N., Delaloge, S., Tomasic, G., Spielmann, M., Esteva, F. J., Rimm, D. L., and Michiels, S. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. [2012] Annals of Oncology (23) 8 : 20592064. Impact factor : 7.384 [16] Andre, F. and Zielinski, C. C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. [2012] Annals of Oncology (23) SUPPL. 6 : vi46-vi51. Impact factor : 7.384 [17] Andre, F. Introduction: recent failures in drug development for TN MBC. [2012] Annals of Oncology (23) 9 : 29-29. Impact factor : 7.384 [18] Andre, F., Nowak, F., Arnedos, M., Lacroix, L., Viens, P., and Calvo, F. Biomarker discovery, development, and implementation in France: A report from the French National Cancer Institute and Cooperative Groups. [2012] Clinical Cancer Research (18) 6 : 1555-1560. Impact factor : 7.837 [19] Andre, Fabrice, Dieci, Maria V., Dubsky, Peter, Sotiriou, Christos, Curigliano, Giuseppe, Denkert, Carsten, and Loi, Sherene Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. [2012] Clinical Cancer Research. Impact factor : 7.837 [20] Angevin, E., Trillet-Lenoir, V., Isambert, N., Alexandre, J., Valleix, F., Podoll, T., Miyashita, I., Yamada, T., Kaneko, Y., and Morimoto, C. First-in-human phase 1 administration of YS110, a humanized monoclonal antibody directed against the CD26 molecule in cancer patients. [2012] Annals of Oncology (23) 9 : 170-171. Impact factor : 7.384 [21] Antoniou, Antonis C., Kuchenbaecker, Karoline B., Soucy, Penny, Beesley, Jonathan, Chen, Xiaoqing, McGuffog, Lesley, Lee, Andrew, Barrowdale, Daniel, Healey, Sue, Sinilnikova, Olga M., Caligo, Maria A., Loman, Niklas, Harbst, Katja, Lindblom, Annika, Arver, Brita, Rosenquist, Richard, Karlsson, Per, Nathanson, Kate, Domchek, Susan, Rebbeck, Tim, Jakubowska, Anna, Lubinski, Jan, Jaworska, Katarzyna, Durda, Katarzyna, Zlowowcka-Perlowska, Elzbieta, Osorio, Ana, Duran, Mercedes, Andres, Raquel, Benitez, Javier, Hamann, Ute, Hogervorst, Frans B., van Os, Theo A., Verhoef, Senno, Meijers-Heijboer, Hanne E. J., Wijnen, Juul, Garcia, Encarna B. G., Ligtenberg, Marjolijn J., Kriege, Mieke, Collee, Margriet, Ausems, Margreet G. E. M., Oosterwijk, Jan C., Peock, Susan, Frost, Debra, Ellis, Steve D., Platte, Radka, Fineberg, Elena, Evans, D. Gareth, Lalloo, Fiona, Jacobs, Chris, Eeles, Ros, Adlard, Julian, Davidson, Rosemarie, Cole, Trevor, Cook, Jackie, Paterson, Joan, Douglas, Fiona, Brewer, Carole, Hodgson, Shirley, Morrison, Patrick J., Walker, Lisa, Rogers, Mark T., Donaldson, Alan, Dorkins, Huw, Godwin, Andrew K., Bove, Betsy, Stoppa-Lyonnet, Dominique, Houdayer, Claude, Buecher, Bruno, de Pauw, Antoine, Mazoyer, Sylvie, Calender, Alain, Leone, Melanie, Bressac-de Paillerets, Brigitte, Caron, Olivier, Sobol, Hagay, Frenay, Marc, Prieur, Fabienne, Ferrer, Sandra Fert, Mortemousque, Isabelle, Buys, Saundra, Daly, Mary, Miron, Alexander, Terry, Mary Beth, Hopper, John L., John, Esther M., Southey, Melissa, Goldgar, David, Singer, Christian F., Fink-Retter, Anneliese, Tea, Muy Kheng, Kaulich, Daphne Geschwantler, Hansen, Thomas V. O., Nielsen, Finn C., Barkardottir, Rosa B., Gaudet, Mia, Kirchhoff, Tomas, Joseph, Vijai, Dutra-Clarke, Ana, Offit, Kenneth, Piedmonte, Marion, Kirk, Judy, Cohn, David, Hurteau, Jean, Byron, John, Fiorica, James, Toland, Amanda E., Montagna, Marco, Oliani, Cristina, Imyanitov, Evgeny, Isaacs, Claudine, ANNUAL REPORT 2012 / GUSTAVE ROUSSY 73 GUSTAVE ROUSSY’S PUBLICATIONS Tihomirova, Laima, Blanco, Ignacio, Lazaro, Conxi, Teule, Alex, Del Valle, J., Gayther, Simon A., Odunsi, Kunle, Gross, Jenny, Karlan, Beth Y., Olah, Edith, Teo, Soo Hwang, Ganz, Patricia A., Beattie, Mary S., Dorfling, Cecelia M., van Rensburg, Elizabeth Jansen, Diez, Orland, Kwong, Ava, Schmutzler, Rita K., Wappenschmidt, Barbara, Engel, Christoph, Meindl, Alfons, Ditsch, Nina, Arnold, Norbert, Heidemann, Simone, Niederacher, Dieter, Preisler-Adams, Sabine, Gadzicki, Dorothea, Varon-Mateeva, Raymonda, Deissler, Helmut, Gehrig, Andrea, Sutter, Christian, Kast, Karin, Fiebig, Britta, Schaefer, Dieter, Caldes, Trinidad, de la Hoya, Miguel, Nevanlinna, Heli, Muranen, Taru A., Lesperance, Bernard, Spurdle, Amanda B., Neuhausen, Susan L., Ding, Yuan C., Wang, Xianshu, Fredericksen, Zachary, Pankratz, Vernon S., Lindor, Noralane M., Peterlongo, Paolo, Manoukian, Siranoush, Peissel, Bernard, Zaffaroni, Daniela, Bonanni, Bernardo, Bernard, Loris, Dolcetti, Riccardo, Papi, Laura, Ottini, Laura, Radice, Paolo, Greene, Mark H., Loud, Jennifer T., Andrulis, Irene L., Ozcelik, Hilmi, Mulligan, Anna Marie, Glendon, Gord, Thomassen, Mads, Gerdes, Anne Marie, Jensen, Uffe B., Skytte, Anne Bine, Kruse, Torben A., Chenevix-Trench, Georgia, Couch, Fergus J., Simard, Jacques, Easton, Douglas F., Collaborator, CIMBA Study, Collaborator, SWE BRCA Study, Collaborator, HEBON Study, Collaborator, EMBRACE Study, Collaborator, GEMO Study, and Investigators, K. C. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. [2012] Breast Cancer Research (14) 1. Impact factor : 5.872 [22] [23] Antony-Debré, I., Bluteau, D., Itzykson, R., Baccini, V., Renneville, A., Boehlen, F., Morabito, M., Droin, N., Deswarte, C., Chang, Y., Leverger, G., Solary, E., Vainchenker, W., Favier, R., and Raslova, H. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. [2012] Blood (120) 13 : 2719-2722. Impact factor : 9.060 Arnault, J. P., Mateus, C., Escudier, B., Tomasic, G., Wechsler, J., Hollville, E., Soria, J. C., Malka, D., Sarasin, A., Larcher, M., André, J., Kamsu-Kom, N., Boussemart, L., Lacroix, L., Spatz, A., Eggermont, A. M., Druillennec, S., Vagner, S., Eychène, A., Dumaz, N., and Robert, C. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. [2012] Clinical Cancer Research (18) 1 : 263-272. Impact factor : 7.837 [24] Arnedos, M., Scott, V., Job, B., De La Cruz, J., Commo, F., Mathieu, M. C., Wolp-Diniz, R., Richon, C., Campone, M., Bachelot, T., Dalenc, F., Dessen, P., Lacroix, L., Lazar, V., Soria, J. C., Delaloge, S., and Andre, F. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer. [2012] European Journal of Cancer (48) 15 : 2293-2299. Impact factor : 5.061 [25] Arnedos, Monica, André, Fabrice, Farace, Françoise, Lacroix, Ludovic, Besse, Benjamin, Robert, Caroline, Soria, Jean Charles, and Eggermont, Alexander M. M. The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy. [2012] Molecular Oncology (6) 2 : 204-210. Impact factor : 6.701 [26] Auvray, C., Delahaye, A., Pflumio, F., Haddad, R., Amsellem, S., Miri-Nezhad, A., Broix, L., Yacia, A., Bulle, F., Fichelson, S., and Vigon, I. HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4. [2012] Haematologica (97) 2 : 168-178. Impact factor : 5.935 [27] Ayala-Ramirez, M., Chougnet, C. N., Habra, M. A., Palmer, J. L., Leboulleux, S., Cabanillas, M. E., Caramella, C., Anderson, P., Al Ghuzlan, A., Waguespack, S. G., Deandreis, D., Baudin, E., and Jimenez, C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. [2012] Journal of Clinical Endocrinology and Metabolism (97) 11 : 4040-4050. Impact factor : 6.430 [28] Azim, Hatem A., Michiels, Stefan, Bedard, Philippe L., Singhal, Sandeep K., Criscitiello, Carmen, Ignatiadis, Michail, Haibe-Kains, Benjamin, Piccart, Martine J., Sotiriou, Christos, and Loi, Sherene Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. [2012] Clinical cancer research : an official journal of the American Association for Cancer Research (18) 5 : 1341-1351. Impact factor : 7.837 [29] Azizi, Amedeo A., Fox, Richard, Grill, Jacques, Mirow, Cora, Gnekow, Astrid, Walker, David, Perilongo, Giorgio, Opocher, Enrico, Wheatley, Keith, and van Meeteren, Antoinette Y. N. S. Children below the age of two treated for optic pathway glioma- a multinational, retrospective multivariate analysis of risk factors. [2012] Neuro-Oncology (14) supp 1 : i79-i79. Impact factor : 6.180 [30] Bachelot, T., Ferrero, J., Cropet, C., Bourgier, C., Abadie-Lacourtoisie, S., Levy, C., Legouffe, E., Lortholary, A., Pujade-Lauraine, E., and Treilleux, I. Translational studies within the TAMRAD randomized GINECO trial: evidence for TOR1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer (MBC). [2012] Annals of Oncology (23) 2. Impact factor : 7.384 74 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [31] Bachner, M., Loriot, Y., Gross-goupil, M., Zucali, P. A., Horwich, A., Germa-lluch, J. R., Kollmannsberger, C., Stoiber, F., Fléchon, A., Oechsle, K., Gillessen, S., Oldenburg, J., Cohn-cedermark, G., Daugaard, G., Morelli, F., Sella, A., Harland, S., Kerst, M., Gampe, J., Dittrich, C., Fizazi, K., and De Santis, M. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: A retrospective validation of the sempet trial. [2012] Annals of Oncology (23) 1 : 59-64. Impact factor : 7.384 [32] Barret, M., Dalban, C., Taieb, J., Malka, D., Mansourbakht, T., Latko, E., and Antoun, S. Sarcopenia affects treatment toxicity in metastatic colorectal cancer patients: results of a prospective multicenter study. [2012] Annals of Oncology (23) 9 : 511-512. Impact factor : 7.384 [33] Basch, E., Ryan, C. J., Kheoh, T., Fizazi, K., Logothetis, C. J., Rathkopf, D. E., Smith, M. R., Mainwaring, P. N., Hao, Y., Griffin, T., Li, S., Meyers, M., Molina, A., and Cleeland, C. THE IMPACT OF ABIRATERONE ACETATE (AA) THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAIVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). [2012] Annals of Oncology (23) 9 : 295-295. Impact factor : 7.384 [34] Bastie, J. N., Aucagne, R., Droin, N., Solary, E., and Delva, L. Heterogeneity of molecular markers in chronic myelomonocytic leukemia: A disease associated with several gene alterations. [2012] Cellular and Molecular Life Sciences (69) 17 : 2853-2861. Impact factor : 5.615 [35] Bazin, H., Andre, F., Mathieu, M., Ho-Pun-Cheung, A., Lopez-Crapez, E., Mathis, G., and Garnero, P. PREDICTION OF DISEASE OUTCOME WITH QUANTITATIVE MEASUREMENT OF HER-2 RECEPTOR EXPRESSION AND DIMERIZATION IN PATIENTS WITH BREAST CANCER. [2012] Annals of Oncology (23) 9 : 84-84. Impact factor : 7.384 [36] Beleoken, E., Sobesky, R., Le Caer, J. P., Roche, B., Mustapha, M. Z., Guettier, C., Sebagh, M., Johanet, C., Samuel, D., Bourhis, J. H., Duclos-Vallee, J. C., and Ballot, E. AUTOIMMUNE-LIKE HEPATITIS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION: A NEW ENTITY CHARACTERISED BY USING A PROTEOMIC APPROACH. [2012] Journal of Hepatology (56) 2. Impact factor : 9.858 [37] Bendell, J., Roda, D., Mateo, J., Hollebecque, A., Mattos-Arruda, L., Meng, R., Isakoff, S., Molife, L. R., Tabernero, J., and Cervantes Ruiperez, A. PHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR GDC-0068 WITH DOCETAXEL (D) OR MODIFIED FOLFOX6 (F) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. [2012] Annals of Oncology (23) 9 : 159-159. Impact factor : 7.384 [38] Benhamou, Ygal, Assie, Cyrielle, Boelle, Pierre Yves, Buffet, Marc, Grillberger, Rana, Malot, Sandrine, Wynckel, Alain, Presne, Claire, Choukroun, Gabriel, Poullin, Pascale, Provot, Francois, Gruson, Didier, Hamidou, Mohamed, Bordessoule, Dominique, Pourrat, Jacques, Mira, Jean Paul, Le Guern, Veronique, Pouteil-Noble, Claire, Daubin, Cedric, Vanhille, Philippe, Rondeau, Eric, Palcoux, Jean Bernard, Mousson, Christiane, Vigneau, Cecile, Bonmarchand, Guy, Guidet, Bertrand, Galicier, Lionel, Azoulay, Elie, Rottensteiner, Hanspeter, Veyradier, Agnes, Coppo, Paul, and Refer, Thrombotic Microangiopathies Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. [2012] Haematologica (97) 8 : 1181-1186. Impact factor : 5.935 [39] Bennetzen, M. V., Marino, G., Pultz, D., Morselli, E., Faergeman, N. J., Kroemer, G., and Andersen, J. S. Phosphoproteomic analysis of cells treated with longevity-related autophagy inducers. [2012] Cell Cycle (11) 9 : 18271840. Impact factor : 5.243 [40] Bennouna, J., Ducreux, M., Asselain, B., Phelip, J., Andre, T., Senellart, H., and Commenges, B. EFFICACY AND SAFETY OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN DAILY PRACTICE IN 765 FRENCH PATIENTS WITH MCRC: THE CONCERT COHORT AT A MAXIMUM OF 24 MONTHS FOLLOW-UP. [2012] Annals of Oncology (23) 9 : 218-218. Impact factor : 7.384 [41] Benusiglio, P. R., Malka, D., De Pauw, A., Buecher, B., Rouleau, E., Colas, C., Grandjouan, S., Blayau, M., Delaloge, S., and Caron, O. Germline mutations in cdh1 and the hereditary diffuse gastric and lobular breast cancer syndrome. [2012] Annals of Oncology (23) 9 : 175-175. Impact factor : 7.384 [42] Bergmann, L., Kube, U., Albiges, L., Eymard, J., Schmidinger, M., Bamias, A., Ktiouet, M., Fischer, G., Xanthaki, D., and Guderian, G. Pooled analysis of non-interventional studies of everolimus in patients with metastatic renal cell carcinoma (MRCC) refractory to anti-VEGF therapy. [2012] Annals of Oncology (23) 9 : 278-278. Impact factor : 7.384 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 75 GUSTAVE ROUSSY’S PUBLICATIONS [43] Bergthold, Guillaume, Piette, Caroline, Raquin, Marie Anne, Dufour, Christelle, Varlet, Pascale, Dhermain, Frederic, Puget, Stephanie, Sainte-Rose, Christian, Abely, Michel, CANALE, Sandra, and Grill, Jacques Clinical and radiological predictive factors of chemosensitivity in pediatric low grade gliomas: a single center study. [2012] Neuro-Oncology (14) supp 1 : i76-i76. Impact factor : 6.180 [44] Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., and Pentheroudakis, G. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. [2012] Annals of Oncology (23) SUPPL. 7 : vii131-vii138. Impact factor : 7.384 [45] Bertrand, J., Despeaux, M., Joly, S., Bourogaa, E., Gallay, N., Demur, C., Bonnevialle, P., Louache, F., Maguer-Satta, V., Vergnolle, N., Payrastre, B., and Racaud-Sultan, C. Sex differences in the GSK3+Æ-mediated survival of adherent leukemic progenitors. [2012] Oncogene (31) 6 : 694-705. Impact factor : 7.357 [46] Besse, B., Le Moulec, S., Senellart, H., Mazieres, J., Barlesi, F., Dansin, E., Robinot, G., Perol, M., Moro-Sibilot, D., and Soria, J. Phase II study of bevacizumab in combination with 1st-line chemotherapy or 2nd-line erlotinib in non-squamous NSCLC (NS-NSCLC) patients with asymptomatic untreated brain metastases (ML21823). [2012] Annals of Oncology (23) 9 : 426-427. Impact factor : 7.384 [47] Besse, B. and Le chevalier, T. Developments in the treatment of early NSCLC: When to use chemotherapy. [2012] Annals of Oncology (23) SUPPL. 10 : x52-x59. Impact factor : 7.384 [48] Besse, B., Salgia, R., Solomon, B., Shaw, A., Kim, D., Schachar, R., Wilner, K., Reisman, A., Bartlett, C. H., and Iyer, S. Visual disturbances in patients (PTS) with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib. [2012] Annals of Oncology (23) 9 : 416-416. Impact factor : 7.384 [49] Bianchini, D., Loriot, Y., Ileana, E., Sandhu, S., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., and Massard, C. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study. [2012] Annals of Oncology (23) 9 : 304-305. Impact factor : 7.384 [50] Bidard, F., Ligthart, S. T., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Viens, P., Pierga, J., and Terstappen, L. W. M. M. Automated quantitative HER2 assessment in circulating tumor cells: discrepancies with primary tumor in neoadjuvant and metastatic trials. [2012] Annals of Oncology (23) 2. Impact factor : 7.384 [51] Bidard, F. C., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Cottu, P., Beuzeboc, P., Rolland, E., Mathiot, C., and Pierga, J. Y. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: A prospective observational study. [2012] Breast Cancer Research (14) 1. Impact factor : 5.872 [52] Blay, J. Y., Pérol, D., and Le Cesne, A. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. [2012] Annals of Oncology (23) 7 : 1659-1665. Impact factor : 7.384 [53] Bluteau, D., Glembotsky, A. C., Raimbault, A., Balayn, N., Gilles, L., Rameau, P., Nurden, P., Alessi, M. C., Debili, N., Vainchenker, W., Heller, P. G., Favier, R., and Raslova, H. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. [2012] Blood (120) 13 : 2708-2718. Impact factor : 9.060 [54] Boichard, A., Croux, L., Al Ghuzlan, A., Broutin, S., Dupuy, C., Leboulleux, S., Schlumberger, M., Bidart, J. M., and Lacroix, L. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. [2012] Journal of Clinical Endocrinology and Metabolism (97) 10 : E2031-E2035. Impact factor : 6.430 [55] Bonvalot, S., De Baere, T., Mendiboure, J., Paci, A., Farace, F., Drouard-Troalen, L., Bonnet, L., Hakime, A., Bonniaud, G., Raynard, B., Israel, P., Le Cesne, A., Eggermont, A. M., Laplanche, A., and Muret, J. Hyperthermic pelvic perfusion with tumor necrosis factor-a for locally advanced cancers: Encouraging results of a phase II study. [2012] Annals of Surgery (255) 2 : 281-286. Impact factor : 6.329 [56] Bonvalot, S., Desai, A., Coppola, S., Le péchoux, C., Terrier, P., Dômont, J., and Le Cesne, A. The treatment of desmoid tumors: A stepwise clinical approach. [2012] Annals of Oncology (23) SUPPL. 10 : x158-x166. Impact factor : 7.384 [57] Bonvalot, S., Meeus, P., Stoeckle, E., Bui, B., Le Cesne, A., Penel, N., Ray-Coquard, I. L., Coindre, J., Chemin, C., Blay, J., and Network, Netsarc Natl Organisation of sarcoma patient management in reference centers in NETSARC network: analysis of the quality of resection. [2012] Annals of Oncology (23) 9 : 482-482. Impact factor : 7.384 76 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [58] Borget, I., Cadranel, J., Pignon, J. P., Quoix, E., Coudert, B., Westeel, V., Dansin, E., Madelaine, J., Madroszyk, A., Friard, S., Daniel, C., Morin, F., and Chouaid, C. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. [2012] EUROPEAN RESPIRATORY JOURNAL (39) 1 : 172-179. Impact factor : 6.355 [59] Borget, I., Perol, M., Perol, D., Lavole, A., Greillier, L., Gervais, R., Zalcman, G., Chabaud, S., Vergnenegre, A., and Chouaid, C. Cost-utility analysis of maintenance therapy with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502-ECO phase III study. [2012] Annals of Oncology (23) 9 : 397-398. Impact factor : 7.384 [60] Boubakour-Azzouz, I., Bertrand, P., Claes, A., Lopez, B. S., and Rougeon, F. Terminal deoxynucleotidyl transferase requires KU80 and XRCC4 to promote N-addition at non-V(D)J chromosomal breaks in non-lymphoid cells. [2012] Nucleic Acids Research (40) 17 : 8381-8391. Impact factor : 8.278 [61] Bouche, O., Le Cesne, A., Rios, M., Chaigneau, L., Bui, B., Xavier, P., and Blay, J. Real-life management of advanced gastrointestinal stromal tumors (GIST) treated with imatinib in France. [2012] Annals of Oncology (23) 9 : 236-236. Impact factor : 7.384 [62] Bourgier, C., Levy, A., Vozenin, M. C., and Deutsch, E. Pharmacological strategies to spare normal tissues from radiation damage: Useless or overlooked therapeutics? [2012] Cancer and Metastasis Reviews (31) 3-4 : 699-712. Impact factor : 7.787 [63] Bracarda, S., Hutson, T. E., Porta, C., Figlin, R. A., Calvo, E., Grünwald, V., Ravaud, A., Motzer, R., Kim, D., Anak, O., Panneerselvam, A., and Escudier, B. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: A RECORD-1 subgroup analysis. [2012] British Journal of Cancer (106) 9 : 1475-1480. Impact factor : 5.082 [64] Braem, M. G. M., Onland-Moret, N. C., Schouten, L. J., Tjonneland, A., Hansen, L., Dahm, C. C., Overvad, K., Lukanova, A., Dossus, L., Floegel, A., Boeing, H., Clavel-Chapelon, F., Chabbert-Buffet, N., Fagherazzi, G., Trichopoulou, A., Benetou, V., Goufa, I., Pala, V., Galasso, R., Mattiello, A., Sacerdote, C., Palli, D., Tumino, R., Gram, I. T., Lund, E., Gavrilyuk, O., Sanchez, M. J., Quiros, R., Gonzales, C. A., Dorronsoro, M., Huerta Castano, J. M., Gurrea, A. B., Idahl, A., Ohlson, N., Lundin, E., Jirstrom, K., Wirfalt, E., Allen, N. E., Tsilidis, K. K., Kaw, K. T., Bueno-de-Mesquita, H. B., Dik, V. K., Rinaldi, S., Fedirko, V., Norat, T., Riboli, E., Kaaks, R., and Peeters, P. H. M. Coffee and tea consumption and the risk of ovarian cancer: A prospective cohort study and updated meta-analysis. [2012] American Journal of Clinical Nutrition (95) 5 : 1172-1181. Impact factor : 6.504 [65] Brennan, K., Garcia-Closas, M., Orr, N., Fletcher, O., Jones, M., Ashworth, A., Swerdlow, A., Thorne, H., Riboli, E., Vineis, P., Dorronsoro, M., Clavel-Chapelon, F., Panico, S., Onland-Moret, N. C., Trichopoulos, D., Kaaks, R., Khaw, K. T., Brown, R., and Flanagan, J. M. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. [2012] Cancer Research (72) 9 : 2304-2313. Impact factor : 8.650 [66] Bussone, Guillaume, Tamby, Mathieu C., Calzas, Cynthia, Kherbeck, Nada, Sahbatou, Younes, Sanson, Claire, Ghazal, Khaldoun, Dib, Hanadi, Weksler, Babette B., Broussard, Cedric, Verrecchia, Franck, Yaici, Azzedine, Witko-Sarsat, Veronique, Simonneau, Gerald, Guillevin, Loic, Humbert, Marc, and Mouthon, Luc IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. [2012] ANNALS OF THE RHEUMATIC DISEASES (71) 4 : 596-605. Impact factor : 9.111 [67] Calvo, E., Escudier, B., Motzer, R. J., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Gr++nwald, V., Thompson, J. A., Ravaud, A., Kim, D., Panneerselvam, A., Anak, O., and Figlin, R. A. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. [2012] European Journal of Cancer (48) 3 : 333-339. Impact factor : 5.061 [68] Cano, C. E., Sandi, M. J., Hamidi, T., Calvo, E. L., Turrini, O., Bartholin, L., Loncle, C., Secq, V., Garcia, S., Lomberk, G., Kroemer, G., Urrutia, R., and Iovanna, J. L. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. [2012] EMBO Molecular Medicine (4) 9 : 964-979. Impact factor : 7.795 [69] Cao, C., Yan, T. D., Deraco, M., Elias, D., Glehen, O., Levine, E. A., Moran, B. J., Morris, D. L., Chua, T. C., Piso, P., Sugarbaker, P. H., Baratti, D., Kusamura, S., Gilly, F. N., Shen, P., and Mohamed, F. Importance of gender in diffuse malignant peritoneal mesothelioma. [2012] Annals of Oncology (23) 6 : 1494-1498. Impact factor : 7.384 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 77 GUSTAVE ROUSSY’S PUBLICATIONS [70] Caputo, S., Benboudjema, L., Sinilnikova, O., Rouleau, E., Béroud, C., Lidereau, R., Sevenet, N., Bonnet, F., Longy, M., Hardouin, A., Vaur, D., Krieger, S., Uhrhammer, N., Bignon, Y. J., Peyrat, J. P., Revillion, F., Fournier, J., Remenieras, A., Mazoyer, S., léone, M., Sobol, H., Noguchi, T., Bourdon, V., Rey, J. M., Bronner, M., Jonveaux, P., Philippe, C., Delnatte, C., Coulet, F., Castera, L., Caux-Moncoutier, V., Houdayer, C., Stoppa-Lyonnet, D., Delvincourt, C., Gorisse, M. C., Bièche, I., Lefol, C., Muller, D., Abecassis, J., Toulas, C., Guillaud-Bataille, M., and Paillerets, B. B. D. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. [2012] Nucleic Acids Research (40) D1 : D992-D1002. Impact factor : 8.278 [71] Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., Marotti, L., Penault-Llorca, F., Kotti-Kitromilidou, A. M., Rodger, A., and Harbeck, N. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. [2012] European Journal of Cancer (48) 18 : 3355-3377. Impact factor : 5.061 [72] Carmona-Gutierrez, D., Sommer, C., Andryushkova, A., Kroemer, G., and Madeo, F. A higher spirit: Avoiding yeast suicide during alcoholic fermentation. [2012] Cell Death and Differentiation (19) 6 : 913-914. Impact factor : 8.371 [73] Carson, C., Omolo, B., Chu, H., Zhou, Y., Sambade, M. J., Peters, E. C., Tompkins, P., Simpson, D. A., Thomas, N. E., Fan, C., Sarasin, A., Dessen, P., Shields, J. M., Ibrahim, J. G., and Kaufmann, W. K. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. [2012] Pigment Cell and Melanoma Research (25) 4 : 514-526. Impact factor : 5.839 [74] Carson, C., Omolo, B., Chu, H., Zhou, Y., Tompkins, P., Simpson, D., Fan, C., Sarasin, A., Dessen, P., Ibrahim, J., Kaufmann, W., and Thomas, N. Using a gene signature to predict metastases in melanoma patients. [2012] Journal of investigative dermatology (132) 1 : S27-S27. Impact factor : 6.193 [75] Casali, P. G., Reichardt, P., Kang, Y., Blay, J., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., Badalamenti, G., Blackstein, M., Le Cesne, A., Schoffski, P., Maki, R., Xu, J., Nishida, T., Kuss, I., Laurent, D., and Demetri, G. D. Clinical benefit with regorafenib across subgroups and post-progression in patients with advanced gastrointestinal stromal tumor (GIST) after progression on imatinib (IM) and sunitinib (SU): phase 3 grid trial update. [2012] Annals of Oncology (23) 9 : 478-479. Impact factor : 7.384 [76] Cassier, P. A., Gelderblom, H., Stacchiotti, S., Thomas, D., Maki, R. G., Kroep, J. R., Van Der Graaf, W. T., Italiano, A., Seddon, B., D+¦mont, J., Bompas, E., Wagner, A. J., and Blay, J. Y. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. [2012] Cancer (118) 6 : 1649-1655. Impact factor : 5.201 [77] Castedo, M., Senovilla, L., Vitale, I., and Kroemer, G. Tetraploid cancer cell precursors in ovarian carcinoma. [2012] Cell Cycle (11) 17 : 3157-3158. Impact factor : 5.243 [78] Cella, D., Kaiser, K., Beaumont, J., Diaz, J., McCann, L., Mehmud, F., Lata, S., Bono, P., Porta, C., and Escudier, B. Quality of life (QOL) among renal cell carcinoma (RCC) patients in a randomized double blind cross-over patient preference study of pazopanib (P) versus sunitinib (S). [2012] Annals of Oncology (23) 9 : 261-262. Impact factor : 7.384 [79] Colin, C., De Vathaire, F., Noël, A., Charlot, M., Devic, C., Foray, N., and Valette, P. J. Updated relevance of mammographic screening modalities in women previously treated with chest irradiation for hodgkin disease. [2012] Radiology (265) 3 : 669-676. Impact factor : 6.339 [80] Coppo, Paul and VEYRADIER, Agnès Microangiopathies thrombotiques : référentiels hémostase/Société française d’hématologie (Thrombotic microangiopathic syndromes: SFH recommendations]. [2012] Hématologie (18) 4 : 221232. Impact factor : 5.935 [81] Coriat, Romain, Nicco, Carole, Chéreau, Christiane, Mir, Olivier, Alexandre, J., Ropert, Stanislas, Weill, Bernard, Chaussade, Stanislas, Goldwasser, François, and Batteux, Frédéric Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. [2012] Molecular cancer therapeutics (11) 10 : 2284-2293. Impact factor : 5.599 [82] Cortés, J., Caralt, M., Delaloge, S., Cortes-Funes, H., Pierga, J. Y., Pritchard, K. I., Bollag, D. T., and Miles, D. W. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. [2012] European Journal of Cancer (48) 4 : 475-481. Impact factor : 5.061 78 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [83] Cosnefroy, O., Tocco, A., Lesbats, P., Thierry, S., Calmels, C., Wiktorowicz, T., Reigadas, S., Kwon, Y., De Cian, A., Desfarges, S., Bonot, P., San Filippo, J., Litvak, S., Le Cam, E., Rethwilm, A., Fleury, H., Connell, P. P., Sung, P., Delelis, O., Andréola, M. L., and Parissi, V. Stimulation of the human RAD51 nucleofilament restricts HIV-1 integration in vitro and in infected cells. [2012] Journal of Virology (86) 1 : 513-526. Impact factor : 5.076 [84] Cousin, S., Hollebecque, A., Koscielny, S., Varga, A., Baracos, V., Soria, J., and Antoun, S. BODY COMPOSITION IS LINKED TO TOXICITY AND OUTCOME IN PATIENTS (PTS) INCLUDED IN PHASE I TRIALS. [2012] Annals of Oncology (23) 9 : 168-169. Impact factor : 7.384 [85] Criollo, A., Chereau, F., Malik, S. A., Niso-Santano, M., Marino, G., Galluzzi, L., Maiuri, M. C., Baud, V., and Kroemer, G. Autophagy is required for the activation of NF+¦B. [2012] Cell Cycle (11) 1 : 194-199. Impact factor : 5.243 [86] Criollo, A., Chereau, F., Malik, S. A., Niso-Santano, M., Marino, G., Galluzzi, L., Maiuri, M. C., Baud, V., and Kroemer, G. Autophagy is required for the activation of NFkB (erratum : Cell Cycle 11, 1 (194-199)). [2012] Cell Cycle (11) 24 : 4673-4673. Impact factor : 5.243 [87] Cufer, T., Cardoso, F., Werutsky, G., Bonnefoi, H., Brain, E., Cataliotti, L., Dal Lago, L., Delaloge, S., Jassem, J., van Tienhoven, G., Van’t Veer, L., Westenberg, H., Marreaud, S., Bogaerts, J., Rutgers, E., and Cameron, D. The EORTC Breast Cancer Group: Major achievements of 50 years of research and future directions. [2012] European Journal of Cancer, Supplement (10) 1 : 27-33. Impact factor : 5.061 [88] Daboussi, F., Zaslavskiy, M., Poirot, L., Loperfido, M., Gouble, A., Guyot, V., Leduc, S., Galetto, R., Grizot, S., Oficjalska, D., Perez, C., Delacôte, F., Dupuy, A., Chion-Sotinel, I., Le Clerre, D., Lebuhotel, C., Danos, O., Lemaire, F., Oussedik, K., Cédrone, F., Epinat, J. C., Smith, J., Yanez-Munoz, R. J., Dickson, G., Popplewell, L., Koo, T., Vandendriessche, T., Chuah, M. K., Duclert, A., Duchateau, P., and Pâques, F. Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. [2012] Nucleic Acids Research (40) 13 : 6367-6379. Impact factor : 8.278 [89] Dalmay, C., De Menorval, M. A., Français, O., Mir, L. M., and Le Pioufle, B. A microfluidic device with removable packaging for the real time visualisation of intracellular effects of nanosecond electrical pulses on adherent cells. [2012] Lab on a Chip - Miniaturisation for Chemistry and Biology (12) 22 : 4709-4715. Impact factor : 5.697 [90] Damm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronné, L., Scourzic, L., Chesnais, V., Guerci-Bresler, A., Slama, B., Beyne-Rauzy, O., Schmidt-Tanguy, A., Stamatoullas-Bastard, A., Dreyfus, F., Prébet, T., De Botton, S., Vey, N., Morgan, M. A., Cross, N. C. P., Preudhomme, C., Birnbaum, D., Bernard, O. A., and Fontenay, M. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. [2012] Blood (119) 14 : 3211-3218. Impact factor : 9.060 [91] David, M., Petit, D., and Bertoglio, J. Cell cycle regulation of Rho signaling pathways. [2012] Cell Cycle (11) 16 : 30033010. Impact factor : 5.243 [92] de Lara, C. Tunon, Giard, S., Baron, M., Le Bouedec, G., Garbay, J. R., Blanchot, J., Mollard, J., Charitansky, H., Martin-Francoise, S., and Macgrogan, G. Sentinel Node Biopsy in Extensive Ductal Carcinoma in Situ (DCIS) Results of the French Prospective Trial CINNAMOME. [2012] European Journal of Cancer (48) 1 : S190-S191. Impact factor : 5.061 [93] de Leval, L., Bonnet, C., Copie-Bergman, C., Seidel, L., Baia, M., Bri+¿re, J., Molina, T. J., Fabiani, B., Petrella, T., Bosq, J., Gisselbrecht, C., Siebert, R., Tilly, H., Haioun, C., Fillet, G., and Gaulard, P. Diffuse large B-cell lymphoma of waldeyer’s ring has distinct clinicopathologic features: A GELA study. [2012] Annals of Oncology (23) 12 : 3143-3151. Impact factor : 7.384 [94] De Masson, A., Bouaziz, J. D., De Latour, R. P., Wittnebel, S., Ribaud, P., Rubio, M. T., Micol, J. B., Suarez, F., Nguyen, S., Dalle, J. H., Yakouben, K., Robin, M., Xhaard, A., Adès, L., Bourhis, J. H., Rybojad, M., Bagot, M., and Socié, G. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. [2012] Blood (120) 25 : 5089-5090. Impact factor : 9.060 [95] De Ruysscher, D., Ramaekers, B. L. T., Joore, M. A., Lueza, B., Bonastre, J., Mauguen, A., Pignon, J., Le Pechoux, C., Grutters, J. P., and Grp, Mar LC Collaborative MODIFIED FRACTIONATION RADIOTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY FOR UNRESECTED NON-SMALL CELL LUNG CANCER PATIENTS: A COST-EFFECTIVENESS ANALYSIS. [2012] Annals of Oncology (23) 9 : 397-397 . Impact factor : 7.384 [96] Decorsière, A., Toulas, C., Fouque, F., Tilkin-Mariamé, A. F., Selves, J., Guimbaud, R., Chipoulet, E., Delmas, C., Rey, J. M., Pujol, P., Favre, G., Millevoi, S., and Vagner, S. Decreased efficiency of MSH6 mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families. [2012] Cell Cycle (11) 13 : 2578-2580. Impact factor : 5.243 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 79 GUSTAVE ROUSSY’S PUBLICATIONS [97] Delbaldo, C., Michiels, S., Rolland, E., Syz, N., Soria, J. C., Le chevalier, T., and Pignon, J. P. WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. [2012] Cochrane database of systematic reviews (4). Impact factor : 5.703 [98] Demetri, G. D., Garrett, C. R., Schöffski, P., Shah, M. H., Verweij, J., Leyvraz, S., Hurwitz, H. I., Pousa, A. L., Le Cesne, A., Goldstein, D., Paz-Ares, L., Blay, J. Y., McArthur, G. A., Xu, Q., Huang, X., Harmon, C. S., Tassell, V., Cohen, D. P., and Casali, P. G. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. [2012] Clinical Cancer Research (18) 11 : 3170-3179. Impact factor : 7.837 [99] Demetri, G. D., Le Cesne, A., Chawla, S. P., Brodowicz, T., Maki, R. G., Bach, B. A., Smethurst, D. P., Bray, S., Hei, Y. J., and Blay, J. Y. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. [2012] European Journal of Cancer (48) 4 : 547-563. Impact factor : 5.061 [100] Deutsch, E., Rivera, C., and Rivera, S. NEW DRUGS ON THE HORIZON TARGETING STEM CELLS IN NSCLC. [2012] Annals of Oncology (23) 1 : 18-18. Impact factor : 7.384 [101] Dib, Hanadi, Tamby, Mathieu C., Bussone, Guillaume, Regent, Alexis, Berezne, Alice, Lafine, Claudine, Broussard, Cedric, Simonneau, Gerald, Guillevin, Loic, Witko-Sarsat, Veronique, Humbert, Marc, and Mouthon, Luc Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. [2012] EUROPEAN RESPIRATORY JOURNAL (39) 6 : 1405-1414. Impact factor : 6.355 [102] Dienstmann, R., Andre, F., Soria, J., Tabernero, J., De Braud, F. G. M., Cereda, R., Bahleda, R., Hollebecque, A., Delmonte, A., and Camboni, M. G. SIGNIFICANT ANTITUMOR ACTIVITY OF E-3810, A NOVEL FGFR AND VEGFR INHIBITOR, IN PATIENTS WITH FGFR1 AMPLIFIED BREAST CANCER. [2012] Annals of Oncology (23) 9 : 116-117. Impact factor : 7.384 [103] Dogan, S., Goubar, A., Arnedos, M., Delaloge, S., and Andre, F. EVOLUTION AND LANDSCAPE OF CLINICAL TRIALS FOR BREAST CANCER PATIENTS. [2012] Annals of Oncology (23) 2. Impact factor : 7.384 [104] DRAKE, C. G., EGGERMONT, Alexander M., FINN, Olivera J., and KERR, D. J. Combination immunotherapy approaches. [2012] Annals of Oncology (23) SUP8 - Advances in Immuno-oncology. Impact factor : 7.384 [105] Dromain, C., Thibault, F., Diekmann, F., Fallenberg, E. M., Jong, R. A., Koomen, M., Hendrick, R. E., Tardivon, A., and Toledano, A. Dual-energy contrast-enhanced digital mammography: Initial clinical results of a multireader, multicase study. [2012] Breast Cancer Research (14) 3. Impact factor : 5.872 [106] Ducreux, M., Lievre, A., Artru, P., Guiu, M., Merlin, J., Sabourin, J. C., Viguier, J., Bastie, A., Seronde, A., and LAURENT-PUIG, P. REVIEW OF THE CURRENT STATUS OF KRAS MUTATION TESTING IN FRANCE IN 2011: THE FLASH-KRAS STUDY. [2012] Annals of Oncology (23) 9 : 85-85. Impact factor : 7.384 [107] Ducreux, Michel, Davidenko, Irina, Propper, David, Cardellino, Giovanni Gerardo, Garin, Avgust, Bridgewater, John, Jain, Minesh, Kupcinskas, Limas, Safina, Sufiya, Fittipaldo, Alberto, Bordogna, Walter, Hillenbach, Carina, and Klughammer, Barbara EXPLORATORY SERUM BIOMARKER ANALYSES FROM BO21129, A PHASE II STUDY OF ERLOTINIB IN SECOND-LINE PANCREATIC CANCER: POTENTIAL ROLE OF AMPHIREGULIN? [2012] Annals of Oncology (23) 4 : 7-7. Impact factor : 7.384 [108] Ducreux, Michel, Peeters, Marc, Siena, Salvatore, Douillard, Jean Yves, Punt, Cornelis, Braun, Stephan, Rong, Alan, and Sidhu, Roger BENEFIT OF ADDING PANITUMUMAB (PMAB) TO 1ST/2ND-LINE CHEMOTHERAPY IN PATIENTS WITH KRAS WT MCRC: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS. [2012] Annals of Oncology (23) 4 : 26-27. Impact factor : 7.384 [109] Duell, E. J., Sala, N., Travier, N., Munoz, X., Boutron-Ruault, M. C., Clavel-Chapelon, F., Barricarte, A., Arriola, L., Navarro, C., Sanchez-Cantalejo, E., Quiros, J. R., Krogh, V., Vineis, P., Mattiello, A., Tumino, R., Khaw, K., Wareham, N., Allen, N. E., Peeters, P. H., Numans, M. E., Bueno-de-Mesquita, H. B., Van Oijen, M. G. H., Bamia, C., Benetou, V., Trichopoulos, D., Canzian, F., Kaaks, R., Boeing, H., Bergmann, M. M., Lund, E., Ehrnström, R., Johansen, D., Hallmans, G., Stenling, R., Tjonneland, A., Overvad, K., Ostergaard, J. N., Ferrari, P., Fedirko, V., Jenab, M., Nesi, G., Riboli, E., and Gonzalez, C. A. Genetic variation in alcohol dehydrogenase (ADH1A, ADH1B, ADH1C, ADH7) and aldehyde dehydrogenase (ALDH2), alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and nutrition (EPIC) Cohort. [2012] Carcinogenesis (33) 2 : 361-367. Impact factor : 5.635 80 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] Duffaud, F., Huynh, T., Cassier, P., Boucher, E., Bouche, O., Le Cesne, A., Landi, B., Mancini, J., Marchal, F., and Blay, J. FINAL RESULTS OF A FRENCH SARCOMA GROUP (FSG) RETROSPECTIVE REVIEW OF 110 PATIENTS WITH PRIMARY LOCALIZED GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE DUODENUM. [2012] Annals of Oncology (23) 9 : 482-482. Impact factor : 7.384 Dufour, C., Beaugrand, A., Le Deley, M. C., Bourdeaut, F., André, N., Leblond, P., Bertozzi, A. I., Frappaz, D., Rialland, X., Fouyssac, F., Edan, C., Grill, J., Quidot, M., and Varlet, P. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: A multicenter study. [2012] Cancer (118) 15 : 3812-3821. Impact factor : 5.201 Dunet, Vincent, Rossier, Christine, Buck, Alfred, Stupp, Roger, and Prior, John O. Performance of 18F-fluoro-ethyltyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. [2012] Journal of nuclear medicine : official publication, Society of Nuclear Medicine (53) 2 : 207-214. Impact factor : 5.774 Durand, J. P., Deplanque, G., Montheil, V., Gornet, J. M., Scotte, F., Mir, O., Cessot, A., Coriat, R., Raymond, E., Mitry, E., Herait, P., Yataghene, Y., and Goldwasser, F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. [2012] Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (23) 1 : 200205. Impact factor : 7.384 Dutertre, Charles Antoine, Amraoui, Sonia, DeRosa, Annalisa, Jourdain, Jean Pierre, Vimeux, Lene, Goguet, Matthieu, Degrelle, Severine, Feuillet, Vincent, Liovat, Anne Sophie, Mueller-Trutwin, Michaela, Decroix, Nipa, Deveau, Christiane, Meyer, Laurence, Goujard, Cecile, Loulergue, Pierre, Launay, Odile, Richard, Yolande, and Hosmalin, Anne Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNF alpha overproduction in response to microbial products. [2012] Blood (120) 11 : 2259-2268. Impact factor : 9.060 Dutta, B., Pusztai, L., Qi, Y., André, F., Lazar, V., Bianchini, G., Ueno, N., Agarwal, R., Wang, B., Shiang, C. Y., Hortobagyi, G. N., Mills, G. B., Symmans, W. F., and Bal+ízsi, G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. [2012] British Journal of Cancer (106) 6 : 1107-1116. Impact factor : 5.082 Edeline, J., Loriot, Y., Culine, S., Massard, C., Albiges, L., Blesius, A., Escudier, B., and Fizazi, K. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. [2012] European Journal of Cancer (48) 8 : 1141-1146. Impact factor : 5.061 Eggermont, A. M. M. Can immuno-oncology offer a truly pan-tumour approach to therapy? [2012] Annals of Oncology (23) SUPPL.8 : viii53-viii57. Impact factor : 7.384 Eggermont, A. M. M., Suciu, S., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Santinami, M., Sals, F., Schadendorf, D., Patel, P., Dummer, R., Robert, C., Keilholz, U., Yver, A., and Spatz, A. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. [2012] European Journal of Cancer (48) 2 : 218-225. Impact factor : 5.061 Elias, D. WHEN TO THINK OF SURGERY PLUS OR MINUS HIPEC FOR PERITONEAL CARCINOMATOSIS. [2012] Annals of Oncology (23) 9 : 35-35. Impact factor : 7.384 Ernoult-Lange, M., Baconnais, S., Harper, M., Minshall, N., Souquere, S., Boudier, T., Bénard, M., Andrey, P., Pierron, G., Kress, M., Standart, N., Le Cam, E., and Weil, D. Multiple binding of repressed mRNAs by the P-body protein Rck/p54. [2012] RNA (18) 9 : 1702-1715. Impact factor : 5.088 Escudier, B., Eisen, T., Porta, C., Patard, J. J., Khoo, V., Algaba, F., Mulders, P., and Kataja, V. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. [2012] Annals of Oncology (23) SUPPL. 7 : vii65-vii71. Impact factor : 7.384 [122] Escudier, B., Albiges, L., Massard, C., Loriot, Y., and Fizazi, K. How to select amongst available options for the treatment of advanced RCC? [2012] Annals of Oncology (23) SUPPL. 10 : x309-x312. Impact factor : 7.384 [123] Escudier, B., Osanto, S., Ljungberg, B., Porta, C., Wagstaff, J., Mulders, P., Gore, M., Bex, A., Bellmunt, J., Bracarda, S., Franklin, A., Honoré, P. H., Ravaud, A., Steijn, J. V., Aziz, Z., and Akaza, H. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. [2012] Cancer Treatment Reviews (38) 2 : 127-132. Impact factor : 6.024 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 81 GUSTAVE ROUSSY’S PUBLICATIONS [124] Escudier, B. Emerging immunotherapies for renal cell carcinoma. [2012] Annals of Oncology (23) SUPPL.8 : viii35-viii40. Impact factor : 7.384 [125] Escudier, B., Steelman, L., Cesic, D., and Berkenblit, A. PATIENT PREFERENCE FOR TIVOZANIB HYDROCHLORIDE OR SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC): TAURUS STUDY. [2012] Annals of Oncology (23) 9 : 293-293. Impact factor : 7.384 [126] Escudier, B., Bracarda, S., Maroto, J. P., Szczylik, C., Nathan, P., Negrier, S., Slimane, K., May, C., Porta, C., and Gruenwald, V. OPEN-LABEL PHASE II TRIAL OF FIRST-LINE EVEROLIMUS MONOTHERAPY IN PATIENTS WITH ADVANCED PAPILLARY RENAL CELL CARCINOMA: RAPTOR INTERIM ANALYSIS. [2012] Annals of Oncology (23) 9 : 264-264. Impact factor : 7.384 [127] Fabre, C., Koscielny, S., Mohty, M., Fegueux, N., Blaise, D., Maillard, N., Tabrizi, R., Michallet, M., Société, G., Yakoub-Agha, I., Garban, F., Uzunov, M., François, S., Contentin, N., Lapusan, S., and Bourhis, J. H. Younger donor’s age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: A retrospective study from the société française de greffe de moelle. [2012] Haematologica (97) 4 : 482-490. Impact factor : 5.935 [128] Fadoukhair, Z., Lefeuvre, D., Hofert, K., Lanoy, E., Rahhali, R., Mathieu, M., Mazouni, C., and Delaloge, S. PROFESSIONAL ATTITUDES TOWARDS TREATMENT OF RARE HISTOLOGICAL SUBTYPES OF CARCINOMAS OF THE BREAST: AN INTERNATIONAL PRACTICE SURVEY (PARIS STUDY). [2012] Annals of Oncology (23) 9 : 110-110. Impact factor : 7.384 [129] Fagherazzi, G., Chabbert-Buffet, N., Fabre, A., Guillas, G., Boutron-Ruault, M. C., Mesrine, S., and ClavelChapelon, F. Hip circumference is associated with the risk of premenopausal ER-/PR breast cancer. [2012] International Journal of Obesity (36) 3 : 431-439. Impact factor : 5.221 [130] Farace, F., Le Moulec, S., Mazieres, J., Senellart, H., Dansin, E., Madroszyk, A., Quantin, X., Berard, H., and Besse, B. CIRCULATING ENDOTHELIAL CELLS (CEC), CIRCULATING ENDOTHELIAL PROGENITORS (CEP) AND CIRCULATING TUMOUR CELLS (CTC) AS MARKERS FOR RESPONSE TO BEVACIZUMAB/CARBOPLATIN/ PACLITAXEL (B plus CP) OR BEVACIZUMAB/ERLOTINIB (B plus E) IN ADVANCED NON-SQUAMOUS NON-SM. [2012] Annals of Oncology (23) 9 : 406-407. Impact factor : 7.384 [131] Farace, F. F., Lombard-Bohas, C., Mitry, E., Ychou, M., Bengrine-Lefevre, L., Lecomte, T., Joly, K., Ducreux, M., and Baudin, E. PREDICTIVE VALUE OF CIRCULATING ENDOTHELIAL CELL (CEC) LEVELS IN METASTATIC OR LOCALLY ADVANCED NEUROENDOCRINE DIGESTIVE TUMOR PATIENTS TREATED WITH CHEMOTHERAPY AND BEVACIZUMAB. [2012] Annals of Oncology (23) 9 : 85-85. Impact factor : 7.384 [132] Fauvet, R., Brzakowski, M., Morice, P., Resch, B., Marret, H., Graesslin, O., and Daraï, E. Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: Results of a French multicenter study. [2012] Annals of Oncology (23) 6 : 1481-1487. Impact factor : 7.384 [133] Felip, E., Carcereny, E., Barlesi, F., Gandhi, L., Sequist, L. V., Kim, S. W., Groen, H. J. M., Besse, B., Kim, D. W., Smit, E., Akimov, M., Avsar, E., Bailey, S., Ofosu-Appiah, W., and Garon, E. B. PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NONSMALL CELL LUNG CANCER (NSCLC). [2012] Annals of Oncology (23) 9 : 152-152. Impact factor : 7.384 [134] Ferme, Christophe, CHAIBI, Pascal, and ROCHAND, Henri Les modalités des traitements spécifiques du lymphome de Hodgkin des sujets âgés. Prise en charge des hémopathies malignes du sujet âgés. Seconde partie. [2012] Hématologie (18) SUP2 : 19-22. Impact factor : 5.935 [135] Ferrand, F. R., Gourzones, C., Verillaud, B., Saada, E., Lang, P., Schneider, V., Amiel, C., Guigay, J., and Busson, P. PLASMATIC EPSTEIN-BARR VIRUS MICRO-RNA-BART-17 IN NASOPHARYNGEAL CARCINOMAS PATIENTS: HIGH POTENTIAL AS A TUMOR BIOMARKER ASSOCIATED TO EBV DNA CONCENTRATION. [2012] Annals of Oncology (23) 9 : 337-337. Impact factor : 7.384 [136] Ferrari, A., De Salvo, G. L., Oberlin, O., Casanova, M., De Paoli, A., Rey, A., Minard, V., Orbach, D., Carli, M., Brennan, B., Vannoesel, M. M., Morosi, C., Stevens, M. C., and Bisogno, G. Synovial sarcoma in children and adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. [2012] European Journal of Cancer (48) 9 : 1370-1375. Impact factor : 5.061 82 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [137] Ferreira, Celine, Dieffenbach, Geoffrey, Barbosa, Carmela, Cuny, Pascale, and Grill, Jacques ANTI-TUMORAL EFFECT OF THE HDACi SAHA ON PEDIATRIC GLIAL TUMORS. [2012] Neuro-Oncology (14) supplt 1 : 39-39. Impact factor : 6.180 [138] Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T., Cornfeld, M., and Hudes, G. R. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. [2012] European Journal of Cancer (48) 1 : 85-93. Impact factor : 5.061 [139] Fizazi, K., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J. M., Houedé, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J. F., Baciuchka, M., Laguerre, B., Fléchon, A., Ravaud, A., Cojean-Zelek, I., Oudard, S., Labourey, J. L., Lagrange, J. L., Chinet-Charrot, P., Linassier, C., Deplanque, G., Beuzeboc, P., Geneve, J., Davin, J. L., Tournay, E., and Culine, S. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. [2012] European Journal of Cancer (48) 2 : 209-217. Impact factor : 5.061 [140] Fizazi, K., Albiges, L., Massard, C., Escudier, B., and Loriot, Y. Novel and bone-targeted agents for CRPC. [2012] Annals of Oncology (23) SUPPL. 10 : x264-x267. Impact factor : 7.384 [141] Fizazi, K., Scher, H. I., Saad, F., Sternberg, C. N., Miller, K., Mulders, P., Chi, K., Basch, E., Hirmand, M., and De Bono, J. S. IMPACT OF ENZALUTAMIDE, AN ANDROGEN RECEPTOR SIGNALING INHIBITOR, ON TIME TO FIRST SKELETAL RELATED EVENT (SRE) AND PAIN IN THE PHASE 3 AFFIRM STUDY. [2012] Annals of Oncology (23) 9 : 295-296. Impact factor : 7.384 [142] Fizazi, K., Brown, J. E., Carducci, M., Shore, N. D., Sieber, P., Kueppers, F., Karsh, L., Wei, R., and Goessl, C. DENOSUMAB IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DENOSUMAB OR ZOLEDRONIC ACID: 2-YEAR OPEN-LABEL EXTENSION PHASE RESULTS FROM THE PIVOTAL PHASE 3 STUDY. [2012] Annals of Oncology (23) 9 : 309-309. Impact factor : 7.384 [143] Fouret, R., Laffaire, J., Hofman, P., Beau-Faller, M., Mazieres, J., Validire, P., Girard, P., Camilleri-Bröet, S., Vaylet, F., Leroy-Ladurie, F., Soria, J. C., and Fouret, P. A comparative and integrative approach identifies ATPase Family, AAA Domain Containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. [2012] Clinical Cancer Research (18) 20 : 5606-5616. Impact factor : 7.837 [144] Franciszkiewicz, Katarzyna, Boissonnas, Alexandre, Boutet, Marie, Combadière, Christophe, and Mami-Chouaib, Fathia Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response. [2012] Cancer Research (72) 24 : 6325-6332. Impact factor : 8.650 [145] Frisan, E., Vandekerckhove, J., De Thonel, A., Pierre-Eugène, C., Sternberg, A., Arlet, J. B., Floquet, C., Gyan, E., Kosmider, O., Dreyfus, F., Gabet, A. S., Courtois, G., Vyas, P., Ribeil, J. A., Zermati, Y., Lacombe, C., Mayeux, P., Solary, E., Garrido, C., Hermine, O., and Fontenay, M. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. [2012] Blood (119) 6 : 1532-1542. Impact factor : 9.060 [146] Galluzzi, L., Kepp, O., and Kroemer, G. Reverse Warburg: Straight to cancer. [2012] Cell Cycle (11) 6 : 1059-1060. Impact factor : 5.243 [147] Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El Deiry, W. S., Fulda, S., Gottlieb, E., Green, D. R., Hengartner, M. O., Kepp, O., Knight, R. A., Kumar, S., Lipton, S. A., Lu, X., Madeo, F., Malorni, W., Mehlen, P., Néez, G., Peter, M. E., Piacentini, M., Rubinsztein, D. C., Shi, Y., Simon, H. U., Vandenabeele, P., White, E., Yuan, J., Zhivotovsky, B., Melino, G., and Kroemer, G. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. [2012] Cell Death and Differentiation (19) 1 : 107-120. Impact factor : 8.371 [148] Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., and Kroemer, G. Molecular mechanisms of cisplatin resistance. [2012] Oncogene (31) 15 : 1869-1883. Impact factor : 7.357 [149] Galluzzi, L., Vitale, I., Senovilla, L., Eisenberg, T., Carmona-Gutierrez, D., Vacchelli, E., Robert, T., Ripoche, H., Jägemann, N., Paccard, C., Servant, N., Hupé, P., Lazar, V., Dessen, P., Barillot, E., Zischka, H., Madeo, F., and Kroemer, G. Independent transcriptional reprogramming and apoptosis induction by cisplatin. [2012] Cell Cycle (11) 18 : 3472-3480. Impact factor : 5.243 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 83 GUSTAVE ROUSSY’S PUBLICATIONS [150] Galluzzi, L., Kepp, O., and Kroemer, G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. [2012] EMBO Journal (31) 5 : 1055-1057. Impact factor : 9.822 [151] Galluzzi, L., Kepp, O., and Kroemer, G. Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy. [2012] Oncogene (31) 23 : 2805-2808. Impact factor : 7.357 [152] Galluzzi, L., Kepp, O., Trojel-Hansen, C., and Kroemer, G. Non-apoptotic functions of apoptosis-regulatory proteins. [2012] EMBO Reports (13) 4 : 322-330. Impact factor : 7.189 [153] Galluzzi, Lorenzo, Marsili, Sabrina, Vitale, Ilio, Senovilla, Laura, Michels, Judith, Garcia, Pauline, Vacchelli, Erika, Chatelut, Etienne, Castedo, Maria, and Kroemer, Guido Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. [2012] Cell Cycle (12) 3. Impact factor : 5.243 [154] Garbay, D., Le Cesne, A., Penel, N., Chevreau, C., Marec-Berard, P., Blay, J. Y., Debled, M., Isambert, N., Thyss, A., Bompas, E., Collard, O., Salas, S., Coindre, J. M., Bui, B., and Italiano, A. Chemotherapy in patients with desmoid tumors: A study from the French Sarcoma Group (FSG). [2012] Annals of Oncology (23) 1 : 182-186. Impact factor : 7.384 [155] Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Spatz, A., Grob, J. J., Malvehy, J., Newton-Bishop, J., Stratigos, A., Pehamberger, H., and Eggermont, A. M. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012. [2012] European Journal of Cancer (48) 15 : 23752390. Impact factor : 5.061 [156] Gaspar, N., Rey, A., Bérard, P. M., Michon, J., Gentet, J. C., Tabone, M. D., Roché, H., Defachelles, A. S., Lejars, O., Plouvier, E., Schmitt, C., Bui, B., Boutard, P., Taque, S., Munzer, M., Vannier, J. P., Plantaz, D., Enz-Werlé, N., and Oberlin, O. Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: The French EW93 study. [2012] European Journal of Cancer (48) 9 : 1376-1385. Impact factor : 5.061 [157] Gauler, T. C., Besse, B., Mauguen, A., Meric, J. B., Gounant, V., Fischer, B., Overbeck, T. R., Krissel, H., Laurent, D., Tiainen, M., Commo, F., Soria, J. C., and Eberhardt, W. E. E. Phase II trial of ptk787/zk 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage iiib/iv non-small-cell lung cancer (nsclc). [2012] Annals of Oncology (23) 3 : 678-687. Impact factor : 7.384 [158] Gautier, E. F., Picard, M., Laurent, C., Marty, C., Villeval, J. L., Demur, C., Delhommeau, F., Hexner, E., Giraudier, S., Bonnevialle, N., Ducommun, B., Récher, C., Laurent, G., Manenti, S., and Mansat-De Mas, V. The cell cycle regulator CDC25A is a target for JAK2 V617F oncogene. [2012] Blood (119) 5 : 1190-1199. Impact factor : 9.060 [159] Geoerger, B., Kieran, M. W., Grupp, S., Perek, D., Clancy, J., Krygowski, M., Ananthakrishnan, R., Boni, J. P., Berkenblit, A., and Spunt, S. L. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. [2012] European Journal of Cancer (48) 2 : 253-262. Impact factor : 5.061 [160] Geoerger, B., Estlin, E. J., Aerts, I., Kearns, P., Gibson, B., Corradini, N., Doz, F., Lardelli, P., Miguel, B. D., Soto, A., Prados, R., and Vassal, G. A phase 1 and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study. [2012] European Journal of Cancer (48) 3 : 289-296 . Impact factor : 5.061 [161] Ghesquières, H., Cartron, G., Seymour, J. F., Delfau-Larue, M. H., Offner, F., Soubeyran, P., Perrot, A., Brice, P., Bouabdallah, R., Sonet, A., Dupuis, J., Casasnovas, O., Catalano, J. V., Delmer, A., Jardin, F., Verney, A., Dartigues, P., and Salles, G. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. [2012] Blood (120) 13 : 2650-2657. Impact factor : 9.060 [162] Gibault, L., Ferreira, C., Pérot, G., Audebourg, A., Chibon, F., Bonnin, S., Lagarde, P., Vacher-Lavenu, M. C., Terrier, P., Coindre, J. M., and Aurias, A. From PTEN loss of expression to RICTOR role in smooth muscle differentiation: Complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas. [2012] Modern Pathology (25) 2 : 197-211. Impact factor : 5.253 [163] Gnekow, Astrid K., Falkenstein, Fabian, Walker, David, Perilongo, Giorgio, Picton, Sue, Grill, Jacques, Kortmann, Rolf Dieter, Stokland, Tore, van Meeteren, Antoinette Schouten, Slavc, Irene, Faldum, Andreas, de Salvo, Gian Luca, and Worki, SIOP-Europe Low Grade Glioma SIOP-LGG 2004-COHORT DESCRIPTION OF A COMPREHENSIVE TREATMENT STRATEGY FOR LOW GRADE GLIOMA IN CHILDREN AND ADOLESCENTS INCLUDING A RANDOMISED CHEMOTHERAPY TRIAL AND A RADIOTHERAPY TRIAL. [2012] Neuro-Oncology (14) supplt 1 : 74-74. Impact factor : 6.180 84 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [164] Goere, D., Flament, C., Chaput-Gras, N., and Zitvogel, L. CONTRIBUTION OF IMMUNOGENIC CELL DEATH (ICD) TO THE ANTI-TUMOR ACTIVITY OF CATUMAXOMAB (ANTI-EPCAM X ANTI-CD3). [2012] Annals of Oncology (23) 9 : 169170. Impact factor : 7.384 [165] Gomez-Roca, C. A., Lacroix, L., Massard, C., De Baere, T., Deschamps, F., Pramod, R., Bahleda, R., Deutsch, E., Bourgier, C., Angevin, E., Lazar, V., Ribrag, V., Koscielny, S., Chami, L., Lassau, N., Dromain, C., Robert, C., Routier, E., Armand, J. P., and Soria, J. C. Sequential research-related biopsies in phase I trials: Acceptance, feasibility and safety. [2012] Annals of Oncology (23) 5 : 1301-1306. Impact factor : 7.384 [166] Gonzales, Emmanuel, Grosse, Brigitte, Cassio, Doris, Davit-Spraul, Anne, Fabre, Monique, and Jacquemin, Emmanuel Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. [2012] Journal of Hepatology (57) 3 : 695-698. Impact factor : 9.858 [167] Gonzalez, C. A., Lujan-Barroso, L., Bueno-de-Mesquita, H. B., Jenab, M., Duell, E. J., Agudo, A., Tjonneland, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., Touillaud, M., Teucher, B., Kaaks, R., Boeing, H., Steffen, A., Trichopoulou, A., Roukos, D., Karapetyan, T., Palli, D., Tagliabue, G., Mattiello, A., Tumino, R., Ricceri, F., Siersema, P. D., Numans, M. E., Peeters, P. P. H., Parr, C. L., Skeie, G., Lund, E., Quiros, J. R., Sanchez-Cantalejo, E., Navarro, C., Barricarte, A., Dorronsoro, M., Ehrnström, R., Regner, S., Khaw, K. T., Wareham, N., Key, T. J., Crowe, F. L., Blaker, H., Romieu, I., and Riboli, E. Fruit and vegetable intake and the risk of gastric adenocarcinoma: A reanalysis of the european prospective investigation into cancer and nutrition (EPIC-EURGAST) study after a longer follow-up. [2012] International Journal of Cancer (131) 12 : 2910-2919. Impact factor : 6.198 [168] Gonzàlez, C. A., Megraud, F., Buissonniere, A., Lujan Barroso, L., Agudo, A., Duell, E. J., Boutron-Ruault, M. C., Clavel-Chapelon, F., Palli, D., Krogh, V., Mattiello, A., Tumino, R., Sacerdote, C., Quiros, J. R., Sanchez-Cantalejo, E., Navarro, C., Barricarte, A., Dorronsoro, M., Khaw, K. T., Wareham, N., Allen, N. E., Tsilidis, K. K., Bas Bueno-De-Mesquita, H., Jeurnink, S. M., Numans, M. E., Peeters, P. H. M., Lagiou, P., Valanou, E., Trichopoulou, A., Kaaks, R., Lukanova-McGregor, A., Bergman, M. M., Boeing, H., Manjer, J., Lindkvist, B., Stenling, R., Hallmans, G., Mortensen, L. M., Overvad, K., Olsen, A., Tjonneland, A., Bakken, K., Dumeaux, V., Lund, E., Jenab, M., Romieu, I., Michaud, D., Mouw, T., Carneiro, F., Fenge, C., and Riboli, E. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: The Eurgast-EPIC project. [2012] Annals of Oncology (23) 5 : 1320-1324. Impact factor : 7.384 [169] Gore, M. E., Bellmunt, J., Eisen, T., Escudier, B., Mickisch, G., Patard, J., Porta, C., Ravaud, A., Schmidinger, M., Schöffski, P., Sternberg, C. N., Szczylik, C., De Nigris, E., Wheeler, C., and Kirpekar, S. Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. [2012] European Journal of Cancer (48) 7 : 1038-1047. Impact factor : 5.061 [170] Goss, G., Lu, S., Felip, E., Ardizzoni, A., Georgoulias, V., Gadgeel, S., Chand, V., Gu, Y., Olivo, Y. S., and Soria, J. LUX-LUNG 8: A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB VS. ERLOTINIB IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG AS SECOND-LINE THERAPY FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY. [2012] Annals of Oncology (23) 9 : 174-174. Impact factor : 7.384 [171] Gourzones, C., Barjon, C., and Busson, P. Host-tumor interactions in nasopharyngeal carcinomas. [2012] Seminars in Cancer Biology (22) 2 : 127-136. Impact factor : 7.436 [172] Gourzones, C., Jimenez, A. S., and Busson, P. Author reply : Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. [2012] Cancer (118) 18 : 4634-4634. Impact factor : 5.201 [173] Graf, N., Van Tinteren, H., Bergeron, C., Pein, F., Heuvel-Eibrink, M. M., Sandstedt, B., Schenk, J. P., Godzinski, J., Oldenburger, F., Furtwängler, R., and De Kraker, J. Characteristics and outcome of stage II and III non-anaplastic Wilms’ tumour treated according to the SIOP trial and study 93-01. [2012] European Journal of Cancer (48) 17 : 3240-3248. Impact factor : 5.061 [174] Gram, I. T., Lukanova, A., Brill, I., Braaten, T., Lund, E., Lundin, E., Overvad, K., Tjonneland, A., Clavel-Chapelon, F., Chabbert-Buffet, N., Bamia, C., Trichopoulou, A., Zylis, D., Masala, G., Berrino, F., Galasso, R., Tumino, R., Sacerdote, C., Gavrilyuk, O., Kristiansen, S., Rodriguez, L., Bonet, C., Huerta, J. M., Barricarte, A., Sanchez, M. J., Dorronsoro, M., Jirström, K., Almquist, M., Idahl, A., Bueno-de-Mesquita, H. B., Braem, M., Onland-Moret, C., Tsilidis, K. K., Allen, N. E., Fedirko, V., Riboli, E., and Kaaks, R. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. [2012] International Journal of Cancer (130) 9 : 2204-2210. Impact factor : 6.198 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 85 GUSTAVE ROUSSY’S PUBLICATIONS [175] Gravis, G., Fizazi, K., Lobbedez, F. Joly, Oudard, S., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., Rolland, F., Theodore, C., Deplanque, G., Ferrero, J. M., Pouessel, D., Mourey, L., Beuzeboc, P., Zanetta, S., Esterni, B., Habibian, M., and Soulie, M. SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403). [2012] Annals of Oncology (23) 9 : 294-294. Impact factor : 7.384 [176] Gronchi, A., Bui, B. N., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R. J., Demetri, G. D., Le Cesne, A., Lardelli, P., Pérez, I., Nieto, A., Tercero, J. C., Alfaro, V., Tamborini, E., and Blay, J. Y. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. [2012] Annals of Oncology (23) 3 : 771-776. Impact factor : 7.384 [177] Gross-goupil, M., Fourcade, A., Blot, E., Penel, N., Négrier, S., Culine, S., Chaigneau, L., Lesimple, T., Priou, F., Lortholary, A., Kaminsky, M. C., Provencal, J., Voog, E., Bouzy, J., Laplanche, A., and Fizazi, K. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. [2012] European Journal of Cancer (48) 5 : 721-727. Impact factor : 5.061 [178] Grote, V. A., Kaaks, R., Nieters, A., Tjonneland, A., Halkjaer, J., Overvad, K., Skjelbo Nielsen, M. R., BoutronRuault, M. C., Clavel-Chapelon, F., Racine, A., Teucher, B., Becker, S., Pischon, T., Boeing, H., Trichopoulou, A., Cassapa, C., Stratigakou, V., Palli, D., Krogh, V., Tumino, R., Vineis, P., Panico, S., Rodriguez, L., Duell, E. J., Sanchez, M. J., Dorronsoro, M., Navarro, C., Gurrea, A. B., Siersema, P. D., Peeters, P. H. M., Ye, W., Sund, M., Lindkvist, B., Johansen, D., Khaw, K. T., Wareham, N., Allen, N. E., Travis, R. C., Fedirko, V., Jenab, M., Michaud, D. S., Chuang, S. C., Romaguera, D., Bueno-de-Mesquita, H. B., and Rohrmann, S. Inflammation marker and risk of pancreatic cancer: A nested case-control study within the EPIC cohort. [2012] British Journal of Cancer (106) 11 : 1866-1874. Impact factor : 5.082 [179] Grote, Verena A., Rohrmann, Sabine, Dossus, Laure, Nieters, Alexandra, Halkjaer, Jytte, Tjonneland, Anne, Overvad, Kim, Stegger, Jakob, Chabbert-Buffet, Nathalie, Boutron-Ruault, Marie Christine, Clavel-Chapelon, Françoise, Teucher, Birgit, Becker, Susen, Montonen, Jukka, Boeing, Heiner, Trichopoulou, Antonia, Lagiou, Pagona, Trichopoulos, Dimitrios, Palli, Domenico, Sieri, Sabina, Tumino, Rosario, Vineis, Paolo, Mattiello, Amalia, Argüelles, Marcial, Duell, Eric J., Molina-Montes, Esther, Larranaga, Nerea, Chirlaque, Maria Dolores, Gurrea, Aurelio Barricarte, Jeurnink, Suzanne M., Peeters, Petra Hm, Ye, Weimin, Sund, Malin, Lindkvist, Björn, Johansen, Dorthe, Khaw, Kay Tee, Wareham, Nick, Crowe, Francesca L., Romieu, Isabelle, Rinaldi, Sabina, Jenab, Mazda, Romaguera, Dora, Michaud, Dominique S., Riboli, Elio, Bas Bueno-De-Mesquita, H., and Kaaks, Rudolf The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. [2012] International Journal of Cancer (130) 10 : 2428-2437. Impact factor : 6.198 [180] Guiu, B., Deschamps, F., Aho, S., Munck, F., Dromain, C., Boige, V., Malka, D., Leboulleux, S., Ducreux, M., Schlumberger, M., Baudin, E., and De Baere, T. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. [2012] Journal of Hepatology (56) 3 : 609617. Impact factor : 9.858 [181] Guiu, S., Michiels, S., André, F., Cortes, J., Denkert, C., Di Leo, A., Hennessy, B. T., Sorlie, T., Sotiriou, C., Turner, N., Van de Vijver, M., Viale, G., Loi, S., and Reis-Filho, J. S. Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement. [2012] Annals of Oncology (23) 12 : 2997-3006. Impact factor : 7.384 [182] Hadj-Rabia, S., Oriot, D., Soufir, N., Dufresne, H., Taieb, A., Sarasin, A., and Bodemer, C. Unexpected extradermatological findings in 31 Xeroderma Pigmentosum type C patients. [2012] Journal of investigative dermatology (132) 2 : S96-S96. Impact factor : 6.193 [183] Hainaut, P., Ma, X., Lacas, B., Tsao, M., Douillard, J., Rousseau, V., Dunant, A., Seymour, L., Filipits, M., Graziano, S., and Grp, LACE Bio Study LACE-BIO POOLED ANALYSIS OF THE PROGNOSTIC AND PREDICTIVE VALUE OF TP53 MUTATIONS IN COMPLETELY RESECTED NON SMALL CELL LUNG CANCER (NSCLC). [2012] Annals of Oncology (23) 9 : 389-389. Impact factor : 7.384 [184] Hannani, D., Ma, Y., Yamazaki, T., Déchanet-Merville, J., Kroemer, G., and Zitvogel, L. Harnessing yo T cells in anticancer immunotherapy. [2012] Trends in Immunology (33) 5 : 199-206. Impact factor : 9.486 [185] Hartl, D. M., Bahleda, R., Hollebecque, A., Bosq, J., Massard, C., and Soria, J. C. Bevacizumab-induced laryngeal necrosis. [2012] Annals of Oncology (23) 1 : 276-278. Impact factor : 7.384 86 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [186] Hartl, D. M., Leboulleux, S., Al Ghuzlan, A., Baudin, E., Chami, L., Schlumberger, M., and Travagli, J. P. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. [2012] Annals of Surgery (255) 4 : 777-783. Impact factor : 6.329 [187] Hebert, G., Netzer, F., Fourcade, A., Ducreux, M., Minvielle, E., and Lemare, F. IATRIGGER PROJECT: DEVELOPMENT AND VALIDATION OF A TOOL TO EVALUATE ADVERSE DRUGS EVENTS IN ONCOLOGY PATIENTS. [2012] Annals of Oncology (23) 9 : 456-456. Impact factor : 7.384 [188] Helissey, C., Vedrine, L., Ceccaldi, B., Houlgatte, A., Mullot, H., Bauduceau, O., Chargari, C., Massard, C., Fizazi, K., and Le Moulec, S. CONTINUOUS INFUSION BLEOMYCIN IN THE BEP REGIMEN: A THERAPEUTIC ALTERNATIVE IN THE MANAGEMENT OF PATIENTS WITH GERM-CELL TUMORS? [2012] Annals of Oncology (23) 9 : 285-285. Impact factor : 7.384 [189] Hofman, P., Ilie, M., Hofman, V., Roux, S., Valent, A., Bernheim, A., Alifano, M., Leroy-Ladurie, F., Vaylet, F., Rouquette, I., Validire, P., Beau-Faller, M., Lacroix, L., Soria, J. C., and Fouret, P. Immunohistochemistry to identify egfr mutations or ALK rearrangements in patients with lung adenocarcinoma. [2012] Annals of Oncology (23) 7 : 17381743. Impact factor : 7.384 [190] Hollebecque, A., Houede, N., Cohen, E. E. W., Italiano, A., Yuan, Z., Westwood, P., Bumgardner, W., Benhadji, K. A., and Soria, J. C. A PHASE 1 STUDY OF LY2584702, A P70S6 KINASE INHIBITOR, WITH ERLOTINIB OR EVEROLIMUS IN PATIENT WITH ADVANCED SOLID TUMORS. [2012] Annals of Oncology (23) 1 : 16-16. Impact factor : 7.384 [191] HOOS, A., EGGERMONT, Alexander M., FINN, Olivera J., and KERR, D. J. Evolution of end points for cancer immunotherapy trials (English). [2012] Annals of Oncology (23) SUP8 - Advances in Immuno-oncology. Impact factor : 7.384 [192] Houdayer, C., Caux-Moncoutier, V., Krieger, S., Barrois, M., Bonnet, F., Bourdon, V., Bronner, M., Buisson, M., Coulet, F., Gaildrat, P., Lefol, C., léone, M., Mazoyer, S., Muller, D., Remenieras, A., Révillion, F., Rouleau, E., Sokolowska, J., Vert, J. P., Lidereau, R., Soubrier, F., Sobol, H., Sevenet, N., Bressac-de Paillerets, B., Hardouin, A., Tosi, M., Sinilnikova, O. M., and Stoppa-Lyonnet, D. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. [2012] Human Mutation (33) 8 : 1228-1238. Impact factor : 5.213 [193] Hüsing, A., Canzian, F., Beckmann, L., Garcia-Closas, M., Diver, W. R., Thun, M. J., Berg, C. D., Hoover, R. N., Ziegler, R. G., Figueroa, J. D., Isaacs, C., Olsen, A., Viallon, V., Boeing, H., Masala, G., Trichopoulos, D., Peeters, P. H. M., Lund, E., Ardanaz, E., Khaw, K. T., Lenner, P., Kolonel, L. N., Stram, D. O., Le Marchand, L., McCarty, C. A., Buring, J. E., Lee, I. M., Zhang, S., Lindström, S., Hankinson, S. E., Riboli, E., Hunter, D. J., Henderson, B. E., Chanock, S. J., Haiman, C. A., Kraft, P., and Kaaks, R. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. [2012] Journal of Medical Genetics (49) 9 : 601-608. Impact factor : 5.703 [194] Ilie, S. M., Ruginescu, I., Saada, E., Ferrand, F. R., Schilf, A., Janot, F., and Guigay, J. THE USEFULNESS OF G8 EVALUATION IN THERAPEUTIC DECISION AND PREDICTION OF TOLERANCE IN LOCALLY ADVANCED OR METASTATIC SQUAMOUS CELL HEAD AND NECK CANCER (SCCHN) PATIENTS OLDER THAN 65 YEARS. [2012] Annals of Oncology (23) 9 : 345-345. Impact factor : 7.384 [195] Ilie, S. M., Ruginescu, I., Saada, E., Ferrand, F. R., Schilf, A., Janot, F., and Guigay, J. THE TOLERANCE OF TPF CHEMOTHERAPY REGIME STANDARD OR MODIFIED IN HEAD NECK CANCER PATIENTS OVER 65 YEARS OLD. [2012] Annals of Oncology (23) 9 : 341-341. Impact factor : 7.384 [196] Italiano, A., Garbay, D., Cioffi, A., Maki, R. G., and Bui, B. Advanced pleomorphic liposarcomas: Clinical outcome and impact of chemotherapy. [2012] Annals of Oncology (23) 8 : 2205-2206. Impact factor : 7.384 [197] Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J.-Y., Maki, R. G., Schwartz, G. K., Antonescu, C. R., Singer, S., Coindre, J.-M., and Bui, B. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. [2012] Annals of Oncology (23) 6 : 1601-1601. Impact factor : 7.384 [198] Italiano, A., Cioffi, A., Penel, N., Levra, M. G., Delcambre, C., Kalbacher, E., Chevreau, C., Bertucci, F., Isambert, N., Blay, J. Y., Bui, B., Antonescu, C., D’Adamo, D. R., Maki, R. G., and Keohan, M. L. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. [2012] Cancer (118) 13 : 3330-3336. Impact factor : 5.201 [199] Itzykson, R., Droin, N., and Solary Les progrès récents dans la leucémie myélomonocytaire chronique [Recent advances in chronic myelomonocytic leukemia]. [2012] Hématologie (18) 1 : 24-36. Impact factor : 5.935 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 87 GUSTAVE ROUSSY’S PUBLICATIONS [200] Jabbour, Elias, Mathisen, Michael S., and O’Brien, Susan 10 Years of Progress in Chronic Myelogenous Leukemia. [2012] JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (10) 9 : 1049-1053. Impact factor : 5.112 [201] Jacquel, A., Obba, S., Boyer, L., Dufies, M., Robert, G., Gounon, P., Lemichez, E., Luciano, F., Solary, E., and Auberger, P. Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. [2012] Blood (119) 19 : 4527-4531. Impact factor : 9.060 [202] Jaeger, D., Guo, J., Korbenfeld, E., Zemanova, M., Leonhartsberger, N., Stauch, K., Boeckenhoff, A., Yu, J., Mardiak, J., and Escudier, B. SORAFENIB IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) AND BASELINE HYPERTENSION OR DIABETES: SUBANALYSIS OF THE NON-INTERVENTIONAL PREDICT STUDY. [2012] Annals of Oncology (23) 9 : 279-280. Impact factor : 7.384 [203] Jakszyn, Paula, Agudo, Antonio, Lujan-Barroso, Leila, Bueno-de-Mesquita, H. Bas, Jenab, Mazda, Navarro, Carmen, Palli, Domenico, Boeing, Heiner, Manjer, Jonas, Numans, Mattijs E., Igali, Laszlo, Boutron-Ruault, Marie Christine, Clavel-Chapelon, Francoise, Morois, Sophie, Grioni, Sara, Panico, C. S., Tumino, Rosario, Sacerdote, Carlotta, Ramon Quiros, J., Molina-Montes, Esther, Huerta Castano, Jose Ma, Barricarte, Aurelio, Amiano, Pilar, Khaw, Kay Tee, Wareham, Nicholas, Allen, Naomi E., Key, Timothy J., Jeurnink, Suzanne M., Peeters, Petra H. M., Bamia, Christina, Valanou, Elisabeth, Trichopoulou, Antonia, Kaaks, Rudolf, Lukanova, Annekatrin, Bergmann, Manuela M., Lindkvist, Bjorn, Stenling, Roger, Johansson, Ingegerd, Dahm, Christina C., Overvad, Kim, Olsen, Anja, Tjonneland, Anne, Skeie, Guri, Ragnhild Broderstad, Ann, Lund, Eiliv, Michaud, Dominique S., Mouw, Traci, Riboli, Elio, and Gonzalez, Carlos A. Dietary intake of heme iron and risk of gastric cancer in the European prospective investigation into cancer and nutrition study. [2012] International Journal of Cancer (130) 11 : 2654-2663. Impact factor : 6.198 [204] Janne, P. A., Shepherd, F. A., Domerg, C., Le Teuff, G., Kratzke, R., Hainaut, P., Pignon, J., Rosell, R., Soria, J., and Tsao, M. PROGNOSTIC AND PREDICTIVE VALUES OF KRAS IN EGFR-BASED SUBGROUPS AND COMBINED WITH P53 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC): A LACE-BIO STUDY. [2012] Annals of Oncology (23) 9 : 74-74. Impact factor : 7.384 [205] Jemaá, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L., Senovilla, L., Marino, G., Malik, S. A., Rello-Varona, S., Lissa, D., Antoccia, A., Tailler, M., Schlemmer, F., Harper, F., Pierron, G., Castedo, M., and Kroemer, G. Selective killing of p53-deficient cancer cells by SP600125. [2012] EMBO Molecular Medicine (4) 6 : 500-514. Impact factor : 7.795 [206] Jemaá, M., Galluzzi, L., Kepp, O., Boilève, A., Lissa, D., Senovilla, L., Harper, F., Pierron, G., Berardinelli, F., Antoccia, A., Castedo, M., Vitale, I., and Kroemer, G. Preferential killing of p53-deficient cancer cells by reversine. [2012] Cell Cycle (11) 11 : 2149-2158. Impact factor : 5.243 [207] Jerusalem, G., Marinsek, N., Ricci, J., Etchberger, J., Degun, R., Benelli, G., Saletan, S., and Andre, F. PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTORPOSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE. [2012] Annals of Oncology (23) 9 : 122-122. Impact factor : 7.384 [208] Jeurnink, S. M., Büchner, F. L., Bueno-de-Mesquita, H. B., Siersema, P. D., Boshuizen, H. C., Numans, M. E., Dahm, C. C., Overvad, K., Tjonneland, A., Roswall, N., Clavel-Chapelon, F., Boutron-Ruault, M. C., Morois, S., Kaaks, R., Teucher, B., Boeing, H., Buijsse, B., Trichopoulou, A., Benetou, V., Zylis, D., Palli, D., Sieri, S., Vineis, P., Tumino, R., Panico, S., Ocké, M. C., Peeters, P. H. M., Skeie, G., Brustad, M., Lund, E., Sànchez-cantalejo, E., Navarro, C., Amiano, P., Ardanaz, E., Ramon Quiro, J., Hallmans, G., Johansson, I., Lindkvist, B., Regnér, S., Khaw, K. T., Wareham, N., Key, T. J., Slimani, N., Norat, T., Vergnaud, A. C., Romaguera, D., and Gonzalez, C. A. Variety in vegetable and fruit consumption and the risk of gastric and esophageal cancer in the European prospective investigation into cancer and nutrition. [2012] International Journal of Cancer (131) 6 : E963-E973. Impact factor : 6.198 [209] Johansson, C. Hertzman, Azimi, A., Pernemalm, M., Pawitan, Y., Stolt, M. Frostvik, Lazar, V., Lundeberg, J., Lehtio, J., Egyhazi, S., and Hansson, J. PROTEOMICS AND GENE EXPRESSION PROFILING OF MELANOMA CHEMOTHERAPY RESPONSE IN TUMORS. [2012] Annals of Oncology (23) 5 : 27-27. Impact factor : 7.384 [210] Julian-Reynier, C., Fabre, R., Coupier, I., Stoppa-Lyonnet, D., Lasset, C., Caron, O., Mouret-Fourme, E., Berthet, P., Faivre, L., Frenay, M., Gesta, P., Gladieff, L., Bouhnik, A. D., Protière, C., and Noguès, C. BRCA1/2 carriers: Their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis. [2012] Genetics in Medicine (14) 5 : 527-534. Impact factor : 5.560 88 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [211] Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., Weiswald, L. B., Lantuas, D., Morgand, L., Pham, E., Gonin, P., Dangles-Marie, V., Job, B., Dessen, P., Bruno, A., Pierré, A., De Thé, H., Soliman, H., Nunes, M., Lardier, G., Calvet, L., Demers, B., Prévost, G., Vrignaud, P., Roman-Roman, S., Duchamp, O., and Berthet, C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. [2012] Clinical Cancer Research (18) 19 : 5314-5328. Impact factor : 7.837 [212] Jung, K. O., Khan, A. M., Tan, B. Y. L., Hu, Y., Simon, G. G., Nascimento, E. J. M., Lemonnier, F., Brusic, V., Miotto, O., Tan, T. W., Marques, E. T. A., Dhalia, R., Salmon, J., and August, J. T. West nile virus T-cell ligand sequences shared with other flaviviruses: A multitude of variant sequences as potential altered peptide ligands. [2012] Journal of Virology (86) 14 : 7616-7624. Impact factor : 5.076 [213] Kazma, R., Babron, M. C., Gaborieau, V., Génin, E., Brennan, P., Hung, R. J., Mclaughlin, J. R., Krokan, H. E., Elvestad, M. B., Skorpen, F., Anderssen, E., Vooder, T., Välk, K., Metspalu, A., Field, J. K., Lathrop, M., Sarasin, A., and Benhamou, S. Lung cancer and DNA repair genes: Multilevel association analysis from the international lung cancer consortium. [2012] Carcinogenesis (33) 5 : 1059-1064. Impact factor : 5.635 [214] Kharaziha, P., Rodriguez, P., Li, Q., Rundqvist, H., Björklund, A. C., Augsten, M., Ullén, A., Egevad, L., Wiklund, P., Nilsson, S., Kroemer, G., Grander, D., and Panaretakis, T. Targeting of distinct signaling cascades and cancerassociated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. [2012] Cell Death and Disease (3) 1. Impact factor : 6.044 [215] Kieffer, V., Dellatolas, G., Chevignard, M., Puget, S., Dhermain, F., Grill, J., and Dufour, C. Neurocognitive outcome and academic achievement in adult survivors of childhood medulloblastoma. [2012] Neuro-Oncology (14) suuplt 3 : 67-67. Impact factor : 6.180 [216] Kieffer, Virginie, Dellatolas, Georges, Chevignard, Mathilde, Puget, Stephanie, Dhermain, Frederic, Grill, Jacques, and Dufour, Christelle Neurocognitive outcome and academic achievement in adult survivors of childhood medulloblastoma. [2012] Neuro-Oncology (14) supplt 1 : 129-129. Impact factor : 6.180 [217] Kieusseian, A., de la Grange, P. B., Burlen-Defranoux, O., Godin, I., and Cumano, A. Immature hematopoietic stem cells undergo maturation in the fetal liver. [2012] Development (Cambridge) (139) 19 : 3521-3530. Impact factor : 6.208 [218] Kilday, J. P., Mitra, B., Domerg, C., Ward, J., Andreiuolo, F., Osteso-Ibanez, T., Mauguen, A., Varlet, P., Le Deley, M. C., Lowe, J., Ellison, D. W., Gilbertson, R. J., Coyle, B., Grill, J., and Grundy, R. G. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: A prospective european clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG. [2012] Clinical Cancer Research (18) 7 : 2001-2011. Impact factor : 7.837 [219] Kilday, John Paul, Mitra, Biswaroop, Domerg, Caroline, Ward, Jennifer, Andreiuolo, Felipe, Osteso-Ibanez, Teresa, Mauguen, Audrey, Varlet, Pascale, Le Deley, Marie Cecile, Lowe, James, Ellison, David W., Gilbertson, Richard J., Coyle, Beth, Grill, Jacques, and Grundy, Richard G. GAIN OF 1q25 PREDICTS POOR PROGRESSIONFREE SURVIVAL FOR PEDIATRIC INTRACRANIAL EPENDYMOMAS AND ENABLES PATIENT RISK STRATIFICATION: A EUROPEAN CLINICAL TRIAL COHORT ANALYSIS ON BEHALF OF CCLG, SFOP AND SIOP. [2012] Neuro-Oncology (14) suuplt 1 : 37-37. Impact factor : 6.180 [220] Kirkwood, J. M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., and Dummer, R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. [2012] Clinical Cancer Research (18) 2 : 555-567. Impact factor : 7.837 [221] Kraeber-Bodéré, F., Carlier, T., Naegelen, V. M., Shochat, E., Lumbroso, J., Trampal, C., Nagarajah, J., Chua, S., Hugonnet, F., Stokkel, M., Gleeson, F., and Tessier, J. Differences in the biologic activity of 2 novel MEK inhibitors revealed by18F-FDG PET: Analysis of imaging data from 2 phase I trials. [2012] Journal of Nuclear Medicine (53) 12 : 1836-1846. Impact factor : 5.774 [222] Ladoire, S., Mignot, G., Dalban, C., Chevriaux, A., Arnould, L., Rébé, C., Apetoh, L., Boidot, R., Penault-Llorca, F., Fumoleau, P., Roché, H., Spielmann, M., Levy, C., Lortholary, A., Eichler, F., Mesleard, C., Bonnetain, F., and Ghiringhelli, F. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. [2012] Annals of Oncology (23) 10 : 2552-2561. Impact factor : 7.384 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 89 GUSTAVE ROUSSY’S PUBLICATIONS [223] Ladroue, C., Hoogewijs, D., Gad, S., Carcenac, R., Storti, F., Barrois, M., Gimenez-Roqueplo, A. P., Leporrier, M., Casadevall, N., Hermine, O., Kiladjian, J. J., Baruchel, A., Fakhoury, F., Bressac-de Paillerets, B., Feunteun, J., Mazure, N., Pouysségur, J., Wenger, R. H., Richard, S., and Gardie, B. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. [2012] Haematologica (97) 1 : 9-14. Impact factor : 5.935 [224] Lainey, E., Sebert, M., Thépot, S., Scoazec, M., Bouteloup, C., Leroy, C., De Botton, S., Galluzzi, L., Fenaux, P., and Kroemer, G. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. [2012] Cell Cycle (11) 21 : 4079-4092. Impact factor : 5.243 [225] Lajous, M., Tondeur, L., Fagherazzi, G., Lauzon-Guillain, B., Boutron-Ruaualt, M. C., and Clavel-Chapelon, F. Processed and unprocessed red meat consumption and incident type 2 diabetes among French women. [2012] Diabetes Care (35) 1 : 128-130. Impact factor : 7.735 [226] Lamperti, M., Bodenham, A. R., Pittiruti, M., Blaivas, M., Augoustides, J. G., Elbarbary, M., Pirotte, T., Karakitsos, D., Ledonne, J., Doniger, S., Scoppettuolo, G., Feller-Kopman, D., Schummer, W., Biffi, R., Desruennes, E., Melniker, L. A., and Verghese, S. T. International evidence-based recommendations on ultrasound-guided vascular access. [2012] Intensive Care Medicine (38) 7 : 1105-1117. Impact factor : 5.258 [227] Lassau, N., Chapotot, L., Benatsou, B., Vilgrain, V., Kind, M., Lacroix, J., Cuinet, M., Taieb, S., Aziza, R., Sarran, A., Labbe, C., Gallix, B., Lucidarme, O., Ptak, Y., Rocher, L., Caquot, L. M., Chagnon, S., Marion, D., Luciani, A., Uzan-Augui, J., and Koscielny, S. Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: The french multicenter support for innovative and expensive techniques study. [2012] Investigative Radiology (47) 12 : 711-716. Impact factor : 5.460 [228] Laulier, C. and Lopez, B. S. The secret life of Bcl-2: Apoptosis-independent inhibition of DNA repair by Bcl-2 family members. [2012] Mutation Research - Reviews in Mutation Research (751) 2 : 247-257 . Impact factor : 6.426 [229] Laurent-Matha, V., Huesgen, P. F., Masson, O., Derocq, D., Prébois, C., Gary-Bobo, M., Lecaille, F., Rebière, B., Meurice, G., Oréar, C., Hollingsworth, R. E., Abrahamson, M., Lalmanach, G., Overall, C. M., and LiaudetCoopman, E. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. [2012] FASEB Journal (26) 12 : 5172-5181 . Impact factor : 5.704 [230] Le Cesne, Axel, Cresta, Sara, Maki, Robert G., Blay, Jean Yves, Verweij, Jaap, Poveda, Andrés, Casali, Paolo G., Balana, Carme, Schöffski, Patrick, Grosso, Federica, Lardelli, Pilar, Nieto, Antonio, Alfaro, Vicente, and Demetri, George D. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. [2012] European Journal of Cancer (48) 16 : 3036-3044. Impact factor : 5.061 [231] Lebbe, C., Robert, C., Ricard, S., Sassolas, B., Grange, F., Saiag, P., Lhomel, C., and Mortier, L. Evolution of sun protection measures in children in France. [2012] Journal of investigative dermatology (132) 2 : S71-S71. Impact factor : 6.193 [232] Leblond, Pierre, Lansiaux, Amelie, Rialland, Xavier, Gentet, Jean Claude, Geoerger, Birgit, Frappaz, Didier, Aerts, Isabelle, and Bernier-Chastagner, Valerie MULTICENTRIC PHASE I STUDY OF CILENGITIDE (CGT) IN COMBINATION WITH RADIATION THERAPY IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: PRELIMINARY RESULTS. [2012] Neuro-Oncology (14) supplt 1 : 29-29. Impact factor : 6.180 [233] Lecarpentier, J., Noguès, C., Mouret-Fourme, E., Gauthier-Villars, M., Lasset, C., Fricker, J. P., Caron, O., Stoppa-Lyonnet, D., Berthet, P., Faivre, L., Bonadona, V., Buecher, B., Coupier, I., Gladieff, L., Gesta, P., Eisinger, F., Frénay, M., Luporsi, E., Lortholary, A., Colas, C., Dugast, C., Longy, M., Pujol, P., Tinat, J., Lidereau, R., and Andrieu, N. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). [2012] Breast Cancer Research (14) 4. Impact factor : 5.872 [234] Leenders, M., Chuang, S. C., Dahm, C. C., Overvad, K., Ueland, P. M., Midttun, O., Vollset, S. E., Tjonneland, A., Halkjaer, J., Jenab, M., Clavel-Chapelon, F., Boutron-Ruault, M. C., Kaaks, R., Canzian, F., Boeing, H., Weikert, C., Trichopoulou, A., Bamia, C., Naska, A., Palli, D., Pala, V., Mattiello, A., Tumino, R., Sacerdote, C., Van Duijnhoven, F. J. B., Peeters, P. H. M., Van Gils, C. H., Lund, E., Rodriguez, L., Duell, E. J., Pérez, M. J. S., MolinaMontes, E., Castano, J. M. H., Barricarte, A., Larranaga, N., Johansen, D., Lindkvist, B., Sund, M., Ye, W., Khaw, K. T., Wareham, N. J., Michaud, D. S., Riboli, E., Xun, W. W., Allen, N. E., Crowe, F. L., Bueno-de-Mesquita, H. B., and Vineis, P. Plasma cotinine levels and pancreatic cancer in the EPIC cohort study. [2012] International Journal of Cancer (131) 4 : 997-1002. Impact factor : 6.198 90 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [235] Lefebvre, J. L., Andry, G., Chevalier, D., Luboinski, B., Collette, L., Traissac, L., De raucourt, D., Langendijk, J. A., Rame, J. P., Crispino, S., Chiamenti, C., van den Beek, J. M. H., David, J. M., and Bernier, J. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. [2012] Annals of Oncology (23) 10 : 2708-2714. Impact factor : 7.384 [236] Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J. P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R. A., Mak, T., Bastard, C., Bernard, O. A., de Leval, L., and Gaulard, P. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with T FH-like features and adverse clinical parameters. [2012] Blood (120) 7 : 1466-1469. Impact factor : 9.060 [237] Leufkens, A. M., Van Duijnhoven, F. J. B., Boshuizen, H. C., Siersema, P. D., Kunst, A. E., Mouw, T., Tjonneland, A., Olsen, A., Overvad, K., Boutron-Ruault, M. C., Clavel-Chapelon, F., Morois, S., Krogh, V., Tumino, R., Panico, S., Polidoro, S., Palli, D., Kaaks, R., Teucher, B., Pischon, T., Trichopoulou, A., Orfanos, P., Goufa, I., Peeters, P. H. M., Skeie, G., Braaten, T., Rodriguez, L., Lujan-Barroso, L., Sànchez-Pérez, M. J., Navarro, C., Barricarte, A., Zackrisson, S., Almquist, M., Hallmans, G., Palmqvist, R., Tsilidis, K. K., Khaw, K. T., Wareham, N., Gallo, V., Jenab, M., Riboli, E., and Bueno-de-Mesquita, H. B. Educational level and risk of colorectal cancer in EPIC with specific reference to tumor location. [2012] International Journal of Cancer (130) 3 : 622-630. Impact factor : 6.198 [238] Levi, F., Boige, V., Rougier, P., Hebbar, M., Smith, D., Focan, C., Guimbaud, R., Carvalho, C., Bouchahda, M., and Ducreux, M. SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL. [2012] Annals of Oncology (23) 9 : 194-194. Impact factor : 7.384 [239] Levy, L., Herrera, A., Devauchelle, P., Bonvalot, S., Deutsch, E., and Le Pechoux, C. NBTXR3 NANOPARTICLES FOR RADIOENHANCEMENT: RATIONALE FOR THE FIRST-IN-MAN STUDY IN ADVANCED SOFT TISSUE SARCOMA. [2012] Annals of Oncology (23) 1 : 17-18. Impact factor : 7.384 [240] Li, D., Duell, E. J., Yu, K., Risch, H. A., Olson, S. H., Kooperberg, C., Wolpin, B. M., Jiao, L., Dong, X., Wheeler, B., Arslan, A. A., Bueno-de-Mesquita, H. B., Fuchs, C. S., Gallinger, S., Gross, M., Hartge, P., Hoover, R. N., Holly, E. A., Jacobs, E. J., Klein, A. P., Lacroix, A., Mandelson, M. T., Petersen, G., Zheng, W., Agalliu, I., Albanes, D., BoutronRuault, M. C., Bracci, P. M., Buring, J. E., Canzian, F., Chang, K., Chanock, S. J., Cotterchio, M., Gaziano, J. M., Giovannucci, E. L., Goggins, M., Hallmans, G., Hankinson, S. E., Hoffman Bolton, J. A., Hunter, D. J., Hutchinson, A., Jacobs, K. B., Jenab, M., Khaw, K. T., Kraft, P., Krogh, V., Kurtz, R. C., McWilliams, Robert R., Mendelsohn, J. B., Patel, A. V., Rabe, K. G., Riboli, E., Shu, X. O., Tjonneland, A., Tobias, G. S., Trichopoulos, D., Virtamo, J., Visvanathan, K., Watters, J., Yu, H., Zeleniuch-Jacquotte, A., Amundadottir, L., and Stolzenberg-Solomon, R. Z. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. [2012] Carcinogenesis (33) 7 : 1384-1390. Impact factor : 5.635 [241] Li, Qian, Chuang, Shu Chun, Eluf-Neto, Jose, Menezes, Ana, Matos, Elena, Koifman, Sergio, Wünsch-Filho, Victor, Fernandez, Leticia, Daudt, Alexander W., Curado, Maria Paula, Winn, Deborah M., Franceschi, Silvia, Herrero, Rolando, Castellsague, Xavier, Morgenstern, Hal, Zhang, Zuo Feng, Lazarus, Philip, Muscat, Joshua, McClean, Michael, Kelsey, Karl T., Hayes, Richard B., Purdue, Mark P., Schwartz, Stephen M., Chen, Chu, Benhamou, Simone, Olshan, Andrew F., Yu, Guopei, Schantz, Stimson, Ferro, Gilles, Brennan, Paul, Boffetta, Paolo, and Hashibe, Mia Vitamin or mineral supplement intake and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. [2012] International journal of cancer.Journal international du cancer (131) 7 : 1686-1699. Impact factor : 6.198 [242] Liew, Aaron, Andre, Franck, De Menorval, Marie Amelie, O’Brien, Timothy, and Mir, Lluis Optimal Electrogene Transfer Method for Human Mesenchymal Stem Cells. [2012] MOLECULAR THERAPY (20) supplt 1 : S242-S242. Impact factor : 7.041 [243] Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., Bilynskyy, B., Charu, V., Beuzeboc, P., Rader, M., Viniegra, M., Saad, F., Ke, C., Braun, A., and Jun, S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. [2012] European Journal of Cancer (48) 16 : 3082-3092. Impact factor : 5.061 [244] Little, M. P., Azizova, T. V., Bazyka, D., Bouffler, S. D., Cardis, E. S. C., Chekin, S., Chumak, V. V., Cucinotta, F. A., De Vathaire, F., Hall, P., Harrison, J. D., Hildebrandt, G., Ivanov, V., Kashcheev, V. V., Klymenko, S. V., Kreuzer, M., Laurent, O., Ozasa, K., Schneider, T., Tapio, S., Taylor, A. M., Tzoulaki, I., Vandoolaeghe, W. L., Wakeford, R., Zablotska, L. B., Zhang, W., and Lipshultz, S. E. Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks. [2012] Environmental Health Perspectives (120) 11 : 1503-1511. Impact factor : 7.260 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 91 GUSTAVE ROUSSY’S PUBLICATIONS [245] Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., Mathurin, P., Fartoux, L., Lin, D.-Y., Bruix, J., Poon, R. T., Sherman, M., Blanc, J.-F., Finn, R., Tak, W.Y., Chao, Y., Ezzeddine, R., Liu, D., Walters, I., and Park, J.-W. BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY. [2012] Journal of Hepatology (56) 2. Impact factor : 9.858 [246] Longaud-Vales, Audrey, Grill, Jacques, Puget, Stephanie, Sainte-Rose, Christian, Dufour, Christelle, Kieffer, Virginie, and Dellatolas, Geoerges NEUROPSYCHOLOGICAL ASSESSMENT IN CHILDREN AND ADOLESCENTS TREATED FOR FRONTAL LOBE TUMOURS. [2012] Neuro-Oncology (14) supplt 1 : 112-113. Impact factor : 6.180 [247] Lordier, L., Pan, J., Naim, V., Jalil, A., Badirou, I., Rameau, P., Larghero, J., Debili, N., Rosselli, F., Vainchenker, W., and Chang, Y. Presence of a defect in karyokinesis during megakaryocyte endomitosis. [2012] Cell Cycle (11) 23 : 4385-4389. Impact factor : 5.243 [248] Loriot, Y., Massard, C., and Fizazi, K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. [2012] Annals of Oncology (23) 5 : 1085-1094. Impact factor : 7.384 [249] Loulergue, Pierre, Mir, Olivier, and Sogni, Philippe Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C. [2012] AIDS (London, England) (26) 5 : 655-656. Impact factor : 6.407 [250] Lutz, M. P., Zalcberg, J. R., Ducreux, M., Ajani, J. A., Allum, W., Aust, D., Bang, Y. J., Cascinu, S., Hölscher, A., Jankowski, J., Jansen, E. P. M., Kisslich, R., Lordick, F., Mariette, C., Moehler, M., Oyama, T., Roth, A., Rueschoff, J., Ruhstaller, T., Seruca, R., Stahl, M., Sterzing, F., Van Cutsem, E., Van Der Gaast, A., Van Lanschot, J., Ychou, M., and Otto, F. Highlights of the EORTC st. gallen international expert consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. [2012] European Journal of Cancer (48) 16 : 2941-2953. Impact factor : 5.061 [251] Macfarlane, T. V., Macfarlane, G. J., Thakker, N. S., Benhamou, S., Bouchardy, C., Ahrens, W., Pohlabeln, H., Lagiou, P., Lagiou, A., Castellsague, X., Agudo, A., Slamova, A., Plzak, J., Merletti, F., Richiardi, L., Talamini, R., Barzan, L., Kjaerheim, K., Canova, C., Simonato, L., Conway, D. I., Mckinney, P. A., Thomson, P., Sloan, P., Znaor, A., Healy, C. M., McCartan, B. E., Marron, M., and Brennan, P. Role of medical history and medication use in the aetiology of upper aerodigestive tract cancers in Europe: The ARCAGE study. [2012] Annals of Oncology (23) 4 : 1053-1060. Impact factor : 7.384 [252] Maibach, R., Roebuck, D., Brugieres, L., Capra, M., Brock, P., Dall’Igna, P., Otte, J. B., De Camargo, B., Zsiros, J., Zimmermann, A., Aronson, D., Childs, M., Scopinaro, M., Morland, B., Plaschkes, J., Czauderna, P., and Perilongo, G. Prognostic stratification for children with hepatoblastoma: The SIOPEL experience. [2012] European Journal of Cancer (48) 10 : 1543-1549. Impact factor : 5.061 [253] Maio, M., Bondarenko, I., Robert, C., Thomas, L., Garbe, C., Testori, A., Francis, S., Chin, K., and Wolchok, J. FOUR-YEAR SURVIVAL UPDATE FOR METASTATIC MELANOMA (MM) PATIENTS (PTS) TREATED WITH IPILIMUMAB (IPI) plus DACARBAZINE (DTIC) ON PHASE 3 STUDY CA184-024. [2012] Annals of Oncology (23) 9 : 367-367. Impact factor : 7.384 [254] Malka, D., Boige, V., Faron, M., Caramella, C., Boucher, E., Rivera, P., De Baere, T., Goere, D., Pignon, J., and Ducreux, M. HEPATIC ARTERIAL INFUSION (HAI) OF OXALIPLATIN PLUS INTRAVENOUS (IV) FLUOROURACIL (FU), LEUCOVORIN (LV) AND CETUXIMAB FOR FIRST-LINE TREATMENT OF UNRESECTABLE COLORECTAL LIVER METASTASES (CRLM): FINAL RESULTS OF A MULTICENTER PHASE 2 STUDY (CHOICE). [2012] Annals of Oncology (23) 9 : 198-198. Impact factor : 7.384 [255] Malka, D., Boige, V., Jacques, N., Vimond, N., Adenis, A., Boucher, E., Pierga, J. Y., Conroy, T., Chauffert, B., François, E., Guichard, P., Galais, M. P., Cvitkovic, F., Ducreux, M., and Farace, F. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. [2012] Annals of Oncology (23) 4 : 919-927. Impact factor : 7.384 [256] Malouf, G. G., Brugières, L., Le Deley, M. C., Faivre, S., Fabre, M., Paradis, V., Aerts, I., Le Tourneau, C., Dreyer, C., Branchereau, S., Belghiti, J., and Raymond, E. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. [2012] Cancer (118) 20 : 4981-4990. Impact factor : 5.201 92 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [257] Man, C. H., Wei-Man Lun, S., Hui, J. W. Y., To, K. F., Choy, K. W., Wing-Hung Chan, A., Chow, C., Tin-Yun Chung, G., Tsao, S. W., Tak-Chun Yip, T., Busson, P., and Lo, K. W. Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. [2012] Journal of Pathology (226) 3 : 471-481. Impact factor : 7.585 [258] Mangoni, M., Vozenin, M. C., Biti, G., and Deutsch, E. Normal tissues toxicities triggered by combined antiangiogenic and radiation therapies: hurdles might be ahead. [2012] British Journal of Cancer (107) 2 : 308-314. Impact factor : 5.082 [259] Mardiak, J., Ma, J., Korbenfeld, E., Zemanova, M., Leonhartsberger, N., Stauch, K., Boeckenhoff, A., Yu, J., Escudier, B., and Jaeger, D. SORAFENIB IN PATIENTS WITH RENAL CELL CARCINOMA AND BRAIN, BONE OR LUNG METASTASES: SUBANALYSIS OF THE NON-INTERVENTIONAL PREDICT STUDY. [2012] Annals of Oncology (23) 9 : 270-270. Impact factor : 7.384 [260] Marie, I., Guillevin, L., Menard, J. F., Hatron, P. Y., Cherin, P., Amoura, Z., Cacoub, P., Bachelez, H., Buzyn, A., Le Roux, G., Ziza, J. M., Brice, P., Munck, J. N., Sarrot-Reynauld, F., Piette, J. C., and Larroche, C. Hematological malignancy associated with polymyositis and dermatomyositis. [2012] Autoimmunity Reviews (11) 9 : 615-620. Impact factor : 7.975 [261] Marron, M., Boffetta, P., Moller, H., Ahrens, W., Pohlabeln, H., Benhamou, S., Bouchardy, C., Lagiou, P., Lagiou, A., Slamova, A., Schejbalovà, M., Merletti, F., Richiardi, L., Kjaerheim, K., Agudo, A., Castellsague, X., Macfarlane, T. V., Macfarlane, G. J., Talamini, R., Barzan, L., Canova, C., Simonato, L., Biggs, A. M., Thomson, P., Conway, D. I., Mckinney, P. A., Znaor, A., Healy, C. M., McCartan, B. E., Brennan, P., and Hashibe, M. Risk of upper aerodigestive tract cancer and type of alcoholic beverage: A European multicenter case-control study. [2012] European Journal of Epidemiology (27) 7 : 499-517. Impact factor : 5.118 [262] Marthey, L., Sa-Cunha, A., Blanc, J. F., Cueff, A., Francois, E., Trouilloud, I., Malka, D., Bachet, J., Coriat, R., and Taieb, J. FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA. RESULTS OF AN AGEO MULTICENTRIC PROSPECTIVE STUDY. [2012] Annals of Oncology (23) 9 : 238-238. Impact factor : 7.384 [263] Martinez-Garcia, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S., Kraeber-Bodéré, F., Rojo, F., Routier, E., Guarin, E., Xu, Z. X., Rueger, R., Tessier, J. J. L., Shochat, E., Blotner, S., Naegelen, V. M., and Soria, J. C. First-inhuman, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a firstin-class dual MEK/RAF inhibitor in patients with solid tumors. [2012] Clinical Cancer Research (18) 17 : 4806-4819. Impact factor : 7.837 [264] Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettinic, J. L., Zitvogel, L., and Kroemer, G. Erratum: Chemotherapy induces ATP release from tumor cells (Cell Cycle (2009) 8:22 (3723-3728)). [2012] Cell Cycle (11) 20 : 3901-3901. Impact factor : 5.243 [265] Martins, Isabelle, Tesniere, Antoine, Kepp, Oliver, Michaud, Mickael, Schlemmer, Frederic, Senovilla, Laura, Séror, Claire, Métivier, Didier, Perfettinic, Jean Luc, Zitvogel, Laurence, and Kroemer, Guido Erratum to Martins I, et al. Cell Cycle Volume 8, Issue 22; pp. 3723rÇô8. [2012] Cell Cycle (11) 20 : 3901-3901. Impact factor : 5.243 [266] Massard, C., Borget, I., Deley, M. C. L., Taylor, M., Gomez-Roca, C., Soria, J. C., and Farace, F. Prognostic value of circulating VEGFR2 + bone marrow-derived progenitor cells in patients with advanced cancer. [2012] European Journal of Cancer (48) 9 : 1354-1362. Impact factor : 5.061 [267] Mathieu, M. C., Mazouni, C., Kesty, N. C., Zhang, Y., Scott, V., Passeron, J., Arnedos, M., Schnabel, C. A., Delaloge, S., Erlander, M. G., and André, F. Breast cancer index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. [2012] Annals of Oncology (23) 8 : 2046-2052. Impact factor : 7.384 [268] Mazieres, J., Peters, S., Cortot, A., Besse, B., Barlesi, F., Beau-Faller, M., Urban, T., Moro-Sibilot, D., Milia, J., and Gautschi, O. LUNG CANCER HARBORING HER2 MUTATION: EPIDEMIOLOGICAL CHARACTERISTICS AND THERAPEUTIC PERSPECTIVES. [2012] Annals of Oncology (23) 9 : 403-403. Impact factor : 7.384 [269] Mazouni, C., Spyratos, F., Romain, S., Fina, F., Bonnier, P., Ouafik, L. H., and Martin, P. M. A nomogram to predict individual prognosis in node-negative breast carcinoma. [2012] European Journal of Cancer (48) 16 : 2954-2961. Impact factor : 5.061 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 93 GUSTAVE ROUSSY’S PUBLICATIONS [270] Meijnders, P., Carde, P., Girinsky, T., Kluin-Nelemans, J. C., Henry-Amar, M., Raemaekers, J. M. M., Karrasch, M., and van der Maazen, R. Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy. [2012] European Journal of Cancer, Supplement (10) 1 : 105-111. Impact factor : 5.061 [271] Mendiola, C., Davidenko, I., Colombo, N., Korach, J., Selle, F., Gocze, P., Chmielowska, E., Pautier, P., Bollag, D., and Oza, A. M. ROSIA: A SINGLE-ARM STUDY IN MORE THAN 1000 PATIENTS (PTS) RECEIVING FRONT-LINE BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) FOR OVARIAN CANCER (OC). [2012] Annals of Oncology (23) 9 : 322-323. Impact factor : 7.384 [272] Merad, M., Chachaty, E., Gachot, B., Alibay, A. T., Dipalma, M., and Sami, A. EPIDEMIOLOGY, RESISTANCE PROFILE AND ORIGIN OF BACTEREMIA IN NON-NEUTROPENIC PATIENTS WITH SOLID TUMOR. [2012] Annals of Oncology (23) 9 : 503-503. Impact factor : 7.384 [273] Mercadal, L., Metzger, M., Casadevall, N., Haymann, J. P., Karras, A., Boffa, J. J., Flamant, M., Vrtovsnik, F., Stengel, B., and Froissart, M. Timing and determinants of erythropoietin deficiency in chronic kidney disease. [2012] Clinical Journal of the American Society of Nephrology (7) 1 : 35-42. Impact factor : 5.068 [274] Millevoi, S., Moine, H., and Vagner, S. G-quadruplexes in RNA biology. [2012] Wiley Interdisciplinary Reviews: RNA (3) 4 : 495-507. Impact factor : 5.088 [275] Minard-Colin, V., Ichante, J. L., Nguyen, L., Paci, A., Orbach, D., Bergeron, C., Defachelles, A. S., André, N., Corradini, N., Schmitt, C., Tabone, M. D., Blouin, P., Sirvent, N., Goma, G., Geoerger, B., and Oberlin, O. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Société Française des Ca. [2012] European Journal of Cancer (48) 15 : 2409-2416. Impact factor : 5.061 [276] Minois, N., Carmona-Gutierrez, D., Bauer, M. A., Rockenfeller, P., Eisenberg, T., Brandhorst, S., Sigrist, S. J., Kroemer, G., and Madeo, F. Spermidine promotes stress resistance in Drosophila melanogaster through autophagy-dependent and -independent pathways. [2012] Cell Death and Disease (3) 10. Impact factor : 6.044 [277] Mir, O., Boudou-Rouquette, P., Larousserie, F., Babinet, A., Dumaine, V., Anract, P., and Goldwasser, F. Objective response to sorafenib in advanced clear-cell sarcoma. [2012] Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (23) 3 : 807-809. Impact factor : 7.384 [278] Mir, O., Coriat, R., Boudou-Rouquette, P., Durand, J. P., and Goldwasser, F. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. [2012] Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (23) 1 : 280-281 . Impact factor : 7.384 [279] Moniz, H., Gastou, M., Leblanc, T., Hurtaud, C., Cré Tien, A., Lécluse, Y., Raslova, H., Larghero, J., Croisille, L., Faubladier, M., Bluteau, O., Lordier, L., Tchernia, G., Vainchenker, W., Mohandas, N., and Da Costa, L. Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro. [2012] Cell Death and Disease (3) 7. Impact factor : 6.044 [280] Montemurro, M., DOMONT, J., Rutkowski, P., Roth, A. D., von Moos, R., Inauen, R., Dietrich, D., Biaggi, C., Prior, J., and Leyvraz, S. DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS. A MULTICENTER PHASE II TRIAL OF THE SAKK (SAKK 56/07). [2012] Annals of Oncology (23) 9 : 480-480. Impact factor : 7.384 [281] Mordant, P., Loriot, Y., Lahon, B., Castier, Y., Lesèche, G., Soria, J. C., Massard, C., and Deutsch, E. Minimal residual disease in solid neoplasia: New frontier or red-herring? [2012] Cancer Treatment Reviews (38) 2 : 101110. Impact factor : 6.024 [282] Morera, Solange, Grin, Inga, Vigouroux, Armelle, Couve, Sophie, Henriot, Veronique, Saparbaev, Murat, and Ishchenko, Alexander A. Biochemical and structural characterization of the glycosylase domain of MBD4 bound to thymine and 5-hydroxymethyuracil-containing DNA. [2012] Nucleic Acids Research (40) 19 : 9917-9926. Impact factor : 8.278 [283] Morice, P., Kane, A., Muller, E., Fauvet, R., Gouy, S., Pautier, P., Lhomme, C., Darai, E., Duvillard, P., and Uzan, C. PROGNOSTIC FACTORS AFTER CONSERVATIVE TREATMENT OF A LARGE SERIES OF ``STAGE I{‘’} SEROUS BORDERLINE OVARIAN TUMORS. [2012] Annals of Oncology (23) 9 : 322-322. Impact factor : 7.384 94 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [284] Morois, S., Fournier, A., Clavel-Chapelon, F., Mesrine, S., and Boutron-Ruault, M. C. Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: True associations or bias? [2012] European Journal of Epidemiology (27) 6 : 439-452. Impact factor : 5.118 [285] Moss, Robert, Grosse, Thibault, and Thomas, S. Randall Exploration of pressure-natriuresis mechanisms using a lumped, two-nephron whole-kidney model. [2012] FASEB Journal (26). Impact factor : 5.704 [286] Motzer, R. J., Escudier, B., Tomczak, P., Negrier, S., Gore, M. E., Tarazi, J., Hariharan, S., Rosbrook, B., Kim, S., and Rini, B. I. AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS. [2012] Annals of Oncology (23) 9 : 262-262. Impact factor : 7.384 [287] Nakatake, M., Monte-Mor, B., Debili, N., Casadevall, N., Ribrag, V., Solary, E., Vainchenker, W., and Plo, I. JAK2 V617F negatively regulates p53 stabilization by enhancing MDM2 via la expression in myeloproliferative neoplasms. [2012] Oncogene (31) 10 : 1323-1333. Impact factor : 7.357 [288] Natrajan, Rachael, Mackay, Alan, Wilkerson, Paul M., Lambros, Maryou B., Wetterskog, Daniel, Arnedos, Monica, Shiu, Kai Keen, Geyer, Felipe C., Langerod, Anita, Kreike, Bas, Reyal, Fabien, Horlings, Hugo M., van de Vijver, Marc J., Palacios, Jose, Weigelt, Britta, and Reis-Filho, Jorge S. Functional characterization of the 19q12 amplicon in grade III breast cancers. [2012] Breast cancer research : BCR (14) 2 : R53-R53. Impact factor : 5.872 [289] Nault, Jean Charles, Fabre, Monique, Couchy, Gabrielle, Pilati, Camilla, Jeannot, Emmanuelle, Tran Van Nhieu, Jeanne, Saint-Paul, Marie Christine, De Muret, Anne, Redon, Marie José, Buffet, Catherine, Salenave, Sylvie, Balabaud, Charles, Prevot, Sophie, Labrune, Philippe, Bioulac-Sage, Paulette, Scoazec, Jean Yves, Chanson, Philippe, and Zucman-Rossi, Jessica GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. [2012] Journal of Hepatology (56) 1 : 184-191. Impact factor : 9.858 [290] Negretti, L., Blanchard, P., Couanet, D., Kieffer, V., Goma, G., Habrand, J. L., Dhermain, F., Valteau-Couanet, D., Grill, J., and Dufour, C. Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival. [2012] Neuro-Oncology (14) 11 : 1413-1421. Impact factor : 6.180 [291] Nelson, J. B., Fizazi, K., Miller, K., Higano, C., Moul, J. W., Akaza, H., Morris, T., McIntosh, S., Pemberton, K., and Gleave, M. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. [2012] Cancer (118) 22 : 5709-5718. Impact factor : 5.201 [292] Nguyen, L., Paci, A., and Vassal, G. Author reply : Population pharmacokinetics of busulfan in children-letter. [2012] Clinical Cancer Research (18) 9 : 2715-2716. Impact factor : 7.837 [293] Nishida, T., Casali, P. G., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Joensuu, H., Maki, R. G., Rutkowski, P., Hohenberger, P., Gelderblom, H., Leahy, M. G., von Mehren, M., Schoffski, P., Blackstein, M. E., Cesne, A. L., Badalamenti, G., Xu, J.-M., Laurent, D., Kuss, I., Demetri, G. D., and Investigators, G. R. I. D. RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL. [2012] Annals of Oncology (23) 11 : 20-20. Impact factor : 7.384 [294] Noman, Muhammad Zaeem, Buart, Stéphanie, Romero, Pedro, Ketari, Sami, Janji, Bassam, Mari, Bernard, MamiChouaib, Fathia, and Chouaib, Salem Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. [2012] Cancer Research (72) 18 : 4629-4641. Impact factor : 8.650 [295] Nunes, M., Roman-Roman, S., Dessen, P., Bigot, L., Blot, L., Demers, B., Berthet, C., Dangles-Marie, V., Vriganud, P., and Lacroix, L. TRANSLATIONAL RELEVANCE OF PATIENT-DERIVED COLON TUMOR XENOGRAFTS (PDX) TO CORRELATE PATHWAYS ABNORMALITIES WITH RESPONSE TO ANTI-EGFR THERAPY. [2012] Annals of Oncology (23) 1 : 41-42. Impact factor : 7.384 [296] Olmos, D., Ang, J. E., Gomez-Roca, C., Morales-Barrera, R., Vulink, A. J., Massard, C., and Kaye, S. Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase i oncology trial participants - Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase i cancer patients. [2012] European Journal of Cancer (48) 4 : 594-596. Impact factor : 5.061 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 95 GUSTAVE ROUSSY’S PUBLICATIONS [297] Ong, M., Del Conte, G., Bahleda, R., Perotti, A., Damian, S., Lassau, N., Farace, F., Gennaro, D., Stimpson, S., Tinariu, N., Gianni, L., Sessa, C., Micallef, S., Demers, B., Oprea, C., Molife, L. R., and Soria, J. C. A PHASE I STUDY OF OMBRABULIN (O) COMBINED WITH BEVACIZUMAB (B) IN PATIENTS WITH ADVANCED SOLID TUMORS PRELIMINARY RESULTS. [2012] Annals of Oncology (23) 1 : 19-19. Impact factor : 7.384 [298] Opocher, Enrico, de Salvo, Gian Luca, De Paoli, Angela, Simmons, Ian, Sehested, Astrid, Walker, David A., Picton, Susan V., Gnekow, Astrid, Grill, Jacques, Driever, Pablo Hernaiz, Azizi, Amedeo A., Viscardi, Elisabetta, and Perilongo, Giorgio VISUAL OUTCOME OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PROGRESSIVE OPTIC PATHWAY GLIOMA TREATED WITH CHEMOTHERAPY: PRELIMINARY REPORT FROM THE SIOP-LGG 2004 STUDY. [2012] Neuro-Oncology (14) supplt 1 : 72-72. Impact factor : 6.180 [299] Ost, P., Cozzarini, C., Bossi, A., and Meerleer, G. D. Author reply : Salvage radiotherapy: A plea for dose-escalation with intensity-modulated radiotherapy. [2012] European Journal of Cancer (48) 9 : 1415-1416. Impact factor : 5.061 [300] Ott, Alban, Idali, Anouar, Marchais, Antonin, and Gautheret, Daniel NAPP: the Nucleic Acid Phylogenetic Profile Database. [2012] Nucleic Acids Research (40) Database issue : D205-D209. Impact factor : 8.278 [301] Oudard, S., Escudier, B., Thompson, J., Gruenwald, V., Conte, P. F., Bracarda, S., Panneerselvam, A., Gogov, S., Chen, D., and Motzer, R. J. BIOMARKERS OF EVEROLIMUS EFFICACY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): ANALYSIS OF THE PHASE III RECORD-1 TRIAL. [2012] Annals of Oncology (23) 9 : 278279. Impact factor : 7.384 [302] Pallud, J., Llitjos, J. F., Dhermain, F., Varlet, P., Dezamis, E., Devaux, B., Souillard-Scémama, R., Sanai, N., Koziak, M., Page, P., Schlienger, M., Daumas-Duport, C., Meder, J. F., Oppenheim, C., and Roux, F. X. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. [2012] Neuro-Oncology (14) 4 : 496-505. Impact factor : 6.180 [303] Park, A. K., Lee, S. J., Phi, J. H., Wang, K. C., Kim, D. G., Cho, B. K., Haberler, C., Fattet, S., Dufour, C., Puget, S., Sainte-Rose, C., Bourdeaut, F., Grill, J., Delattre, O., Kim, S. K., and Park, W. Y. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. [2012] Neuro-Oncology (14) 2 : 203-214. Impact factor : 6.180 [304] Patel, Pinal S., Forouhi, Nita G., Kuijsten, Anneleen, Schulze, Matthias B., van Woudenbergh, Geertruida J., Ardanaz, Eva, Amiano, Pilar, Arriola, Larraitz, Balkau, Beverley, Barricarte, Aurelio, Beulens, Joline W. J., Boeing, Heiner, Buijsse, Brian, Crowe, Francesca L., Lauzon-Guillan, Blandine, Fagherazzi, Guy, Franks, Paul W., Gonzalez, Carlos, Grioni, Sara, Halkjaer, Jytte, Huerta, José Maria, Key, Timothy J., Kühn, Tilman, Masala, Giovanna, Nilsson, Peter, Overvad, Kim, Panico, Salvatore, Quiros, Jose Ramon, Rolandsson, Olov, Sacerdote, Carlotta, Sanchez, Maria José, Schmidt, Erik B., Slimani, Nadia, Spijkerman, Annemieke M. W., Teucher, Birgit, Tjonneland, Anne, Tormo, Maria Jose, Tumino, Rosario, Van Der, A., van der Schouw, Yvonne T., Sharp, Stephen J., Langenberg, Claudia, Feskens, Edith J. M., Riboli, Elio, and Wareham, Nicholas J. The prospective association between total and type of fish intake and type 2 diabetes in 8 European countries: EPIC-InterAct Study. [2012] American Journal of Clinical Nutrition (95) 6 : 1445-1453. Impact factor : 6.504 [305] Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., DOMONT, J., Pérol, D., Blay, J. Y., and Le Cesne, A. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. [2012] Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Impact factor : 7.384 [306] Pautier, P., Lobbedez, F. Joly, Melichar, B., Kutarska, E., Hall, G., and Reed, N. A PHASE II MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF ORAL STEROID SULPHATASE (STS) INHIBITOR IROSUSTAT (BN83495) VERSUS MEGESTROL ACETATE (MA) IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER (EC). [2012] Annals of Oncology (23) 9 : 329-329. Impact factor : 7.384 [307] Pecquet, C., Diaconu, C. C., Staerk, J., Girardot, M., Marty, C., Royer, Y., Defour, J. P., Dusa, A., Besancenot, R., Giraudier, S., Villeval, J. L., Knoops, L., Courtoy, P. J., Vainchenker, W., and Constantinescu, S. N. Thrombopoietin receptor down-modulation by JAK2 V617F: Restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. [2012] Blood (119) 20 : 4625-4635. Impact factor : 9.060 96 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [308] Perez-Moreno, P., Brambilla, E., Thomas, R., and Soria, J. C. Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. [2012] Clinical Cancer Research (18) 9 : 2443-2451 . Impact factor : 7.837 [309] Pernemalm, A., Branca, M., Petris, D. E., Forshed, J., Lewensohn, R., Besse, B., Lazar, V., den Oord, J., Pawitan, Y., and Lehtio, J. PROTEOMICS ANCHORED SYSTEMS BIOLOGY ANALYSIS OF PROGNOSTIC FACTORS IN PRIMARY LUNG ADENOCARCINOMA TUMOURS. [2012] Annals of Oncology (23) 5 : 38-38. Impact factor : 7.384 [310] Pernot, E., Hall, J., Baatout, S., Benotmane, M. A., Blanchardon, E., Bouffler, S., El Saghire, H., Gomolka, M., Guertler, A., Harms-Ringdahl, M., Jeggo, P., Kreuzer, M., Laurier, D., Lindholm, C., Mkacher, R., Quintens, R., Rothkamm, K., Sabatier, L., Tapio, S., De Vathaire, F., and Cardis, E. Ionizing radiation biomarkers for potential use in epidemiological studies. [2012] Mutation Research - Reviews in Mutation Research (751) 2 : 258-286. Impact factor : 6.426 [311] Peters, Susan, Kromhout, Hans, Olsson, Ann C., Wichmann, Heinz Erich, Brüske, Irene, Consonni, Dario, Landi, Maria Teresa, Caporaso, Neil, Siemiatycki, Jack, Richiardi, Lorenzo, Mirabelli, Dario, Simonato, Lorenzo, Gustavsson, Per, Plato, Nils, Jöckel, Karl Heinz, Ahrens, Wolfgang, Pohlabeln, Hermann, Boffetta, Paolo, Brennan, Paul, Zaridze, David, Cassidy, Adrian, Lissowska, Jolanta, Szeszenia-Dabrowska, Neonila, Rudnai, Peter, Fabianova, Eleonora, Forastiere, Francesco, Bencko, Vladimir, Foretova, Lenka, Janout, Vladimir, Stücker, Isabelle, Dumitru, Rodica Stanescu, Benhamou, Simone, Bueno-de-Mesquita, Bas, Kendzia, Benjamin, Pesch, Beate, Straif, Kurt, Brüning, Thomas, and Vermeulen, Roel Occupational exposure to organic dust increases lung cancer risk in the general population. [2012] Thorax (67) 2 : 111-116. Impact factor : 8.376 [312] Petit, A., Ragu, C., Soler, G., Ottolenghi, C., Schluth, C., Radford-Weiss, I., Schneider-Maunoury, S., Callebaut, I., Dastugue, N., Drabkin, H. A., Bernard, O. A., Romana, S., and Penard-Lacronique, V. Functional analysis of the NUP98-CCDC28A fusion protein. [2012] Haematologica (97) 3 : 379-387. Impact factor : 5.935 [313] Pécuchet, N., Lebbe, C., Mir, O., Billemont, B., Blanchet, B., Franck, N., Viguier, M., Coriat, R., Tod, M., Avril, M. F., and Goldwasser, F. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? [2012] British Journal of Cancer (107) 3 : 455-461. Impact factor : 5.082 [314] Pierceall, W. E., Olaussen, K. A., Rousseau, V., Brambilla, E., Sprott, K. M., Andre, F., Pignon, J. P., Le chevalier, T., Pirker, R., Jiang, C., Filipits, M., Chen, Y., Kutok, J. L., Weaver, D. T., Ward, B. E., and Soria, J. C. Cisplatin benefit is predicted by immunohistochemical analysis of dna repair proteins in squamous cell carcinoma but not adenocarcinoma: Theranostic modeling by nsclc constituent histological subclasses. [2012] Annals of Oncology (23) 9 : 2245-2252. Impact factor : 7.384 [315] Pierga, J. Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Diéras, V., Rolland, E., Mignot, L., Mathiot, C., and Bidard, F. C. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. [2012] Annals of Oncology (23) 3 : 618-624. Impact factor : 7.384 [316] Pietrocola, F., Marino, G., Lissa, D., Vacchelli, E., Malik, S. A., Niso-Santano, M., Zamzami, N., Galluzzi, L., Maiuri, M. C., and Kroemer, G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. [2012] Cell Cycle (11) 20 : 3851-3860. Impact factor : 5.243 [317] Planchard, D., Rahal, A., Lacroix, L., Ngocamus, M., Auger, N., Saulnier, P., Dorfmuller, P., Le chevalier, T., Soria, J., and Besse, B. UPFRONT GENOMIC TESTING FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE MSN STUDY. [2012] Annals of Oncology (7) 6, Supplt 1 : S31-S31. Impact factor : 7.384 [318] Planchard, D., Lueza, B., Rahal, A., Lacroix, L., Ngocamus, M., Auger, N., Saulnier, P., Dorfmuller, P., Le chevalier, T., Celebic, A., Pignon, J. P., Soria, J. C., and Besse, B. UPFRONT GENOMIC TESTING FOR PATIENTS WITH NONSMALL CELL LUNG CANCER RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE MSN STUDY. [2012] Annals of Oncology (23) 5 : 13-13. Impact factor : 7.384 [319] Planchard, D., Camara-Clayette, V., Dorvault, N., Soria, J. C., and Fouret, P. P38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. [2012] Cancer (118) 20 : 5015-5025. Impact factor : 5.201 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 97 GUSTAVE ROUSSY’S PUBLICATIONS [320] Ploquin, A., Olmos, D., Lacombe, D., A’Hern, R., Duhamel, A., Twelves, C., Marsoni, S., Morales-Barrera, R., Soria, J. C., Verweij, J., Voest, E. E., Schöffski, P., Schellens, J. H., Kramar, A., Kristeleit, R. S., Arkenau, H. T., Kaye, S. B., and Penel, N. Prediction of early death among patients enrolled in phase i trials: Development and validation of a new model based on platelet count and albumin. [2012] British Journal of Cancer (107) 7 : 10251030. Impact factor : 5.082 [321] Rahal, Arslane, Boige, Valerie, David, Malka, Rahal, Chahinez, Burtin, Pascal, Sinapi, Isabelle, Elias, Dominique, Goere, Diane, Lacas, Benjamin, and Ducreux, Michel MODIFIED FOLFIRI (MFOLFIRI) AS SECOND LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER (AGC). [2012] Annals of Oncology (23) 4 : 38-38. Impact factor : 7.384 [322] Rahal, C., Cioffi, A., DOMONT, J., Bonvalot, S., Le Pechoux, C., Vilcot, L., Terrier, P., Fayard, F., Rahal, A., and Lecesne, A. VINORELBINE IS AN ACTIVE DRUG IN DESMOID TUMORS/AGGRESSIVE FIBROMATOSIS: INSTITUT GUSTAVE ROUSSY EXPERIENCE. [2012] Annals of Oncology (23) 9 : 486-486 . Impact factor : 7.384 [323] Raphael, J., Hollebecque, A., Le Teuff, G., Massard, C., Bahleda, R., Margery, J., Besse, B., Soria, J., and Planchard, D. EFFICACY AND TOXICITY OBSERVED IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS TREATED IN PHASE I TRIALS AT A SINGLE INSTITUTION. [2012] Annals of Oncology (23) 9 : 496-496. Impact factor : 7.384 [324] Raphael, J., Massard, C., Farace, F., Le Teuff, G., Margery, J., Billiot, F., Besse, B., Hollebecque, A., Soria, J., and Planchard, D. DETECTION OF CIRCULATING TUMOUR CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA. [2012] Annals of Oncology (23) 9 : 94-94. Impact factor : 7.384 [325] Ravaud, A., Oudard, S., De Fromont, M., Chevreau, C., Gravis, G., Zanetta, S., Theodore, C., Jimenez, M., Sevin, E., and Escudier, B. FIRST LINE SUNITINIB IN TYPE I AND II PAPILLARY RENAL CELL CARCINOMA (PRCC): SUPAP- A PHASE II STUDY OF THE FRENCH GENITO-URINARY GROUP (GETUG) AND THE GROUP OF EARLY PHASE TRIALS (GEP). [2012] Annals of Oncology (23) 9 : 263-263. Impact factor : 7.384 [326] Ray-Coquard, I. and Le Cesne, A. A role for maintenance therapy in managing sarcoma. [2012] Cancer Treatment Reviews (38) 5 : 368-378. Impact factor : 6.024 [327] Ray-Coquard, I., Pautier, P., Alexandre, J., Vacher-Lavenu, M., Fabbro, M., Floquet, A., Selle, F., Ferron, G., Chiannilkulchai, N., and Pujade-Lauraine, E. FROM A WEBSITE TO A NATIONAL AND REGIONAL REFERENCE CENTRE NETWORK: THE FRENCH EXPERIENCE FOR RARE OVARIAN TUMORS. [2012] Annals of Oncology (23) 9 : 327-327. Impact factor : 7.384 [328] Rebouissou, S., Hérault, A., Letouzé, E., Neuzillet, Y., Laplanche, A., Ofualuka, K., Maillé, P., Leroy, K., Riou, A., Lepage, M. L., Vordos, D., De La Taille, A., Denoux, Y., Sibony, M., Guyon, F., Lebret, T., Benhamou, S., Allory, Y., and Radvanyi, F. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. [2012] Journal of Pathology (227) 3 : 315-324. Impact factor : 7.585 [329] Reichardt, P., Blay, J. Y., Boukovinas, I., Brodowicz, T., Broto, J. M., Casali, P. G., Decatris, M., Eriksson, M., Gelderblom, H., Kosmidis, P., Le Cesne, A., Pousa, A. L., Schlemmer, M., Verweij, J., and Joensuu, H. Adjuvant therapy in primary GIST: State-of-the-art. [2012] Annals of Oncology (23) 11 : 2776-2781. Impact factor : 7.384 [330] Reiman, T., Lai, R., Veillard, A. S., Paris, E., Soria, J. C., Rosell, R., Taron, M., Graziano, S., Kratzke, R., Seymour, L., Shepherd, F. A., Pignon, J. P., and Sève, P. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials. [2012] Annals of Oncology (23) 1 : 86-93. Impact factor : 7.384 [331] Rello-Varona, S., Lissa, D., Shen, S., Niso-Santano, M., Senovilla, L., Marino, G., Vitale, I., Jemaá, M., Harper, F., Pierron, G., Castedo, M., and Kroemer, G. Autophagic removal of micronuclei. [2012] Cell Cycle (11) 1 : 170-176. Impact factor : 5.243 [332] Réguerre, Y., Martelli, H., Rey, A., Rogers, T., Gaze, M., Arush, M. W. B., Devalck, C., Oberlin, O., Stevens, M., and Orbach, D. Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. [2012] European Journal of Cancer (48) 13 : 2020-2027. Impact factor : 5.061 98 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [333] Richiardi, L., Corbin, M., Marron, M., Ahrens, W., Pohlabeln, H., Lagiou, P., Minaki, P., Agudo, A., Castellsague, X., Slamova, A., Schejbalova, M., Kjaerheim, K., Barzan, L., Talamini, R., Macfarlane, G. J., Macfarlane, T. V., Canova, C., Simonato, L., Conway, D. I., Mckinney, P. A., Sneddon, L., Thomson, P., Znaor, A., Healy, C. M., McCartan, B. E., Benhamou, S., Bouchardy, C., Hashibe, M., Brennan, P., and Merletti, F. Occupation and risk of upper aerodigestive tract cancer: The ARCAGE study. [2012] International Journal of Cancer (130) 10 : 2397-2406. Impact factor : 6.198 [334] Rinaldi, S., Lise, M., Clavel-Chapelon, F., Boutron-Ruault, M. C., Guillas, G., Overvad, K., Tjonneland, A., Halkjaer, J., Lukanova, A., Kaaks, R., Bergmann, M. M., Boeing, H., Trichopoulou, A., Zylis, D., Valanou, E., Palli, D., Agnoli, C., Tumino, R., Polidoro, S., Mattiello, A., Bas Bueno-De-Mesquita, H., Peeters, P. H., Weiderpass, E., Lund, E., Skeie, G., Rodriguez, L., Travier, N., Sanchez, M. J., Amiano, P., Huerta, J. M., Ardanaz, E., Rasmuson, T., Hallmans, G., Almquist, M., Manjer, J., Tsilidis, K. K., Allen, N. E., Khaw, K. T., Wareham, N., Byrnes, G., Romieu, I., Riboli, E., and Franceschi, S. Body size and risk of differentiated thyroid carcinomas: Findings from the EPIC study. [2012] International Journal of Cancer (131) 6 : E1004-E1014 . Impact factor : 6.198 [335] Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., Rogowski, W., Kracht, K., Sun, Y. N., Bass, M. B., Puhlmann, M., and Escudier, B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebocontrolled, phase 2 study. [2012] Cancer (118) 24 : 6152-6161. Impact factor : 5.201 [336] Ritte, R., Lukanova, A., Berrino, F., Dossus, L., Tjonneland, A., Olsen, A., Overvad, T. F., Overvad, K., Clavel-Chapelon, F., Fournier, A., Fagherazzi, G., Rohrmann, S., Teucher, B., Boeing, H., Aleksandrova, K., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Sieri, S., Panico, S., Tumino, R., Vineis, P., Quiros, J. R., Buckland, G., Sanchez, M. J., Amiano, P., Chirlaque, M. D., Ardanaz, E., Sund, M., Lenner, P., Bueno-De-Mesquita, B., Van Gils, C. H., Peeters, P. H. M., KrumHansen, S., Gram, I. T., Lund, E., Khaw, K. T., Wareham, N., Allen, N. E., Key, T. J., Romieu, I., Rinaldi, S., Siddiq, A., Cox, D., Riboli, E., and Kaaks, R. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: A large prospective cohort study. [2012] Breast Cancer Research (14) 3. Impact factor : 5.872 [337] Rodriguez, D. A., Zamorano, S., Lisbona, F., Rojas-Rivera, D., Urra, H., Cubillos-Ruiz, J. R., Armisen, R., Henriquez, D. R., Cheng, H., Letek, M., Vaisar, T., Irrazabal, T., Gonzalez-Billault, C., Letai, A., Pimentel-Muiéos, F. X., Kroemer, G., and Hetz, C. BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1a. [2012] EMBO Journal (31) 10 : 2322-2335. Impact factor : 9.822 [338] Rohrmann, S., Grote, V. A., Becker, S., Rinaldi, S., Tjonneland, A., Roswall, N., Gronbaek, H., Overvad, K., BoutronRuault, M. C., Clavel-Chapelon, F., Racine, A., Teucher, B., Boeing, H., Drogan, D., Dilis, V., Lagiou, P., Trichopoulou, A., Palli, D., Tagliabue, G., Tumino, R., Vineis, P., Mattiello, A., Rodriguez, L., Duell, E. J., Molina-Montes, E., Dorronsoro, M., Huerta, J. M., Ardanaz, E., Jeurnink, S., Peeters, P. H. M., Lindkvist, B., Johansen, D., Sund, M., Ye, W., Khaw, K. T., Wareham, N. J., Allen, N. E., Crowe, F. L., Fedirko, V., Jenab, M., Michaud, D. S., Norat, T., Riboli, E., Buenode-Mesquita, H. B., and Kaaks, R. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. [2012] British Journal of Cancer (106) 5 : 1004-1010. Impact factor : 5.082 [339] Romaguera, D., Vergnaud, A. C., Peeters, P. H., Van Gils, C. H., Chan, D. S. M., Ferrari, P., Romieu, I., Jenab, M., Slimani, N., Clavel-Chapelon, F., Fagherazzi, G., Perquier, F., Kaaks, R., Teucher, B., Boeing, H., Von Rüsten, A., Tjonneland, A., Olsen, A., Dahm, C. C., Overvad, K., Quiros, J. R., Gonzalez, C. A., Sanchez, M. J., Navarro, C., Barricarte, A., Dorronsoro, M., Khaw, K. T., Wareham, N. J., Crowe, F. L., Key, T. J., Trichopoulou, A., Lagiou, P., Bamia, C., Masala, G., Vineis, P., Tumino, R., Sieri, S., Panico, S., May, A. M., Bueno-de-Mesquita, H. B., Büchner, F. L., Wirfält, E., Manjer, J., Johansson, I., Hallmans, G., Skeie, G., Borch, K. B., Parr, C. L., Riboli, E., and Norat, T. Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. [2012] American Journal of Clinical Nutrition (96) 1 : 150-163. Impact factor : 6.504 [340] Romieu, I., Ferrari, P., Rinaldi, S., Slimani, N., Jenab, M., Olsen, A., Tjonneland, A., Overvad, K., Boutron-Ruault, M. C., Lajous, M., Kaaks, R., Teucher, B., Boeing, H., Trichopoulou, A., Naska, A., Vasilopoulo, E., Sacerdote, C., Tumino, R., Masala, G., Sieri, S., Panico, S., Bueno-de-Mesquita, H. B., Van Der, A., Van Gils, C. H., Peeters, P. H. M., Lund, E., Skeie, G., Asli, L. A., Rodriguez, L., Navarro, C., Amiano, P., Sanchez, M. J., Barricarte, A., Buckland, G., Sonestedt, E., Wirf+ñlt, E., Hallmans, G., Johansson, I., Key, T. J., Allen, N. E., Khaw, K. T., Wareham, N. J., Norat, T., Riboli, E., and Clavel-Chapelon, F. Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). [2012] American Journal of Clinical Nutrition (96) 2 : 345-355. Impact factor : 6.504 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 99 GUSTAVE ROUSSY’S PUBLICATIONS [341] Ros, M. M., Bas Bueno-De-Mesquita, H., Kampman, E., Buchner, F. L., Aben, K. K. H., Egevad, L., Overvad, K., Tjonneland, A., Roswall, N., Clavel-Chapelon, F., Boutron-Ruault, M. C., Morois, S., Kaaks, R., Teucher, B., Weikert, S., Ruesten, A. V., Trichopoulou, A., Naska, A., Benetou, V., Saieva, C., Pala, V., Ricceri, F., Tumino, R., Mattiello, A., Peeters, P. H. M., Van Gils, C. H., Gram, I. T., Engeset, D., Chirlaque, M. D., Ardanazx, E., Rodriguez, L., Amanio, P., Gonzalez, C. A., Sanchez, M. J., Ulmert, D., Ernström, R., Ljungberg, B., Allen, N. E., Key, T. J., Khaw, K. T., Wareham, N., Slimani, N., Romieu, I., Kiemeney, L. A., and Riboli, E. Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. [2012] European Journal of Cancer (48) 17 : 3267-3277. Impact factor : 5.061 [342] Ros, M. M., Bueno-de-Mesquita, H. B., Kampman, E., Aben, K. K. H., Buchner, F. L., Jansen, E. H. J. M., Van Gils, C. H., Egevad, L., Overvad, K., Tjonneland, A., Roswall, N., Boutron-Ruault, M. C., Kvaskoff, M., Perquier, F., Kaaks, R., Chang-Claude, J., Weikert, S., Boeing, H., Trichopoulou, A., Lagiou, P., Dilis, V., Palli, D., Pala, V., Sacerdote, C., Tumino, R., Panico, S., Peeters, P. H. M., Gram, I. T., Skeie, G., Huerta, J. M., Barricarte, A., Quiros, J. R., Sanchez, M. J., Buckland, G., Larranaga, N., Ehrnström, R., Wallström, P., Ljungberg, B., Hallmans, G., Key, T. J., Allen, N. E., Khaw, K. T., Wareham, N., Brennan, P., Riboli, E., and Kiemeney, L. A. Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. [2012] American Journal of Clinical Nutrition (96) 4 : 902-910. Impact factor : 6.504 [343] Rossier, Christine, Dunet, Vincent, Tissot, Frederic, Aubry-Rozier, Bereng+ re, Marchetti, Oscar, Marchetti, Olivier, and Boubaker, Ariane Voriconazole-induced periostitis. [2012] European journal of nuclear medicine and molecular imaging (39) 2 : 375-376. Impact factor : 5.114 [344] Rouanne, M., Massard, C., Hollebecque, A., Rousseau, V., Varga, A., Gazzah, A., Neuzillet, Y., Lebret, T., and Soria, J. EVALUATION OF SEXUALITY, QUALITY-OF-LIFE AND DEPRESSION IN ADVANCED CANCER PATIENTS TREATED IN A DRUG DEVELOPMENT UNIT. [2012] Annals of Oncology (23) 9 : 474-474. Impact factor : 7.384 [345] Rousseau, B., Loulergue, P., Mir, O., Krivine, A., Kotti, S., Viel, E., Simon, T., de Gramont, A., Goldwasser, F., Launay, O., and Tournigand, C. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. [2012] Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (23) 2 : 450-457. Impact factor : 7.384 [346] Saad, F., Brown, J. E., Van Poznak, C., Ibrahim, T., Stemmer, S. M., Stopeck, A. T., Diel, I. J., Takahashi, S., Shore, N., Henry, D. H., Barrios, C. H., Facon, T., Senecal, F., Fizazi, K., Zhou, L., Daniels, A., Carrière, P., and Dansey, R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. [2012] Annals of Oncology (23) 5 : 1341-1347. Impact factor : 7.384 [347] Saada, E., Ferrand, F. R., Fekih, M., Hamdan, D., Janot, F., Temam, S., Julieron, M., Leridant, A. M., Schilf, A., and Guigay, J. DOCETAXEL, CARBOPLATIN AND FLUORO-URACIL (TCF) INDUCTION THERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS WITH CONTRAINDICATION FOR CISPLATIN BASED COMBINATION (TPF). [2012] Annals of Oncology (23) 9 : 340-340. Impact factor : 7.384 [348] Sacerdote, Carlotta, Ricceri, Fulvio, Rolandsson, Olov, Baldi, Ileana, Chirlaque, Maria Dolores, Feskens, Edith, Bendinelli, Benedetta, Ardanaz, Eva, Arriola, Larraitz, Balkau, Beverley, Bergmann, Manuela, Beulens, Joline W. J., Boeing, Heiner, Clavel-Chapelon, Françoise, Crowe, Francesca, Lauzon-Guillain, Blandine, Forouhi, Nita, Franks, Paul W., Gallo, Valentina, Gonzalez, Carlos, Halkjaer, Jytte, Illner, Anne Kathrin, Kaaks, Rudolf, Key, Timothy, Khaw, Kay Tee, Navarro, Carmen, Nilsson, Peter M., Dal Ton, Susanne Oksbjerg, Overvad, Kim, Pala, Valeria, Palli, Domenico, Panico, Salvatore, Polidoro, Silvia, Quiros, J. Ramon, Romieu, Isabelle, Sanchez, Maria José, Slimani, Nadia, Sluijs, Ivonne, Spijkerman, Annemieke, Teucher, Birgit, Tjonneland, Anne, Tumino, Rosario, Van Der, A., Vergnaud, Anne Claire, Wennberg, Patrik, Sharp, Stephen, Langenberg, Claudia, Riboli, Elio, Vineis, Paolo, and Wareham, Nicholas Lower educational level is a predictor of incident type 2 diabetes in European countries: the EPIC-InterAct study. [2012] International journal of epidemiology (41) 4 : 1162-1173. Impact factor : 6.982 [349] Sadanandam, A., Sidhu, S. S., Wullschleger, S., Singh, S., Varney, M. L., Yang, C. S., Ashour, A. E., Batra, S. K., and Singh, R. K. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. [2012] British Journal of Cancer (107) 3 : 501-507. Impact factor : 5.082 [350] Sadeghi, S., Albiges, L., Wood, L. S., Black, S. L., Gilligan, T. D., Dreicer, R., Garcia, J. A., Escudier, B. J., and Rini, B. I. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and clinical outcome. [2012] Cancer (118) 13 : 3277-3282. Impact factor : 5.201 100 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [351] Saiag, P., Sassolas, B., Mortier, L., Grange, F., Robert, C., Lhomel, C., and Lebbe, C. Knowledge and attitudes on melanoma prevention and diagnosis among the French population in 2011. [2012] Journal of investigative dermatology (132) 2 : S71-S71. Impact factor : 6.193 [352] Sala, N., Munoz, X., Travier, N., Agudo, A., Duell, E. J., Moreno, V., Overvad, K., Tjonneland, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., Canzian, F., Kaaks, R., Boeing, H., Meidtner, K., Trichopoulos, A., Tsiotas, K., Zylis, D., Vineis, P., Panico, S., Palli, D., Krogh, V., Tumino, R., Lund, E., Bueno-de-Mesquita, H. B., Numans, M. E., Peeters, P. H. M., Quiros, J. R., S+ínchez, M. J., Navarro, C., Ardanaz, E., Dorronsoro, M., Hallmans, G., Stenling, R., Manjer, J., Allen, N. E., Travis, R. C., Khaw, K. T., Jenab, M., Offerhaus, G. J. A., Riboli, E., and Gonzalez, C. A. Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: Results from the EPICEURGAST study. [2012] International Journal of Cancer (130) 10 : 2417-2427. Impact factor : 6.198 [353] Samy, M., Gattolliat, C. H., Pendino, F., Hillion, J., Nguyen, E., Bombard, S., Douc-Rasy, S., Bénard, J., and SégalBendirdjian, E. Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominantnegative hTERT mutant. [2012] Molecular cancer therapeutics (11) 11 : 2384-2393. Impact factor : 5.599 [354] Santen, G. W. E., Sun, Y., Gijsbers, A. C. J., Carré, A., Holvoet, M., van Haeringen, A., Lesnik Oberstein, S. A. J., Tomoda, A., Mabe, H., Polak, M., Devriendt, K., Ruivenkamp, C. A. L., and Bijlsma, E. K. Further delineation of the phenotype of chromosome 14q13 deletions: (Positional) involvement of FOXG1 appears the main determinant of phenotype severity, with no evidence for a holoprosencephaly locus. [2012] Journal of Medical Genetics (49) 6 : 366372. Impact factor : 5.703 [355] Scagliotti, G., Stahel, R. A., Rosell, R., Thatcher, N., and Soria, J. C. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. [2012] European Journal of Cancer (48) 7 : 961-973. Impact factor : 5.061 [356] Scagliotti, G. V., Kim, D.-W., Shaw, A. T., Ou, S.-H. I., Riely, G. J., Gettinger, N., Besse, B., Thomas, M., Salgia, R., Wilner, K., Bartlett, C. H., Polli, A., and Gandara, D. R. A Large Retrospective Analysis Of The Activity Of Pemetrexed (Pem) In Patients (Patients) With Alk Plus Nsclc Before Crizotinib (Criz). [2012] Annals of Oncology (23) 11 : 33-33. Impact factor : 7.384 [357] Scher, H. I., Fizazi, K., Saad, F., Chi, K., Taplin, M., Sternberg, C. N., Armstrong, A. J., Hirmand, M., Selby, B., and De Bono, J. S. ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI). [2012] Annals of Oncology (23) 9 : 297-297 . Impact factor : 7.384 [358] Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Furio, P., Ball, D. W., McCaffrey, J. C., Newbold, K., Allison, R., Martins, R. G., Licitra, L., Shah, M. H., Bodenner, D. L., Elisei, R., Burmeister, L. A., Funahashi, Y., Sellecchia, R., Andresen, C., O’Brien, J. P., and Sherman, S. A PHASE II TRIAL OF THE MULTI-TARGETED KINASE INHIBITOR LENVATINIB (E7080) IN ADVANCED MEDULLARY THYROID CANCER (MTC). [2012] Annals of Oncology (23) 11 : 35-36. Impact factor : 7.384 [359] Schmidinger, M., Gore, M., Porta, C., Négrier, S., and Escudier, B. MRCC management: Past, present and future. [2012] European Journal of Cancer, Supplement (10) 2 : 1-11. Impact factor : 5.061 [360] Schmitz, S., Kaminsky-Forrett, M. C., Henry, S., Zanetta, S., Geoffrois, L., Bompas, E., Moxhon, A., Mignion, L., Guigay, J., Knoops, L., Hamoir, M., and Machiels, J. P. Phase II study of figitumumab in patients with recurrent and/ or metastatic squamous cell carcinoma of the head and neck: Clinical activity and molecular response (GORTEC 2008-02). [2012] Annals of Oncology (23) 8 : 2153-2161. Impact factor : 7.384 [361] Seitz, J., Smith, D., O’Toole, D., Lepere, C., Dromain, C., Gorana, A., Mitry, E., and Ducreux, M. P. A PHASE II TRIAL OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC WELL-DIFFERENTIATED DUODENO-PANCREATIC ENDOCRINE TUMORS (BETTER STUDY). [2012] Annals of Oncology (23) 9 : 378-378. Impact factor : 7.384 [362] Selle, F., Fizazi, K., Biron, P., Gravis-Mescam, G., Bui, B., Bay, J., Flechon, A., Dubot, C., Caty, A., Burcoveanu, D., Delva, R., De Revel, T., Miclea, J. M., Gaulet, M., Horn, E., Provent, S., Temby, I., Brindel, I., Khalil, J., GLIGOROV, J., and Lotz, J.-P. THE TAXIF II PROTOCOL FINAL RESULTS: A PHASE II TRIAL OF HIGH-DOSE CHEMOTHERAPY SUPPORTED BY HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DISSEMINATED GERM-CELL TUMORS FAILING CHEMOTHERAPY AND WITH ADVERSE PROGNOSTIC FACTORS. [2012] Annals of Oncology (23) 9 : 260-260. Impact factor : 7.384 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 101 GUSTAVE ROUSSY’S PUBLICATIONS [363] Serafini, M., Jakszyn, P., Lujàn-Barroso, L., Agudo, A., Bas Bueno-De-Mesquita, H., Van Duijnhoven, F. J. B., Jenab, M., Navarro, C., Palli, D., Boeing, H., Wallström, P., Regnér, S., Numans, M. E., Carneiro, F., BoutronRuault, M. C., Clavel-Chapelon, F., Morois, S., Grioni, S., Panico, S., Tumino, R., Sacerdote, C., Ramon Quiros, J., Molina-Montes, E., Huerta Castano, J. M., Barricarte, A., Amiano, P., Khaw, K. T., Wareham, N., Allen, N. E., Key, T. J., Jeurnink, S. M., Peeters, P. H. M., Bamia, C., Valanou, E., Trichopoulou, A., Kaaks, R., Lukanova, A., Bergmann, M. M., Lindkvist, B., Stenling, R., Johansson, I., Dahm, C. C., Overvad, K., Jensen, M., Olsen, A., Tjonneland, A., Lund, E., Rinaldi, S., Michaud, D., Mouw, T., Riboli, E., and Gonzalez, C. A. Dietary total antioxidant capacity and gastric cancer risk in the European prospective investigation into cancer and nutrition study. [2012] International Journal of Cancer (131) 4 : E544-E554. Impact factor : 6.198 [364] Shankar, A., Hall, G. W., Gorde-Grosjean, S., Hasenclever, D., Leblanc, T., Hayward, J., Lambilliotte, A., Daw, S., Perel, Y., McCarthy, K., Lejars, O., Coulomb, A., Oberlin, W. O., Wallace, W. H., and Landman-Parker, J. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma - An Anglo-French collaborative report. [2012] European Journal of Cancer (48) 11 : 1700-1706. Impact factor : 5.061 [365] Sleijfer, S., Gorlia, T., Lamers, C., Burger, H., Blay, J. Y., Le Cesne, A., Scurr, M., Collin, F., Pandite, L., Marreaud, S., and Hohenberger, P. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: An EORTC-STBSG study. [2012] British Journal of Cancer (107) 4 : 639-645. Impact factor : 5.082 [366] Sluijs, Ivonne, Forouhi, Nita G., Beulens, Joline W. J., van der Schouw, Yvonne T., Agnoli, Claudia, Arriola, Larraitz, Balkau, Beverley, Barricarte, Aurelio, Boeing, Heiner, Bueno-de-Mesquita, H. Bas, Clavel-Chapelon, Françoise, Crowe, Francesca L., Lauzon-Guillain, Blandine, Drogan, Dagmar, Franks, Paul W., Gavrila, Diana, Gonzalez, Carlos, Halkjaer, Jytte, Kaaks, Rudolf, Moskal, Aurelie, Nilsson, Peter, Overvad, Kim, Palli, Domenico, Panico, Salvatore, Quiros, José R., Ricceri, Fulvio, Rinaldi, Sabina, Rolandsson, Olov, Sacerdote, Carlotta, Sanchez, Maria José, Slimani, Nadia, Spijkerman, Annemieke M. W., Teucher, Birgit, Tjonneland, Anne, Tormo, Maria José, Tumino, Rosario, Van Der, A., Sharp, Stephen J., Langenberg, Claudia, Feskens, Edith J. M., Riboli, Elio, and Wareham, Nicholas J. The amount and type of dairy product intake and incident type 2 diabetes: results from the EPIC-InterAct Study. [2012] American Journal of Clinical Nutrition (96) 2 : 382-390. Impact factor : 6.504 [367] Solary, Eric PHAGOCYTES & GRANULOCYTES When monocyte life hangs by a thread. [2012] Blood (119) 12 : 26992700. Impact factor : 9.060 [368] Soria, J. THE CHARACTERIZATION OF LUNG CANCER. [2012] Annals of Oncology (23) 9 : 24-24. Impact factor : 7.384 [369] Soria, J. C., Cortes, J., Massard, C., Armand, J. P., De andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J., Marier, J. F., Beliveau, M., Martell, R. E., and Baselga, J. Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. [2012] Annals of Oncology (23) 2 : 463-471. Impact factor : 7.384 [370] Soria, J. C., Mok, T. S., Cappuzzo, F., and Jänne, P. A. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. [2012] Cancer Treatment Reviews (38) 5 : 416-430. Impact factor : 6.024 [371] Soria, J. C., Dienstmann, R., de Braud, F., Cereda, R., Bahleda, R., Hollebecque, A., Tabernero, J., Delmonte, A., Dromain, C., Lassau, N., Farace, F., Zucchetti, M., Marsoni, S., and Camboni, M. G. FIRST-IN-MAN STUDY OF E-3810, A NOVEL VEGFR AND FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS. [2012] Annals of Oncology (23) 1 : 16-17. Impact factor : 7.384 [372] Soucie, E., Hanssens, K., Mercher, T., Georgin-Lavialle, S., Damaj, G., Livideanu, C., Chandesris, M. O., Acin, Y., Létard, S., De Sepulveda, P., Hermine, O., Bernard, O. A., and Dubreuil, P. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. [2012] Blood (120) 24 : 4846-4849. Impact factor : 9.060 [373] Spano, J. P., Lanoy, E., Mounier, N., Katlama, C., Costagliola, D., and Heard, I. Breast cancer among HIV infected individuals from the ONCOVIH study, in France: Therapeutic implications. [2012] European Journal of Cancer (48) 18 : 3335-3341. Impact factor : 5.061 102 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [374] Speisky, D., Duces, A., Bièche, I., Rebours, V., Hammel, P., Sauvanet, A., Richard, S., Bedossa, P., Vidaud, M., Murat, A., Niccoli, P., Scoazec, J. Y., Ruszniewski, P., and Couvelard, A. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and von Hippel-Lindau patients. [2012] Clinical Cancer Research (18) 10 : 2838-2849. Impact factor : 7.837 [375] Spielmann, M., Luporsi, E., Ray-Coquard, I., De Botton, S., Azria, D., Lasocki, S., Lafuma, A., Mahi, L., Deray, G., and Bugat, R. Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: The AnemOnHe study. [2012] European Journal of Cancer (48) 1 : 101-107. Impact factor : 5.061 [376] Spurdle, A. B., Whiley, P. J., Thompson, B., Feng, B., Healey, S., Brown, M. A., Pettigrew, C., Van Asperen, C. J., Ausems, M. G. E. M., Kattentidt-Mouravieva, A. A., van den Ouweland, A. M. W., Lindblom, A., Pigg, M. H., Schmutzler, R. K., Engel, C., Meindl, A., Caputo, S., Sinilnikova, O. M., Lidereau, R., Couch, F. J., Guidugli, L., Overeem Hansen, T., Thomassen, M., Eccles, D. M., Tucker, K., Benitez, J., Domchek, S. M., Toland, A. E., Rensburg, Elizabeth J. V., Wappenschmidt, B., Borg, A, Vreeswijk, M. P. G., Goldgar, D. E., Hogervorst, F. B., Oldenburg, R. A., Wijnen, J. T., Devilee, P., van der Luijt, R. B., Gille, J. J. P., Adank, M. A., Gomez Garcia, E. B., Blok, M. J., Oosterwijk, J. C., van der Hout, A. H., Michils, G., Legius, E., Teugels, E., Grève, Jacques de, Arnold, N., Deisler, H., Gadzicki, D., Gehrig, A., Heinritz, W., Kast, K., Niederacher, D., Preisler-Adams, S., Sutter, C., VaronMateeva, R., Weber, B. H., Sévenet, N., Bonnet, F., Longy, M., Hardouin, A., Vaur, D., Krieger, S., Uhrhammer, N., Bignon, Y. J., Peyrat, J. P., Revillion, F., Fournier, J., Mazoyer, S., léone, M., Sobol, H., Noguchi, T., Bourdon, V., Remenieras, A., Rey, J. M., Bronner, M., Sokolowska-Gillois, J., Jonveaux, P., Delnatte, C., Coulet, F., Castera, L., Caux-Moncoutier, V., Houdayer, C., Stoppa-Lyonnet, Dominique, Delvincourt, C., Gorisse, M. C., Bièche, I., Lefol, C., Rouleau, E., Abecassis, J., Muller, D., Toulas, C., Guillaud-Bataille, M., Bressac-de Paillerets, B., Barber, R., Bedenham, T., Burgess, L., Campbell, J., Cook, J., Devereau, A., Ejlertsen, B., Fields, M., Gerdes, A. M., Johnston, E., Kruse, T. A., Luharia, A., Mckeown, C., Nathanson, K., Nielsen, F. C., Senter, L., Stayner, B., Sweet, K., Thomas, S., Wallis, Y., and Watts, S. BRCA1 R1699Q variant displaying ambiguous Functional abrogation confers intermediate breast And ovarian cancer risk. [2012] Journal of Medical Genetics (49) 8 : 525-532. Impact factor : 5.703 [377] Stopeck, A. T., Richardson, G., Siena, S., Lipton, A., Brown, J., Fizazi, K., Henry, D., Saad, F., Ke, C., and Braun, A. DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES. [2012] European Journal of Cancer (48) 4 : S8-S8. Impact factor : 5.061 [378] Surdez, D., Benetkiewicz, M., Perrin, V., Han, Z. Y., Pierron, G., Ballet, S., Lamoureux, F., Rëdini, F., Decouvelaere, A. V., Daudigeos-Dubus, E., Geoerger, B., De Pinieux, G., Delattre, O., and Tirode, F. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-B abolishes ewing sarcoma growth. [2012] Cancer Research (72) 17 : 4494-4503. Impact factor : 8.650 [379] Tailler, M., Senovilla, L., Lainey, E., Thépot, S., Métivier, D., Sébert, M., Baud, V., Billot, K., Fenaux, P., Galluzzi, L., Boehrer, S., Kroemer, G., and Kepp, O. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. [2012] Oncogene (31) 30 : 3536-3546. Impact factor : 7.357 [380] Talhaoui, Ibtissam, Couvé, Sophie, Ishchenko, Alexander A., Kunz, Christophe, Schär, Primo, and Saparbaev, Murat 7,8-dihydro-8-oxoadenine, a highly mutagenic adduct, is repaired by Escherichia coli and human mismatch-specific uracil/ thymine-DNA glycosylases. [2012] Nucleic Acids Research. Impact factor : 8.278 [381] Tarakhovsky, A. S. and Kroemer, G. Innate immunity. [2012] Current Opinion in Immunology (24) 1 : 1-2. Impact factor : 8.771 [382] Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita, H., Chen, L., Mécheri, S., Kaplanski, G., Prévost-Blondel, A., Kato, M., Schultze, J. L., Tartour, E., Kroemer, G., Degli-Esposti, M., Chaput, N., and Zitvogel, L. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. [2012] Cancer Research (72) 11 : 2757-2767. Impact factor : 8.650 [383] Testori, A., Suciu, S., van Akkooi, A. C. J., Cook, M., Ghanem, G., Karra Gurunath, R., Keilholz, U., van Kempen, L., Leyvraz, S., Mihm, M., Newton-Bishop, J., Patel, P., Robert, C., Schadendorf, D., De Schaetzen, G., Spatz, A., De Vries, E., and Eggermont, A. M. M. EORTC Melanoma Group achievements. [2012] European Journal of Cancer, Supplement (10) 1 : 112-119. Impact factor : 5.061 [384] Thomas-Schoemann, A., Batteux, F., Mongaret, C., Nicco, C., Chéreau, C., Annereau, M., Dauphin, A., Goldwasser, F., Weill, B., Lemare, F., and Alexandre, J. Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. [2012] Journal of Immunology (189) 11 : 5171-5177. Impact factor : 5.520 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 103 GUSTAVE ROUSSY’S PUBLICATIONS [385] Timofeeva, Maria N., Hung, Rayjean J., Rafnar, Thorunn, Christiani, David C., Field, John K., Bickeböller, Heike, Risch, Angela, McKay, James D., Wang, Yufei, Dai, Juncheng, Gaborieau, Valerie, McLaughlin, John, Brenner, Darren, Narod, Steven A., Caporaso, Neil E., Albanes, Demetrius, Thun, Michael, Eisen, Timothy, Wichmann, H. Erich, Rosenberger, Albert, Han, Younghun, Chen, Wei, Zhu, Dakai, Spitz, Margaret, Wu, Xifeng, Pande, Mala, Zhao, Yang, Zaridze, David, Szeszenia-Dabrowska, Neonilia, Lissowska, Jolanta, Rudnai, Peter, Fabianova, Eleonora, Mates, Dana, Bencko, Vladimir, Foretova, Lenka, Janout, Vladimir, Krokan, Hans E., Gabrielsen, Maiken Elvestad, Skorpen, Frank, Vatten, Lars, Njolstad, Inger, Chen, Chu, Goodman, Gary, Lathrop, Mark, Benhamou, Simone, Vooder, T., Välk, Kristjan, Nelis, Mari, Metspalu, Andres, Raji, Olaide, Chen, Ying, Gosney, John, Liloglou, Triantafillos, Muley, Thomas, Dienemann, Hendrik, Thorleifsson, Gudmar, Shen, Hongbing, Stefansson, Kari, Brennan, Paul, Amos, Christopher I., Houlston, Richard, and Landi, Maria Teresa Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. [2012] Human Molecular Genetics (21) 22 : 4980-4995. Impact factor : 7.692 [386] Travert, M., Huang, Y., de Leval, L., Martin-Garcia, N., Delfau-Larue, M. H., Berger, F., Bosq, J., Brière, J., Soulier, J., Macintyre, E., Marafioti, T., De Reyniès, A., and Gaulard, P. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. [2012] Blood (119) 24 : 5795-5806. Impact factor : 9.060 [387] Tredan, O., You, B., Beuzeboc, P., COEFFIC, D., Lortholary, A., Fellous, M., Rouge, T. De La Motte, Andre, F., Arnould, L., and Ferrero, J. CHARACTERISTICS OF PATIENTS WITH HER2-POSITIVE METASTATIC (MBC) OR LOCALLY ADVANCED BREAST CANCER (ABC), TREATED WITH TRASTUZUMAB (T) AS 1ST LINE-THERAPY AND PROGRESSION-FREE FOR AT LEAST 3 YEARS: INTERIM ANALYSIS OF THE LORHA STUDY. [2012] Annals of Oncology (23) 9 : 125-125. Impact factor : 7.384 [388] Trouilloud, I., Dupont-Gossard, A. C., Artru, P., Lecomte, T., Gauthier, M., Aparicio, T., Thirot-Bidault, A., Malka, D., Bonnetain, F., and Taieb, J. FIRGEM, A SEQUENTIAL FOLFIRI.3 (CPT-11 PLUS FOLINIC ACID PLUS 5-FU) FOLLOWED BY GEMCITABINE OR GEMCITABINE ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA: RESULTS OF A RANDOMIZED MULTICENTER AGEO PHASE II TRIAL. [2012] Annals of Oncology (23) 9 : 237-237 . Impact factor : 7.384 [389] Trouilloud, Isabelle, Dupont-Gossard, Anne Claire, Artru, Pascal, Lecomte, Thierry, Gauthier, Melanie, Aparicio, Thomas, Thirot-Bidault, Anne, Malka, David, Lobry, Celine, Asnacios, Amani, Lacombe, Sophie, Fein, Francine, Dubreuil, Olivier, Zaanan, Aziz, Bonnetain, Franck, Rougier, Philippe, and Taieb, Julien FOLFIRI.3 ALTERNATING WITH GEMCITABINE IN PATIENTS WITH UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA: THE RANDOMIZED MULTICENTER AGEO PHASE II TRIAL FIRGEM. [2012] Annals of Oncology (23) 4 : 6-6. Impact factor : 7.384 [390] Turato, Cristian, Buendia, Marie Annick, Fabre, Monique, Redon, Marie José, Branchereau, Sophie, Quarta, Santina, Ruvoletto, Mariagrazia, Perilongo, Giorgio, Grotzer, Michael Andreas, Gatta, Angelo, and Pontisso, Patrizia Over-expression of SERPINB3 in hepatoblastoma: a possible insight into the genesis of this tumour? [2012] European Journal of Cancer (48) 8 : 1219-1226. Impact factor : 5.061 [391] Turki, A., Hayot, M., Carnac, G., Pillard, F., Passerieux, E., Bommart, S., De Mauverger, E. R., Hugon, G., Pincemail, J., Pietri, S., Lambert, K., Belayew, A., Vassetzky, Y., Juntas Morales, R., Mercier, J., and LaoudjChenivesse, D. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. [2012] Free Radical Biology and Medicine (53) 5 : 1068-1079. Impact factor : 5.271 [392] van Akkooi, A. C. J., Cook, M. G., and Eggermont, A. M. M. Increased sampling will lead to an increase in detection, but is it clinically relevant?: Reply letter regarding: «treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: A nat. [2012] European Journal of Cancer (48) 15 : 2488-2489. Impact factor : 5.061 [393] Van Der Zee, J. A., Van Eijck, C. H., Hop, W. C., Biermann, K., Dicheva, B. M., Seynhaeve, A. L., Koning, G. A., Eggermont, A. M., and Ten Hagen, T. L. Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer. [2012] British Journal of Cancer (107) 7 : 1153-1158. Impact factor : 5.082 [394] Van Der Zwan, J. M., Mallone, S., Van Dijk, B., Bielska-Lasota, M., Otter, R., Foschi, R., Baudin, E., and Links, T. P. Carcinoma of endocrine organs: Results of the RARECARE project. [2012] European Journal of Cancer (48) 13 : 1923-1931. Impact factor : 5.061 104 ANNUAL REPORT 2012 / GUSTAVE ROUSSY [395] Van Laethem, J. L., Verslype, C., Iovanna, J. L., Michl, P., Conroy, T., Louvet, C., Hamme, P., Mitry, E., Ducreux, M., Maraculla, T., Uhl, W., van Tienhoven, G., Bachet, J. B., Chal, R. M., Hendlisz, A., Bali, M., Demetter, P., Ulrich, F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J. P., and Lutz, M. New strategies and designs in pancreatic cancer research: Consensus guidelines report from a European expert panel. [2012] Annals of Oncology (23) 3 : 570-576. Impact factor : 7.384 [396] Varraso, R., Oryszczyn, M. P., Mathieu, N., Le Moual, N., Boutron-Ruault, M. C., Clavel-Chapelon, F., Romieu, I., and Kauffmann, F. Farming in childhood, diet in adulthood and asthma history. [2012] EUROPEAN RESPIRATORY JOURNAL (39) 1 : 67-75. Impact factor : 6.355 [397] Veal, G. J., Nguyen, L., Paci, A., Riggi, M., Amiel, M., Valteau-Couanet, D., Brock, P., Ladenstein, R., and Vassal, G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. [2012] European Journal of Cancer (48) 16 : 3063-3072. Impact factor : 5.061 [398] Vergnaud, A. C., Norat, T., Romaguera, D., Mouw, T., May, A. M., Romieu, I., Freisling, H., Slimani, N., BoutronRuault, M. C., Clavel-Chapelon, F., Morois, S., Kaaks, R., Teucher, B., Boeing, H., Buijsse, B., Tjonneland, A., Halkjaer, J., Overvad, K., Jakobsen, M. U., Rodriguez, L., Agudo, A., Sanchez, M. J., Amiano, P., Huerta, J. M., Gurrea, A. B., Wareham, N., Khaw, K. T., Crowe, F., Orfanos, P., Naska, A., Trichopoulou, A., Masala, G., Pala, V., Tumino, R., Sacerdote, C., Mattiello, A., Bueno-de-Mesquita, H. B., Van Duijnhoven, F. J. B., Drake, I., Wirfält, E., Johansson, I., Hallmans, G., Engeset, D., Braaten, T., Parr, C. L., Odysseos, A., Riboli, E., and Peeters, P. H. M. Fruit and vegetable consumption and prospective weight change in participants of the European prospective investigation into cancer and nutrition-physical activity, nutrition, alcohol, cessation of smoking, eating out of home, and obesity study. [2012] American Journal of Clinical Nutrition (95) 1 : 184-193 . Impact factor : 6.504 [399] Verkooijen, H. M., Hartman, M., Usel, M., Benhamou, S., Neyroud-Caspar, I., Czene, K., Vlastos, G., Chappuis, P. O., Bouchardy, C., and Rapiti, E. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. [2012] International Journal of Cancer (130) 9 : 2103-2110. Impact factor : 6.198 [400] Vey, N., Bourhis, J. H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., Dombret, H., and Olive, D. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. [2012] Blood (120) 22 : 4317-4323 . Impact factor : 9.060 [401] Vielh, P., Richon, C., Meurice, G., Job, B., Lacroix, L., Marthy, V., Motte, N., Valent, A., Caillou, B., Al Ghuzlan, A., Bidart, J. M., El Naggar, A., Lazar, V., Dessen, P., and Schlumberger, M. Molecular Characterization of 61 Cases of Follicular Adenomas and Carcinomas of the Thyroid. [2012] Modern Pathology (25) supplt 2 : 317A-317A. Impact factor : 5.253 [402] Villarreal-garza, C., Cortes, J., Andre, F., and Verma, S. mTOR inhibitors in the management of hormone receptor-positive breast cancer: The latest evidence and future directions. [2012] Annals of Oncology (23) 10 : 2526-2535. Impact factor : 7.384 [403] Walter, T. A., Baudin, E., Kurtz, J. E., Ruszniewski, P., Bengrine-Lefevre, L., Cadiot, G., Dominguez-Tinajero, S., Kraemer, S., Ducreux, M. P., and Mitry, E. A PHASE II TRIAL OF BEVACIZUMAB WITH CAPECITABINE IN PROGRESSIVE, METASTATIC WELL-DIFFERENTIATED DIGESTIVE ENDOCRINE TUMORS (BETTER STUDY). [2012] Annals of Oncology (23) 9 : 378-378. Impact factor : 7.384 [404] Warrick, Emilie, Garcia, Marta, Chagnoleau, Corinne, Chevallier, Odile, Bergoglio, Valerie, Sartori, Daniela, Mavilio, Fulvio, Angulo, Jaime F., Avril, Marie Francoise, Sarasin, Alain, Larcher, Fernando, Del Rio, Marcela, Bernerd, Francoise, and Magnaldo, Thierry Preclinical Corrective Gene Transfer in Xeroderma Pigmentosum Human Skin Stem Cells. [2012] MOLECULAR THERAPY (20) 4 : 798-807. Impact factor : 7.041 [405] Werutsky, G., Ducreux, M., Lutz, M., Mauer, M., Van Cutsem, E., Ruers, T., Folprecht, G., Moehler, M., Aust, D., Van Laethem, J. L., Lordick, F., Nordlinger, B., and Roth, A. The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management. [2012] European Journal of Cancer, Supplement (10) 1 : 51-57. Impact factor : 5.061 [406] Weyemi, U., Lagente-Chevallier, O., Boufraqech, M., Prenois, F., Courtin, F., Caillou, B., Talbot, M., Dardalhon, M., Al Ghuzlan, A., Bidart, J. M., Schlumberger, M., and Dupuy, C. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. [2012] Oncogene (31) 9 : 1117-1129. Impact factor : 7.357 [407] Weyemi, U. and Dupuy, C. The emerging role of ROS-generating NADPH oxidase NOX4 in DNA-damage responses. [2012] Mutation Research - Reviews in Mutation Research (751) 2 : 77-81. Impact factor : 6.426 ANNUAL REPORT 2012 / GUSTAVE ROUSSY 105 GUSTAVE ROUSSY’S PUBLICATIONS [408] Wu, X., Scelo, G., Purdue, M. P., Rothman, N., Johansson, M., Ye, Y., Wang, Z., Zelenika, D., Moore, L. E., Wood, C. G., Prokhortchouk, E., Gaborieau, V., Jacobs, K. B., Chow, W. H., Toro, J. R., Zaridze, D., Lin, J., Lubinski, J., Trubicka, J., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Mates, D., Jinga, V., Bencko, V., Slamova, A., Holcatova, I., Navratilova, M., Janout, V., Boffetta, P., Colt, J. S., Davis, F. G., Schwartz, K. L., Banks, R. E., Selby, P. J., Harnden, P., Berg, C. D., Hsing, A. W., Grubb, Robert L., Boeing, H., Vineis, P., Clavel-Chapelon, F., Palli, D., Tumino, R., Krogh, V., Panico, S., Duell, E. J., Quiros, J. R., Sanchez, M., Navarro, C., Ardanaz, E., Dorronsoro, M., Khaw, K. T., Allen, N. E., Bueno-de-Mesquita, H. B., Peeters, P. H. M., Trichopoulos, D., Linseisen, J., Ljungberg, B., Overvad, K., Tjonneland, A., Romieu, I., Riboli, E., Stevens, V. L., Thun, M. J., Diver, W. R., Gapstur, S. M., Pharoah, P. D., Easton, D. F., Albanes, D., Virtamo, J., Vatten, L., Hveem, K., Fletcher, T., Koppova, K., Cussenot, O., Cancel-tassin, G., Benhamou, S., Hildebrandt, M. A., Pu, X., Foglio, M., Lechner, D., Hutchinson, A., Yeager, M., Fraumeni, Jr, Lathrop, M., Skryabin, K. G., McKay, J. D., Gu, J., Brennan, P., and Chanock, S. J. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. [2012] Human Molecular Genetics (21) 2 : 456-462. Impact factor : 7.692 [409] Wu, Y.-L., Mok, T., Soria, J.-C., Nakagawa, K., Zhang, X., and Miao, A. GEFITINIB/CHEMOTHERAPY VERSUS CHEMOTHERAPY IN EGFR MUTATION-POSITIVE NSCLC AFTER PROGRESSION ON FIRST-LINE GEFITINIB: IMPRESS STUDY DESIGN. [2012] Annals of Oncology (23) 11 : 23-23. Impact factor : 7.384 [410] Yacoubene, K., Merad, M., Alibay, A. T., Di Palma, M., and Sami, A. FAMILY PHYSICIANS (FP) ARE RARELY INVOLVED IN MANAGING ACUTE ONSET SYMPTOMS DURING CANCER TREATMENT. [2012] Annals of Oncology (23) 9 : 517-517. Impact factor : 7.384 [411] Yip, S. C., Cottere, S., and Chernoff, J. Sumoylated protein tyrosine phosphatase 1B localizes to the inner nuclear membrane and regulates the tyrosine phosphorylation of emerin. [2012] Journal of Cell Science (125) 2 : 310-316. Impact factor : 5.877 [412] Zhang, Y., Patel, S., Abdelouahab, H., Wittner, M., Willekens, C., Shen, S., Betems, A., Joulin, V., Opolon, P., Bawa, O., Pasquier, F., Ito, M., Fujii, N., Gonin, P., Solary, E., Vainchenker, W., Coppo, P., De Botton, S., and Louache, F. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. [2012] Cell Death and Disease (3) 10. Impact factor : 6.044 [413] Zitvogel, L. NO CURE WITHOUT IMMUNE RESPONSES IN CANCER TREATED WITH CYTOTOXIC AGENTS. [2012] Annals of Oncology (23) 5 : 8-8. Impact factor : 7.384 [414] Zitvogel, L. and Housseau, F. IKDCs or B220+ NK cells are pre-mNK cells. [2012] Blood (119) 19 : 4345-4346. Impact factor : 9.060 [415] Zsiros, J., Brugières, L., Brock, P., Roebuck, D., Maibach, R., Child, M., Morland, B., Casanova, M., Pariente, D., Paris, C., Camargo, B. D., Ronghe, M., Zimmermann, A., Plaschkes, J., Czauderna, P., and Perilongo, G. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma - A phase II trial of the childhood liver tumour strategy group (SIOPEL). [2012] European Journal of Cancer (48) 18 : 34563464. Impact factor : 5.061 106 ANNUAL REPORT 2012 / GUSTAVE ROUSSY – Photographs: N. Guerbe, Gustave Roussy. Gustave Roussy Communications Department – Design and production: 114, rue Édouard-Vaillant 94805 Villejuif Cedex - France Tel.: 01 42 11 42 11 Fax: 01 42 11 53 00 www.gustaveroussy.fr Follow us: Page Gustave Roussy @gustaveroussy